CUMULATIVE SUPPLEMENT 10
OCTOBER 2001



APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

21ST EDITION

Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Information Technology
Division of Data Management and Services

2001

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

21ST EDITION

Cumulative Supplement 10

October 2001

CONTENTS

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

21ST EDITION

CUMULATIVE SUPPLEMENT 10
OCTOBER 2001

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 21st Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research and products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to place an asterisk (*) to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement.

Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision. [Strength(s) which already exist in the List will not be repeated for context.]

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 21st Edition List will then be added to the "Discontinued Drug Product List" appearing in the 22nd Edition. The current edition Section 2. How To Use The Drug Product Lists describes the layout and usage of the List.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms section in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >**A**>. The Patent and Exclusivity Data are indicated by the symbol **>ADD>** to the left of the line on which new information exists. The **>ADD>** symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>D>** (DELETE) to the left of the line. The information line with the **>D>** symbol is dropped in subsequent Cumulative Supplements for that item.

1.2 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated

Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
BAXTER PHARMACEUTICAL PRODUCTS INC (BAXTER PHARM PROD)	BAXTER HEALTHCARE CORPORATION ANESTHESIA & CRITICAL CARE (BAXTER HLTHCARE CORP)
CAMALL CO INC (CAMALL)	ABC HOLDING CORPORATION (ABC HOLDING)
CIBA VISION CORP DIV NOVARTIS CO (CIBA)	NOVARTIS OPHTHALMICS INC (NOVARTIS)
CIBA VISION OPHTHALMICS (CIBA VISION OPHTHLMC)	NOVARTIS OPHTHALMICS INC (NOVARTIS)
DEY LABORATORIES INC (DEY)	DEY LP (DEY)
KNOLL PHARMACEUTICAL COMPANY (KNOLL PHARM)	ABBOTT LABORATORIES PHARMACEUTICAL PRODUCTS (ABBOTT)
LOTUS BIOCHEMICAL CORPORATION (LOTUS BIOCHEM)	NEW RIVER PHARMACEUTICALS INC (NEW RIVER)
MARSAM PHARMACEUTICALS INC (MARSAM PHARMS)	MARSAM PHARMACEUTICALS LLC (MARSAM PHARMS)
MEDEVA AMERICAS INC (MEDEVA)	CELLTECH PHARMACEUTICALS INC (CELLTECH PHARMS)
MEDEVA PHARMACEUTICALS INC (MEDEVA)	CELLTECH PHARMACEUTICALS INC (CELLTECH PHARMS)
MEDEVA INC (MEDEVA)	CELLTECH PHARMACEUTICALS INC (CELLTECH PHARMS)
MEDEVA PHARMACEUTICALS CA INC (MEDEVA PHARMS CA)	CELLTECH MANUFACTURING CA INC (CELLTECH MFG CA INC)
MEDEVA PHARMACEUTICALS MA INC (MEDEVA PHARMS MA)	CELLTECH MANUFACTURING INC (CELLTECH MFG)
NOVOPHARM LTD (NOVOPHARM)	TEVA PHARMACEUTICALS USA (TEVA)
NOVOPHARM PHARMACEUTICAL CO (NOVOPHARM PHARM)	TEVA PHARMACEUTICALS USA (TEVA)
NOVOPHARM NC INC (NOVOPHARM NC)	TEVA PHARMACEUTICALS USA (TEVA)

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
OHMEDA PHARMACEUTICAL PRODUCTS DIV (OHMEDA)	BAXTER HEATHCARE CORPORATION ANESTHESIA & CRITICAL CARE (BAXTER HLTHCARE CORP)
ROBERTS LABORATORIES INC (ROBERTS LABS)	SHIRE PHARMACEUTICAL DEVELOPMENT INC (SHIRE PHARM)
ROBERTS PHARMACEUTICAL CORP (ROBERTS PHARM)	SHIRE PHARMACEUTICAL DEVELOPMENT INC (SHIRE PHARM)
ZENITH GOLDLINE (ZENITH GOLDLINE)	IVAX PHARMACEUTICALS INC (IVAX PHARMS)
ZENITH GOLDLINE PHARMACEUTICALS INC (ZENITH GOLDLINE)	IVAX PHARMACEUTICALS INC (IVAX PHARMS)

1.3 AVAILABILITY OF THE EDITION

The 21st Edition of the Orange Book and its monthly cumulative supplements are available by subscription from the Government Printing Office:

Superintendent of Documents
Government Printing Office
P.O. Box 371954
Pittsburgh, PA 15250-7954

The telephone number to charge your subscription is 202-512-1800. The cost is $101.00 annually.

The Approved Drug Products with Therapeutic Equivalence Evaluation (Orange Book) and related drug information is also available on the Internet at the Food and Drug Administration, Center for Drug Evaluation and Research, Drug Info page.

There is an Electronic Orange Book Query (EOB) at http://www.fda.gov/cder/ob. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder or applicant number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product. The data is updated concurrently with the publication of the annual edition or monthly cumulative supplements.

The Internet version of the hard copy Orange Book annual edition is at http://www.fda.gov/cder/orange/adp.htm.

The Internet version of the hard copy monthly supplement is at http://www.fda.gov/cder/orange/supplement/cspreface.htm. Changes to the annual edition are listed separately by month.

There are ASCII text files of the Orange Book drug product data at http://www.fda.gov/cder/orange/obreadme.htm. The drug product text files are zipped into zipobtxt.exe. The files are updated concurrently with the publication of the annual edition or monthly cumulative supplements. Appendix A and Appendix B are updated quarterly.

The 21st annual edition of the 2000 Orange Book Patent and Exclusivity List is at http://www.fda.gov/cder/orange/21bookpub.pdf.

The current year Patent and Exclusivity cumulative supplement list that denotes the current month additions is at http://www.fda.gov/cder/orange/supplement/patents.pdf.

The Patent Term Extension and new Patents, Docket Number *95S-0117, is at http://www.fda.gov/cder/orange/docket.pdf. It is updated monthly as soon as available and as otherwise needed.

The Drug Price Competition and Patent Term Restoration Act requires that patent information be filed with all newly submitted Section 505 drug applications. To facilitate industry submission of the information, a patent submission sample format is available in HTML and PDF format at:
http://www.fda.gov/cder/orange/patdecl.pdf
http://www.fda.gov/cder/orange/patdecl.html

The current listing of the Orphan Product Designations and Approvals is available at http://www.fda.gov/orphan/designat/list.htm.

1.4 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2000) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 2000	MAR 2001	JUN 2001	SEP 2001
DRUG PRODUCTS LISTED	10360	10372	10155	10094
SINGLE SOURCE	2682 (25.9%)	2696 (26.0%)	2665 (26.2%)	2643 (26.2%)
MULTISOURCE	7568 (73.1%)	7566 (72.9%)	7380 (72.7%)	7341 (72.7%)
THERAPEUTICALLY EQUIVALENT	7257 (70.0%)	7263 (70.0%)	7078 (69.7%)	7050 (69.8%)
NOT THERAPEUTICALLY EQUIVALENT	311 (3.0%)	303 (2.9%)	302 (3.0%)	291 (2.9%)
EXCEPTIONS[1]	110 (1.1%)	110 (1.1%)	110 (1.1%)	110 (1.1%)
NEW MOLECULAR ENTITIES APPROVED	2	6	3	4
NUMBER OF APPLICANTS	594	582	579	572

[1]Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.5 CUMULATIVE SUPPLEMENT LEGEND

The 21st Edition Orange book (OB) Cumulative Supplement (CS) layout has changed. The new format follows the Annual Edition and previous CS format. The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form;Route and then by trade name. The manner of displaying the individual product information has changed.

The individual product record follows the previous format layout for Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Approval number, product number, and approval date. Two new columns have been added to provide more information. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form;route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be proceeded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.
WDAG	Withdrawn. The applicant holder has notified the FDA in writing that the product in no longer being marketed resulting in the product approval being withdrawn by mutual agreement. The product will be listed in the Discontinued Section.
WDRP	Withdrawn. The application approval has been withdrawn for failure to provide Annual Reports. The product will be moved to the Discontinued Section in the next edition.

1.6 CHANGE OF A THERAPEUTIC EQUIVALENT CODE FOR A DRUG ENTITY

Metaxalone tablets were reviewed in the Drug Efficacy Study Implementation program. FDA published a Federal Register notice on August 15, 1974 (39 FR 29396) finding metaxalone tablets to be effective in the treatment of discomfort associated with acute, painful musculo-skeletal conditions. The Federal Register notice did not require the conduct of a bioavailability/bioequivalence study as a condition of marketing.

On March 6, 2001, URL Mutual Pharmaceutical Co. Inc submitted a citizen petition (Docket No. 01P-0117/CP1) asking FDA to reclassify the drug product metaxalone tablets from one not presenting bioequivalence problems to one that requires an in vivo demonstration of bioequivalence as a condition of approval for an ANDA. To support these assertions, the petition included results of two in vivo bioequivalence fasting studies and three separate in vitro dissolution tests. After a careful review of the data submitted by Mutual, the agency agreed that the firm has demonstrated a lack of correlation between in vitro dissolution and in vivo bioequivalence data of oral metaxalone tablets in two bioequivalence studies. The failure of both Mutual formulations to meet the 90% confidence intervals further supports the lack of in vitro/in vivo correlations.

Therefore, in accordance with our policy as enunciated in Section 1.9 of the Introduction to the 21st Edition of the Orange Book, we are providing a 60 day period in which interested parties may submit comments. The closing date for the comments will be November 30, 2001. The comments should be sent to the Director, Division of Bioequivalence, Office of Generic Drugs, Center for Drug Evaluation and Research, (MPN-2) HFD-650, 7500 Standish Place, Rockville, MD 20855. These comments should include scientific data either supporting or disagreeing with our proposal to change the therapeutic equivalence category for metaxalone tablets from a "non bioproblem" to a "bioproblem" drug.

			ACETAMINOPHEN; ASPIRIN; CODEINE PHOSPHATE					
			CAPSULE; ORAL					
			ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE					
			@ MIKART	150MG;180MG;15MG	N81095 001	OCT 26, 1990	MAY	DISC
			@	150MG;180MG;60MG	N81097 001	OCT 26, 1990	MAY	DISC
			ACETAMINOPHEN; BUTALBITAL					
			CAPSULE; ORAL					
			TRIAPRIN					
			@ DUNHALL	325MG;50MG	N89268 001	JUL 02, 1987	FEB	WDRP
			ACETAMINOPHEN; BUTALBITAL; CAFFEINE					
			CAPSULE; ORAL					
			ANOQUAN					
			@ ROBERTS AND HAUCK	325MG;50MG;40MG	N87628 001	OCT 01, 1986	FEB	WDRP
			TABLET; ORAL					
			BUTALBITAL, ACETAMINOPHEN AND CAFFEINE					
	AB		ABLE	325MG;50MG;40MG	N40390 001	JUL 23, 2001	JUL	NEWA
	AB			500MG;50MG;40MG	N40394 001	JUL 23, 2001	JUL	NEWA
			ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE					
			CAPSULE; ORAL					
			BUTALBITAL; ACETAMINOPHEN; AND CAFFEINE WITH CODEINE PHOSPHATE					
	AB		WEST WARD	325MG;50MG;40MG;30MG	N75618 001	MAR 23, 2001	MAR	NEWA
			FIORICET W/ CODEINE					
	AB	+	NOVARTIS	325MG;50MG;40MG;30MG	N20232 001	JUL 30, 1992	MAR	CFTG
			PHRENILIN WITH CAFFEINE AND CODEINE					
	AB		AMARIN PHARMS	325MG;50MG;40MG;30MG	N74911 001	AUG 22, 2001	AUG	NEWA
			ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE					
			CAPSULE; ORAL					
			ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE					
>D>	AA		MIKART	356.4MG;30MG;16MG	N40109 001	AUG 26, 1997	OCT	CRLD
>A>		+		356.4MG;30MG;16MG	N40109 001	AUG 26, 1997	OCT	CRLD
>D>			DHC PLUS					
>D>	AA	+	PURDUE FREDERICK	356.4MG;30MG;16MG	N88584 001	MAR 04, 1986	OCT	DISC
>A>			@	356.4MG;30MG;16MG	N88584 001	MAR 04, 1986	OCT	DISC
			TABLET; ORAL					
			ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE					
		+	MIKART	712.8MG;60MG;32MG	N40316 001	APR 28, 1999	JAN	CTNA
			ACETAMINOPHEN; CODEINE PHOSPHATE					
			TABLET; ORAL					
			ACETAMINOPHEN AND CODEINE PHOSPHATE					
	AA		MALLINCKRODT	300MG;15MG	N40419 001	MAY 31, 2001	MAY	NEWA
	AA			300MG;30MG	N40419 002	MAY 31, 2001	MAY	NEWA
	AA			300MG;60MG	N40419 003	MAY 31, 2001	MAY	NEWA
			CAPITAL WITH CODEINE					
			@ CARNRICK	325MG;30MG	N83643 001	MAY 31, 1974	FEB	WDRP

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA		MALLINCKRODT	500MG/15ML;7.5MG/15ML	N40418	001	JUN 27, 2001	JUN	NEWA
AA	+	MIKART	500MG/15ML;7.5MG/15ML	N81051	001	AUG 28, 1992	JUN	CDFR
	+		500MG/15ML;5MG/15ML	N81226	001	OCT 27, 1992	JUN	CDFR
	+		500MG/15ML;5MG/15ML	N89557	001	APR 29, 1992	JUN	CDFR
AA		PHARM ASSOC	500MG/15ML;7.5MG/15ML	N40182	001	MAR 13, 1998	JUN	CDFR

TABLET; ORAL

	+	ENDO PHARMS	400MG;5MG	N40288	001	NOV 27, 1998	SEP	CTEC
	+		400MG;7.5MG	N40288	002	NOV 27, 1998	SEP	CTEC
	+		400MG;10MG	N40288	003	NOV 27, 1998	SEP	CTEC
	+	WATSON LABS	325MG;7.5MG	N40248	001	APR 28, 2000	JUL	DISC
	@		325MG;7.5MG	N40248	001	APR 28, 2000	AUG	DISC
	+		750MG;10MG	N40094	004	MAR 22, 1999	APR	NEWA

LORTAB

AA	+	WATSON LABS	325MG;5MG	N40099	001	JUN 25, 1997	JAN	CAHN

NORCO

AA		WATSON LABS	325MG;7.5MG	N40148	003	SEP 12, 2000	APR	NEWA
AA	+		325MG;7.5MG	N40148	003	SEP 12, 2000	JUL	CRLD

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL

PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN

AB		ABLE	650MG;100MG	N75838	001	JUL 11, 2001	JUL	NEWA
	@	HALSEY	325MG;50MG	N70115	001	JUN 12, 1985	MAY	DISC
	@		650MG;100MG	N70116	001	JUN 12, 1985	MAY	DISC
AB		MALLINCKRODT	650MG;100MG	N75738	001	FEB 02, 2001	FEB	NEWA
AB		VINTAGE PHARMS	325MG;50MG	N74843	002	FEB 15, 2001	FEB	NEWA

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET; ORAL

ULTRACET

	+	JOHNSON RW	325MG;37.5MG	N21123	001	AUG 15, 2001	AUG	NEWA

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

ACYCLOVIR

	AP	GENSIA SICOR PHARMS	EQ 50MG BASE/ML	N75627	001	MAR 28, 2001	MAR	NEWA

ACYCLOVIR SODIUM

>D>	AP	AESGEN	EQ 500MG BASE/VIAL	N75015	001	APR 30, 1998	OCT	CAHN
>A>	AP	AM PHARM PARTNERS	EQ 500MG BASE/VIAL	N75015	001	APR 30, 1998	OCT	CAHN

ALBUTEROL

AEROSOL, METERED; INHALATION

ALBUTEROL

>D>	AB	ALPHARMA	0.09MG/INH	N73045	001	AUG 19, 1997	OCT	CAHN
	AB	ARMSTRONG PHARMS	0.09MG/INH	N72273	001	AUG 14, 1996	JUN	CAHN
>A>	AB	GENPHARM	0.09MG/INH	N73045	001	AUG 19, 1997	OCT	CAHN

	ALBUTEROL SULFATE						
	AEROSOL, METERED; INHALATION						
	VENTOLIN HFA						
	+ GLAXO	EQ 0.09MG BASE/INH	N20983 001	APR 19, 2001	APR	NEWA	
	CAPSULE; INHALATION						
	VENTOLIN ROTACAPS						
	@ GLAXO WELLCOME	EQ 0.2MG BASE	N19489 001	MAY 04, 1988	JUL	DISC	
	SOLUTION; INHALATION						
	ACCUNEB						
	+ DEY	EQ 0.021% BASE	N20949 002	APR 30, 2001	APR	NEWA	
	+	EQ 0.042% BASE	N20949 001	APR 30, 2001	APR	NEWA	
	ALBUTEROL SULFATE						
AN	NEPHRON	EQ 0.5% BASE	N75664 001	JUN 26, 2001	JUN	NEWA	
AN	ROXANE	EQ 0.083% BASE	N75129 001	FEB 13, 2001	FEB	NEWA	
	VENTOLIN						
	@ GLAXO WELLCOME	EQ 0.083% BASE	N19773 001	APR 23, 1992	JUL	DISC	
	@	EQ 0.5% BASE	N19269 002	JAN 16, 1987	JUL	DISC	
	TABLET; ORAL						
	@ GLAXO WELLCOME	EQ 2MG BASE	N19112 001	JUL 10, 1986	JUN	DISC	
	@	EQ 4MG BASE	N19112 002	JUL 10, 1986	JUN	DISC	
	ALBUTEROL SULFATE; IPRATROPIUM BROMIDE						
	SOLUTION; INHALATION						
	DUONEB						
	+ DEY	EQ 0.083% BASE;0.017%	N20950 001	MAR 21, 2001	MAR	NEWA	
	ALLOPURINOL						
	TABLET; ORAL						
	ZYLOPRIM						
AB	PROMETHEUS LABS	100MG	N16084 001	AUG 19, 1966	MAY	CAHN	
AB	+	300MG	N16084 002	JAN 14, 1974	MAY	CAHN	
	ALMOTRIPTAN MALATE						
	TABLET; ORAL						
	AXERT						
	PHARMACIA AND UPJOHN	EQ 6.25MG BASE	N21001 001	MAY 07, 2001	MAY	NEWA	
	+	EQ 12.5MG BASE	N21001 002	MAY 07, 2001	MAY	NEWA	
	ALPRAZOLAM						
	SOLUTION; ORAL						
	ALPRAZOLAM						
	@ ROXANE	0.5MG/5ML	N74314 001	OCT 31, 1993	SEP	DISC	
	AMIKACIN SULFATE						
	INJECTABLE; INJECTION						
	AMIKACIN SULFATE						
	@ ABBOTT	EQ 250MG BASE/ML	N63265 001	NOV 30, 1994	APR	DISC	
	@	EQ 250MG BASE/ML	N63266 001	OCT 31, 1994	APR	DISC	
	@	EQ 250MG BASE/ML	N64099 001	JUN 20, 1995	MAY	DISC	
	@ ELKINS SINN	EQ 250MG BASE/ML	N63275 001	MAY 18, 1992	APR	DISC	

AMINOCAPROIC ACID						
TABLET; ORAL						
AMICAR						
AB + IMMUNEX	500MG	N15197 001	JUN 03, 1964	MAY	CFTG	
AMINOCAPROIC						
AB MIKART	500MG	N75602 001	MAY 24, 2001	MAY	NEWA	
AMIODARONE HYDROCHLORIDE						
TABLET; ORAL						
AMIODARONE HCL						
AB BARR	200MG	N75389 001	JAN 25, 2001	JAN	NEWA	
AB TARO	200MG	N75424 001	MAR 30, 2001	MAR	NEWA	
AMITRIPTYLINE HYDROCHLORIDE						
TABLET; ORAL						
AMITRIPTYLINE HCL						
@ TEVA	75MG	N85030 001	NOV 22, 1976	JUL	DISC	
AMLEXANOX						
PASTE; DENTAL						
APHTHASOL						
+ GLAXOSMITHKLINE CONS	5%	N20511 001	DEC 17, 1996	SEP	CAHN	
AMOXICILLIN						
CAPSULE; ORAL						
AMOXICILLIN						
@ LABS ATRAL	250MG	N62528 001	AUG 07, 1985	FEB	WDRP	
@	500MG	N62528 002	AUG 07, 1985	FEB	WDRP	
@ MYLAN	250MG	N62067 001	AUG 14, 1980	APR	DISC	
@	500MG	N62067 002	AUG 14, 1980	APR	DISC	
@ TEVA	250MG	N63030 001	FEB 28, 1989	APR	DISC	
@	500MG	N63031 001	FEB 28, 1989	APR	DISC	
TRIMOX						
@ APOTHECON	250MG	N63099 001	MAR 20, 1992	APR	DISC	
@	500MG	N63099 002	MAR 20, 1992	APR	DISC	
WYMOX						
@ WYETH AYERST	250MG	N62120 001	APR 28, 1978	APR	DISC	
@	500MG	N62120 002	APR 28, 1978	APR	DISC	
FOR SUSPENSION; ORAL						
TRIMOX						
@ APOTHECON	50MG/ML	N61886 001	DEC 09, 1974	MAY	DISC	
@	125MG/5ML	N61886 002	DEC 09, 1974	MAY	DISC	
@	250MG/5ML	N61886 003	DEC 09, 1974	MAY	DISC	
AMOXICILLIN; CLAVULANATE POTASSIUM						
FOR SUSPENSION; ORAL						
AUGMENTIN ES-600						
+ GLAXOSMITHKLINE	600MG/5ML;EQ 42.9MG BASE/5ML	N50755 001	JUN 22, 2001	JUN	NEWA	

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

>A>	CAPSULE, EXTENDED RELEASE; ORAL						
>A>	ADDERALL XR 10						
>A>	SHIRE LABS	2.5MG;2.5MG;2.5MG;2.5MG	N21303 001	OCT 11, 2001	OCT	NEWA	
>A>	ADDERALL XR 20						
>A>	SHIRE LABS	5MG;5MG;5MG;5MG	N21303 002	OCT 11, 2001	OCT	NEWA	
>A>	ADDERALL XR 30						
>A>	+ SHIRE LABS	7.5MG;7.5MG;7.5MG;7.5MG	N21303 003	OCT 11, 2001	OCT	NEWA	
	TABLET; ORAL						
	ADDERALL 7.5						
	SHIRE LABS	1.875MG;1.875MG;1.875MG;1.875MG	N11522 011	AUG 31, 2000	APR	CRLD	

AMPHOTERICIN B

INJECTABLE; INJECTION						
AMPHOTERICIN B						
@ ABBOTT	50MG/VIAL	N64141 001	DEC 23, 1996	MAY	DISC	
INJECTABLE, LIPID COMPLEX; INJECTION						
AMPHOTEC						
+ INTERMUNE PHARMS	50MG/VIAL	N50729 001	NOV 22, 1996	FEB	CAHN	
+	100MG/VIAL	N50729 002	NOV 22, 1996	FEB	CAHN	

AMPICILLIN SODIUM

INJECTABLE; INJECTION					
AMPICILLIN SODIUM					
@ ELKINS SINN	EQ 125MG BASE/VIAL	N62692 001	JUN 24, 1986	MAY	DISC
@	EQ 250MG BASE/VIAL	N62692 002	JUN 24, 1986	MAY	DISC
@	EQ 500MG BASE/VIAL	N62692 003	JUN 24, 1986	MAY	DISC
@	EQ 1GM BASE/VIAL	N62692 004	JUN 24, 1986	MAY	DISC
@	EQ 2GM BASE/VIAL	N62692 005	JUN 24, 1986	MAY	DISC
@	EQ 10GM BASE/VIAL	N62692 006	JUN 24, 1986	MAY	DISC
@ HANFORD GC	EQ 125MG BASE/VIAL	N63143 001	APR 15, 1993	APR	DISC
@	EQ 250MG BASE/VIAL	N63145 001	APR 15, 1993	APR	DISC
@	EQ 500MG BASE/VIAL	N63146 001	APR 15, 1993	APR	DISC
@	EQ 500MG BASE/VIAL	N63147 001	APR 15, 1993	APR	DISC
@	EQ 1GM BASE/VIAL	N62772 001	APR 15, 1993	MAY	DISC
@	EQ 1GM BASE/VIAL	N63139 001	APR 15, 1993	APR	DISC
@	EQ 2GM BASE/VIAL	N63140 001	APR 15, 1993	APR	DISC
@	EQ 2GM BASE/VIAL	N63141 001	APR 15, 1993	APR	DISC
@	EQ 10GM BASE/VIAL	N63142 001	APR 15, 1993	APR	DISC
@ IBI	EQ 125MG BASE/VIAL	N62797 001	JUL 12, 1993	MAY	DISC
@	EQ 2GM BASE/VIAL	N62797 002	JUL 12, 1993	MAY	DISC
@ MARSAM	EQ 10GM BASE/VIAL	N62994 001	SEP 15, 1988	JUL	DISC
OMNIPEN-N					
@ WYETH AYERST	EQ 125MG BASE/VIAL	N62718 001	DEC 16, 1986	MAY	DISC
@	EQ 250MG BASE/VIAL	N62718 002	DEC 16, 1986	MAY	DISC

@	EQ 500MG BASE/VIAL	N62718 003	DEC 16, 1986	MAY	DISC	
@	EQ 1GM BASE/VIAL	N62718 004	DEC 16, 1986	MAY	DISC	
@	EQ 2GM BASE/VIAL	N62718 005	DEC 16, 1986	MAY	DISC	
TOTACILLIN-N						
SMITHKLINE BEECHAM	EQ 10GM BASE/VIAL	N60677 006	MAY 04, 1976	JUL	CTEC	

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL

AMPICILLIN TRIHYDRATE

@ BIOCHEMIE	EQ 250MG BASE	N64082 001	AUG 29, 1995	MAY	DISC	
@	EQ 500MG BASE	N64082 002	AUG 29, 1995	MAY	DISC	

FOR SUSPENSION; ORAL

@ MYLAN	EQ 125MG BASE/5ML	N61829 002	JUL 29, 1974	MAY	DISC	
@	EQ 250MG BASE/5ML	N61829 001	JUL 29, 1974	MAY	DISC	
TOTACILLIN						
@ SMITHKLINE BEECHAM	EQ 125MG BASE/5ML	N60666 001	MAY 07, 1970	FEB	WDRP	
@	EQ 250MG BASE/5ML	N60666 002	MAY 07, 1970	FEB	WDRP	

AMPICILLIN/AMPICILLIN TRIHYDRATE; PROBENECID

FOR SUSPENSION; ORAL

PROBAMPACIN

@ TEVA	EQ 3.5GM BASE/BOT;1GM/BOT	N61741 001	OCT 10, 1973	MAY	DISC	

ARBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

GENESA

@ GENSIA AUTOMEDICS	0.05MG/ML	N20420 001	SEP 12, 1997	MAR	DISC	

ARDEPARIN SODIUM

INJECTABLE; INJECTION

NORMIFLO

@ PHARMACIA AND UPJOHN	5,000 UNITS/0.5ML	N20227 002	MAY 23, 1997	JUL	CAHN	
@	10,000 UNITS/0.5ML	N20227 001	MAY 23, 1997	JUL	CAHN	
@ WYETH AYERST	5,000 UNITS/0.5ML	N20227 002	MAY 23, 1997	MAY	DISC	
@	10,000 UNITS/0.5ML	N20227 001	MAY 23, 1997	MAY	DISC	

ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

INJECTABLE; IV (INFUSION)

INFUVITE PEDIATRIC

+ SABEX	80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG/VIAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL	N21265 001	FEB 21, 2001	FEB	NEWA	

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PHYTONADIONE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

FOR SOLUTION; IV (INFUSION)

M.V.I. PEDIATRIC

>D> + ASTRAZENECA	80MG/VIAL;0.02MG/VIAL;0.00					

				1MG/VIAL;5MG/VIAL;0.01MG/V IAL;0.14MG/VIAL;17MG/VIAL; 0.2MG/VIAL;1MG/VIAL;1.4MG/ VIAL;EQ 1.2MG BASE/VIAL;0.7MG/VIAL;7MG/V IAL	N18920 001	SEP 21, 2000	OCT	CAHN
		+		80MG/VIAL;0.02MG/VIAL;0.00 1MG/VIAL;5MG/VIAL;0.01MG/V IAL;0.14MG/VIAL;17MG/VIAL; 0.2MG/VIAL;1MG/VIAL;1.4MG/ VIAL;EQ 1.2MG BASE/VIAL;0.7MG/VIAL;7MG/V IAL	N18920 001	SEP 21, 2000	FEB	NEWA
>A>		+	NEOSAN PHARMS	80MG/VIAL;0.02MG/VIAL;0.00 1MG/VIAL;5MG/VIAL;0.01MG/V IAL;0.14MG/VIAL;17MG/VIAL; 0.2MG/VIAL;1MG/VIAL;1.4MG/ VIAL;EQ 1.2MG BASE/VIAL;0.7MG/VIAL;7MG/V IAL	N18920 001	SEP 21, 2000	OCT	CAHN
			ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E						
			INJECTABLE; INJECTION						
			M.V.I.-12						
>D>	AP	+	ASTRAZENECA	10MG/ML;0.006MG/ML;0.5UGM/ ML;1.5MG/ML;20 IU/ML;0.04MG/ML;4MG/ML;0.4 MG/ML;0.36MG/ML;0.3MG/ML;3 30 UNITS/ML;1 IU/ML	N08809 004	AUG 08, 1985	OCT	CAHN
>A>	AP	+	NEOSAN PHARMS	10MG/ML;0.006MG/ML;0.5UGM/ ML;1.5MG/ML;20 IU/ML;0.04MG/ML;4MG/ML;0.4 MG/ML;0.36MG/ML;0.3MG/ML;3 30 UNITS/ML;1 IU/ML	N08809 004	AUG 08, 1985	OCT	CAHN
			MVC PLUS						
			@ STERIS	10MG/ML;0.006MG/ML;0.5UGM/ ML;1.5MG/ML;20 IU/ML;0.04MG/ML;4MG/ML;0.4 MG/ML;0.36MG/ML;0.3MG/ML;3 30 UNITS/ML;1 IU/ML	N18439 002	AUG 08, 1985	SEP	DISC
			ASPIRIN; BUTALBITAL; CAFFEINE						
			TABLET; ORAL						
			LANORINAL						
			@ LANNETT	325MG;50MG;40MG	N86986 002	OCT 18, 1985	JUL	DISC	
			ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE						
			TABLET; ORAL						
			INVAGESIC						
	AB		GENEVA PHARMS TECH	385MG;30MG;25MG	N74817 001	NOV 27, 1996	JAN	CAHN	
			INVAGESIC FORTE						
	AB		GENEVA PHARMS TECH	770MG;60MG;50MG	N74817 002	NOV 27, 1996	JAN	CAHN	

		ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE						
		CAPSULE; ORAL						
		PROPOXYPHENE COMPOUND 65						
		@ EON	389MG;32.4MG;65MG	N80044	002	SEP 16, 1983	MAY	DISC
		PROPOXYPHENE COMPOUND-65						
		@ GENEVA PHARMS	389MG;32.4MG;65MG	N83101	002	JUN 24, 1985	MAY	DISC
		ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE						
		TABLET; ORAL						
>D>		ROXIPRIN						
>D>	AA	ROXANE	325MG;4.5MG;0.38MG	N87743	001	JUN 04, 1982	OCT	DISC
>A>		@	325MG;4.5MG;0.38MG	N87743	001	JUN 04, 1982	OCT	DISC
		ATENOLOL						
		TABLET; ORAL						
		ATENOLOL						
		@ GENPHARM	25MG	N74126	003	AUG 26, 1998	JUL	DISC
		@	50MG	N74126	001	MAR 23, 1994	JUL	DISC
		@	100MG	N74126	002	MAR 23, 1994	JUL	DISC
		ATORVASTATIN CALCIUM						
		TABLET; ORAL						
		LIPITOR						
		PFIZER	EQ 10MG BASE	N20702	001	DEC 17, 1996	MAR	CAHN
			EQ 20MG BASE	N20702	002	DEC 17, 1996	MAR	CAHN
			EQ 40MG BASE	N20702	003	DEC 17, 1996	MAR	CAHN
		+	EQ 80MG BASE	N20702	004	APR 07, 2000	MAR	CAHN
		ATROPINE SULFATE						
		INJECTABLE; IM-IV-SC						
		ATROPINE SULFATE ANSYR PLASTIC SYRINGE						
		ABBOTT	0.05MG/ML	N21146	002	JUL 09, 2001	JUL	NEWA
		+	0.1MG/ML	N21146	001	JUL 09, 2001	JUL	NEWA
		ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE						
		TABLET; ORAL						
		DIPHENOXYLATE HCL AND ATROPINE SULFATE						
		@ INWOOD LABS	0.025MG;2.5MG	N85509	001	MAR 09, 1978	FEB	WDRP
	AA	LANNETT	0.025MG;2.5MG	N85372	001	FEB 21, 1978	AUG	CMFD
		@ R AND S PHARMA	0.025MG;2.5MG	N85035	001	JUL 05, 1977	MAY	DISC
		@ WEST WARD	0.025MG;2.5MG	N87765	001	MAR 15, 1982	JUL	DISC
		DIPHENOXYLATE HCL W/ ATROPINE SULFATE						
	AA	EON	0.025MG;2.5MG	N86173	001	AUG 28, 1981	AUG	CMFD
		@ PVT FORM	0.025MG;2.5MG	N85766	001	DEC 22, 1978	MAY	DISC
		AURANOFIN						
		CAPSULE; ORAL						
		RIDAURA						
	+	PROMETHEUS LABS	3MG	N18689	001	MAY 24, 1985	MAY	CAHN

AZATHIOPRINE
TABLET; ORAL
IMURAN

	@ PROMETHEUS LABS	25MG	N16324 002	MAR 21, 1980	MAY	CAHN
AB +		50MG	N16324 001	MAR 20, 1968	MAY	CAHN

AZELASTINE HYDROCHLORIDE
SPRAY, METERED; NASAL
ASTELIN

>D>	+ WALLACE LABS	EQ 0.125MG BASE/SPRAY	N20114 001	NOV 01, 1996	OCT	CAHN
>A>	+ WALLACE PHARMS	EQ 0.125MG BASE/SPRAY	N20114 001	NOV 01, 1996	OCT	CAHN

AZITHROMYCIN DIHYDRATE; TROVAFLOXACIN MESYLATE
FOR SUSPENSION; TABLET; ORAL
TROVAN/ZITHROMAX COMPLIANCE PAK

	@ PFIZER	EQ 1GM BASE;EQ 100MG BASE	N50762 001	DEC 18, 1998	MAY	DISC

BACITRACIN ZINC
POWDER; FOR RX COMPOUNDING
ZIBA-RX

	@ PHARMA TEK	500,000 UNITS/BOT	N61737 001	APR 26, 1973	MAY	DISC

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
OINTMENT; OPHTHALMIC
NEO-POLYCIN

	@ DOW PHARM	500 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N60647 001	APR 19, 1954	FEB	WDRP

BENDROFLUMETHIAZIDE; NADOLOL
TABLET; ORAL
CORZIDE

	KING PHARMS	5MG;40MG	N18647 001	MAY 25, 1983	AUG	CAHN
+		5MG;80MG	N18647 002	MAY 25, 1983	AUG	CAHN

BENZQUINAMIDE HYDROCHLORIDE
INJECTABLE; INJECTION
EMETE-CON

+	PFIZER	EQ 50MG BASE/VIAL	N16820 001	MAR 20, 1974	MAY	CAHN

BETAMETHASONE DIPROPIONATE
CREAM; TOPICAL
BETAMETHASONE DIPROPIONATE

	@ CLAY PARK	EQ 0.05% BASE	N74579 001	NOV 26, 1997	APR	DISC

DISC; TOPICAL
DIPROSONE

	@ SCHERING	EQ 0.1% BASE	N17829 001	MAY 24, 1977	AUG	DISC

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE
CREAM; TOPICAL
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

AB	ALTANA	EQ 0.05% BASE;1%	N75502 001	JUN 05, 2001	JUN	NEWA
AB	TARO	EQ 0.05% BASE;1%	N75673 001	MAY 29, 2001	MAY	NEWA

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

CREAM; TOPICAL

LOTRISONE

AB	+	SCHERING	EQ 0.05% BASE;1%	N18827 001	JUL 10, 1984	MAY	CFTG

BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

BETAXOLOL HCL

AT		BAUSCH AND LOMB	EQ 0.5% BASE	N75630 001	APR 12, 2001	APR	NEWA

BETHANECHOL CHLORIDE

INJECTABLE; INJECTION

URECHOLINE

	@	SIDMAK LABS	5MG/ML	N06536 001	OCT 12, 1948	AUG	CAHN

TABLET; ORAL

DUVOID

	@	WELLSPRING PHARM	10MG	N86262 001	MAR 22, 1978	JUN	CAHN
	@		25MG	N86263 001	MAR 22, 1978	JUN	CAHN
	@		50MG	N85882 003	MAR 22, 1978	JUN	CAHN

URECHOLINE

	@	SIDMAK LABS	5MG	N06536 003	FEB 03, 1949	AUG	CAHN
	@		10MG	N06536 002	OCT 12, 1948	AUG	CAHN
	@		25MG	N06536 004	OCT 12, 1948	AUG	CAHN
	@		50MG	N06536 005	JUN 24, 1980	AUG	CAHN

BIMATOPROST

SOLUTION/DROPS; OPHTHALMIC

LUMIGAN

	+	ALLERGAN	0.03%	N21275 001	MAR 16, 2001	MAR	NEWA

BISMUTH SUBSALICYLATE; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE

TABLET, CHEWABLE, TABLET, CAPSULE; ORAL

HELIDAC

	+	PROMETHEUS LABS	262.4MG;250MG;500MG	N50719 001	AUG 15, 1996	MAY	DISC

BISOPROLOL FUMARATE

TABLET; ORAL

BISOPROLOL FUMARATE

AB		COPLEY PHARM	5MG	N75644 001	JUN 26, 2001	JUN	NEWA
AB			10MG	N75644 002	JUN 26, 2001	JUN	NEWA

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

	@	APOTHECON	2.5MG;6.25MG	N75642 002	DEC 27, 2000	JUN	DISC
	@		5MG;6.25MG	N75642 001	DEC 27, 2000	JUN	DISC
	@		10MG;6.25MG	N75642 003	DEC 27, 2000	JUN	DISC
AB		TEVA	2.5MG;6.25MG	N75686 001	JAN 19, 2001	JAN	NEWA
AB			5MG;6.25MG	N75686 002	JAN 19, 2001	JAN	NEWA
AB			10MG;6.25MG	N75686 003	JAN 19, 2001	JAN	NEWA

BLEOMYCIN SULFATE
INJECTABLE; INJECTION
BLEOMYCIN

>A>	AP	BEDFORD	EQ 15 UNITS BASE/VIAL	N65042 002	OCT 17, 2001	OCT	NEWA
>A>	AP		EQ 30 UNITS BASE/VIAL	N65042 001	OCT 17, 2001	OCT	NEWA

BRIMONIDINE TARTRATE
SOLUTION/DROPS; OPHTHALMIC
ALPHAGAN

		@ ALLERGAN	0.5%	N20490 001	MAR 13, 1997	APR	DISC

ALPHAGAN P

	+	ALLERGAN	0.15%	N21262 001	MAR 16, 2001	MAR	NEWA

BUDESONIDE
CAPSULE; ORAL
ENTOCORT EC

>A>	+	ASTRAZENECA	3MG	N21324 001	OCT 02, 2001	OCT	NEWA

BUPIVACAINE HYDROCHLORIDE
INJECTABLE; SPINAL
MARCAINE

AP	+	ABBOTT	0.75%	N18692 001	MAY 04, 1984	JUN	CAHN

BUPRENORPHINE HYDROCHLORIDE
INJECTABLE; INJECTION
BUPRENEX

AP	+	RECKITT BENCKISER	EQ 0.3MG BASE/ML	N18401 001	DEC 29, 1981	JUL	CAHN

BUPROPION HYDROCHLORIDE
TABLET, EXTENDED RELEASE; ORAL
WELLBUTRIN SR

		GLAXO WELLCOME	50MG	N20358 001	OCT 04, 1996	APR	CTEC
			100MG	N20358 002	OCT 04, 1996	APR	CTEC

BUSPIRONE HYDROCHLORIDE
TABLET; ORAL
BUSPAR

AB		BRISTOL MYERS SQUIBB	5MG	N18731 001	SEP 29, 1986	MAR	CFTG
AB			10MG	N18731 002	SEP 29, 1986	MAR	CFTG
AB			15MG	N18731 003	APR 22, 1996	MAR	NEWA
AB	+		30MG	N18731 004	APR 22, 1996	JUN	CFTG

BUSPIRONE HCL

AB		DANBURY PHARMA	5MG	N74253 001	MAR 28, 2001	MAR	NEWA
AB			10MG	N74253 002	MAR 28, 2001	MAR	NEWA
AB		MYLAN	15MG	N75272 003	MAR 28, 2001	MAR	NEWA
AB		MYLAN TECHNOLOGIES	30MG	N76008 001	JUN 28, 2001	JUN	NEWA
AB		PAR PHARM	7.5MG	N75467 002	MAR 28, 2001	MAR	NEWA

BUTABARBITAL SODIUM
TABLET; ORAL
BUTISOL SODIUM

	+	WALLACE LABS	15MG	N00793 002	JUN 05, 1939	MAY	CTEC

		BUTABARBITAL SODIUM						
		TABLET; ORAL						
		SODIUM BUTABARBITAL						
		@ LANNETT	15MG	N85849 001	AUG 21, 1978	MAY	DISC	
		@	30MG	N85866 001	JUL 20, 1978	MAY	DISC	
		BUTOCONAZOLE NITRATE						
		CREAM; VAGINAL						
		GYNAZOLE-1						
	+	KV PHARM	2%	N19881 001	FEB 07, 1997	SEP	CTNA	
		BUTORPHANOL TARTRATE						
		INJECTABLE; INJECTION						
		BUTORPHANOL TARTRATE						
>A>	AP		2MG/ML	N75697 001	OCT 23, 2001	OCT	NEWA	
		BUTORPHANOL TARTRATE PRESERVATIVE FREE						
>A>	AP	APOTEX	1MG/ML	N75695 001	OCT 23, 2001	OCT	NEWA	
>A>	AP		2MG/ML	N75695 002	OCT 23, 2001	OCT	NEWA	
		SPRAY, METERED; NASAL						
	AB	MYLAN	1MG/SPRAY	N75759 001	AUG 08, 2001	AUG	NEWA	
		STADOL						
	AB +	BRISTOL MYERS SQUIBB	1MG/SPRAY	N19890 001	DEC 12, 1991	AUG	CFTG	
		CALCITONIN, SALMON						
		INJECTABLE; INJECTION						
		CALCITONIN-SALMON						
		@ ASTRAZENECA	200 IU/ML	N73690 001	APR 14, 1995	JUN	DISC	
		CALCITRIOL						
		CAPSULE; ORAL						
>A>		CALCITRIOL						
>A>	AB	TEVA	0.25UGM	N75765 001	OCT 12, 2001	OCT	NEWA	
>A>	AB		0.5UGM	N75765 002	OCT 12, 2001	OCT	NEWA	
		ROCALTROL						
>D>		ROCHE	0.25UGM	N18044 001	AUG 17, 1978	OCT	CFTG	
>A>	AB		0.25UGM	N18044 001	AUG 17, 1978	OCT	CFTG	
>D>	+		0.5UGM	N18044 002	AUG 17, 1978	OCT	CFTG	
>A>	AB +		0.5UGM	N18044 002	AUG 17, 1978	OCT	CFTG	
		CALCIUM ACETATE						
		CAPSULE; ORAL						
		PHOSLO						
		BRAINTREE	EQ 84.5MG CALCIUM	N21160 001	APR 02, 2001	APR	NEWA	
		@	EQ 84.5MG CALCIUM	N21160 001	APR 02, 2001	AUG	DISC	
	+		EQ 169MG CALCIUM	N21160 002	APR 02, 2001	APR	NEWA	
	+ @		EQ 169MG CALCIUM	N21160 002	APR 02, 2001	AUG	DISC	
		PHOSLO GELCAPS						
	+	BRAINTREE	EQ 169MG CALCIUM	N21160 003	APR 02, 2001	AUG	NEWA	
		CAPTOPRIL						
		TABLET; ORAL						
		CAPTOPRIL						
	AB	GENEVA PHARMS TECH	12.5MG	N74481 001	FEB 13, 1996	JAN	CAHN	
	AB		25MG	N74481 002	FEB 13, 1996	JAN	CAHN	

AB		50MG	N74481 003	FEB 13, 1996	JAN	CAHN
AB		100MG	N74481 004	FEB 13, 1996	JAN	CAHN
	CARBACHOL					
	SOLUTION; INTRAOCULAR					
	CARBASTAT					
AT	NOVARTIS	0.01%	N73677 001	APR 28, 1995	FEB	CAHN
	CARBAMAZEPINE					
	TABLET, CHEWABLE; ORAL					
	CARBAMAZEPINE					
AB	CARACO	100MG	N75712 001	JUL 05, 2001	JUL	NEWA
	TABLET, EXTENDED RELEASE; ORAL					
	TEGRETOL-XR					
	NOVARTIS	100MG	N20234 001	MAR 25, 1996	JUL	CRLD
		200MG	N20234 002	MAR 25, 1996	JUL	CRLD
	CARBIDOPA; LEVODOPA					
	TABLET; ORAL					
	CARBIDOPA AND LEVODOPA					
	@ SCS	10MG;100MG	N74080 001	MAR 25, 1994	FEB	WDRP
	@	25MG;100MG	N74080 002	MAR 25, 1994	FEB	WDRP
	@	25MG;250MG	N74080 003	MAR 25, 1994	FEB	WDRP
	CARISOPRODOL					
	TABLET; ORAL					
	CARISOPRODOL					
AA	ABLE	350MG	N40421 001	JUN 21, 2001	JUN	NEWA
	CASPOFUNGIN ACETATE					
	INJECTABLE; IV (INFUSION)					
	CANCIDAS					
+	MERCK RES	50MG/VIAL	N21227 001	JAN 26, 2001	JAN	NEWA
+		70MG/VIAL	N21227 002	JAN 26, 2001	JAN	NEWA
	CEFACLOR					
	CAPSULE; ORAL					
	CECLOR					
AB	CEPH INTL	EQ 250MG BASE	N62205 001	JUL 28, 1979	JUN	CAHN
AB		EQ 500MG BASE	N62205 002	JUL 28, 1979	JUN	CAHN
	FOR SUSPENSION; ORAL					
	CEFACLOR					
	@ ZENITH GOLDLINE	EQ 125MG BASE/5ML	N64087 001	APR 28, 1995	MAY	DISC
	@	EQ 187MG BASE/5ML	N64086 001	APR 28, 1995	MAY	DISC
	@	EQ 250MG BASE/5ML	N64085 001	APR 28, 1995	MAY	DISC
	TABLET, EXTENDED RELEASE; ORAL					
	CECLOR CD					
	LILLY	EQ 375MG BASE	N50673 001	JUN 28, 1996	APR	CTEC
AB +		EQ 500MG BASE	N50673 002	JUN 28, 1996	JAN	CFTG
	CEFACLOR					
AB	ZENITH GOLDLINE	EQ 500MG BASE	N65057 001	JAN 05, 2001	JAN	NEWA

CEFADROXIL/CEFADROXIL HEMIHYDRATE
TABLET; ORAL
CEFADROXIL
@ ZENITH GOLDLINE — EQ 1GM BASE — N62774 001 APR 08, 1987 MAY DISC

CEFAMANDOLE NAFATE
INJECTABLE; INJECTION
MANDOL
@ LILLY — EQ 1GM BASE/VIAL — N62560 001 SEP 10, 1985 MAY DISC
@ — EQ 2GM BASE/VIAL — N62560 002 SEP 10, 1985 MAY DISC

CEFAZOLIN SODIUM
INJECTABLE; INJECTION
CEFAZOLIN SODIUM
AP HIKMA — EQ 500MG BASE/VIAL — N65047 001 SEP 18, 2001 SEP NEWA
AP — EQ 1GM BASE/VIAL — N65047 002 SEP 18, 2001 SEP NEWA
@ TEVA — EQ 250MG BASE/VIAL — N63016 001 MAR 14, 1989 APR DISC
@ — EQ 500MG BASE/VIAL — N63016 002 MAR 14, 1989 APR DISC
@ — EQ 1GM BASE/VIAL — N63016 003 MAR 14, 1989 APR DISC
KEFZOL
@ LILLY — EQ 500MG BASE/VIAL — N62557 001 SEP 10, 1985 MAY DISC
@ — EQ 1GM BASE/VIAL — N62557 002 SEP 10, 1985 MAY DISC

CEFDITOREN PIVOXIL
TABLET; ORAL
SPECTRACEF
+ TAP PHARM — 200MG — N21222 001 AUG 29, 2001 AUG NEWA

CEFONICID SODIUM
INJECTABLE; INJECTION
MONOCID
+ @ SMITHKLINE BEECHAM — EQ 500MG BASE/VIAL — N50579 001 MAY 23, 1984 AUG DISC
+ @ — EQ 1GM BASE/VIAL — N50579 002 MAY 23, 1984 AUG DISC
@ — EQ 1GM BASE/VIAL — N63295 001 JUL 26, 1993 APR DISC
@ — EQ 10GM BASE/VIAL — N50579 004 MAY 23, 1984 AUG DISC

CEFOPERAZONE SODIUM
INJECTABLE; INJECTION
CEFOBID
@ PFIZER — EQ 1GM BASE/VIAL — N63333 001 MAR 31, 1995 MAY DISC
@ — EQ 2GM BASE/VIAL — N63333 002 MAR 31, 1995 MAY DISC

CEFORANIDE
INJECTABLE; INJECTION
PRECEF
@ APOTHECON — 500MG/VIAL — N62579 001 NOV 26, 1984 MAY DISC
@ — 1GM/VIAL — N62579 002 NOV 26, 1984 MAY DISC
@ — 2GM/VIAL — N62579 003 NOV 26, 1984 MAY DISC
@ — 10GM/VIAL — N62579 004 NOV 26, 1984 MAY DISC
@ — 20GM/VIAL — N62579 005 NOV 26, 1984 MAY DISC

CEFOXITIN SODIUM
INJECTABLE; INJECTION
MEFOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER

	@ MERCK	EQ 20MG BASE/ML	N50581 003	SEP 20, 1984	JUL	DISC	
	@	EQ 40MG BASE/ML	N50581 004	SEP 20, 1984	JUL	DISC	

CEFTAZIDIME
INJECTABLE; INJECTION
TAZICEF

AP	ABBOTT	500MG/VIAL	N62662 001	MAR 06, 1986	JAN	CAHN	
AP		1GM/VIAL	N62662 002	MAR 06, 1986	JAN	CAHN	
AP		1GM/VIAL	N64032 001	OCT 31, 1993	JAN	CAHN	
AP		2GM/VIAL	N62662 003	MAR 06, 1986	JAN	CAHN	
AP		2GM/VIAL	N64032 002	OCT 31, 1993	JAN	CAHN	
AP		6GM/VIAL	N62662 004	MAR 06, 1986	JAN	CAHN	

TAZIDIME IN PLASTIC CONTAINER

	@ LILLY	1GM/VIAL	N62739 001	JUL 10, 1986	MAY	DISC	
	@	2GM/VIAL	N62739 002	JUL 10, 1986	MAY	DISC	

CEFUROXIME SODIUM
INJECTABLE; IM-IV
CEFUROXIME

AB	AM PHARM PARTNERS	EQ 750MG BASE/VIAL	N65001 001	MAY 30, 2001	MAY	NEWA	
AB	TEVA	EQ 750MG BASE/VIAL	N64192 002	APR 16, 1998	MAY	CDFR	

CEFUROXIME SODIUM

AB	HANFORD GC	EQ 750MG BASE/VIAL	N64125 001	MAY 30, 1997	MAY	CDFR	

KEFUROX

AB	LILLY	EQ 750MG BASE/VIAL	N62591 001	JAN 10, 1986	MAY	CDFR	

ZINACEF

AB	+ GLAXO WELLCOME	EQ 750MG BASE/VIAL	N50558 002	OCT 19, 1983	MAY	CDFR	

INJECTABLE; INJECTION
CEFUROXIME

AP	AM PHARM PARTNERS	EQ 1.5GM BASE/VIAL	N65001 002	MAY 30, 2001	MAY	NEWA	

CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER

	+ B BRAUN	EQ 15MG BASE/ML	N50780 001	FEB 21, 2001	FEB	NEWA	
	+	EQ 30MG BASE/ML	N50780 002	FEB 21, 2001	FEB	NEWA	

KEFUROX IN PLASTIC CONTAINER

	@ LILLY	EQ 1.5GM BASE/VIAL	N62590 002	JAN 10, 1986	MAY	DISC	

INJECTABLE; INTRAVENOUS

	@ LILLY	EQ 750MG BASE/VIAL	N62590 001	JAN 10, 1986	MAY	DISC	

CEPHALEXIN
CAPSULE; ORAL
CEPHALEXIN

	@ STEVENS J	EQ 500MG BASE	N62869 001	MAR 17, 1988	JUL	DISC	
	@ TEVA	EQ 500MG BASE	N62823 001	FEB 05, 1988	MAY	DISC	

KEFLEX

AB	CEPH INTL	EQ 250MG BASE	N62118 001	MAR 27, 1978	JUN	CAHN	
AB		EQ 500MG BASE	N62118 002	MAR 27, 1978	JUN	CAHN	

FOR SUSPENSION; ORAL
CEPHALEXIN

	@ BARR	EQ 125MG BASE/5ML	N62778 001	AUG 06, 1987	MAY	DISC	

AB	RANBAXY	EQ 125MG BASE/5ML	N65081 001	JUL 27, 2001	JUL	NEWA
AB		EQ 250MG BASE/5ML	N65081 002	JUL 27, 2001	JUL	NEWA
	KEFLEX					
	+ CEPH INTL	EQ 100MG BASE/ML	N62117 001	MAR 27, 1978	JUN	CAHN
AB		EQ 125MG BASE/5ML	N62117 002	MAR 27, 1978	JUN	CAHN
AB	+	EQ 250MG BASE/5ML	N62117 003	MAR 27, 1978	JUN	CAHN
	TABLET; ORAL					
	KEFLET					
	@ LILLY	EQ 250MG BASE	N62745 001	DEC 01, 1986	JUL	DISC
	@	EQ 500MG BASE	N62745 002	DEC 01, 1986	JUL	DISC
	CEPHALOTHIN SODIUM					
	INJECTABLE; INJECTION					
	KEFLIN IN PLASTIC CONTAINER					
	@ LILLY	EQ 1GM BASE/VIAL	N62549 001	SEP 10, 1985	APR	DISC
	@	EQ 2GM BASE/VIAL	N62549 002	SEP 10, 1985	APR	DISC
	CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE					
	TABLET, EXTENDED RELEASE; ORAL					
	ZYRTEC-D 12 HOUR					
	+ PFIZER	5MG;120MG	N21150 001	AUG 10, 2001	AUG	NEWA
	CHLORAMPHENICOL					
	CAPSULE; ORAL					
	CHLORAMPHENICOL					
	@ ZENITH GOLDLINE	250MG	N62247 001	APR 28, 1980	MAY	DISC
	CHLOROMYCETIN					
	@ PARKEDALE	50MG	N60591 001	DEC 08, 1950	MAY	DISC
	@	100MG	N60591 003	DEC 08, 1950	MAY	DISC
	@	250MG	N60591 002	DEC 08, 1950	MAY	DISC
	MYCHEL					
	+ ARMENPHARM	250MG	N60851 001	JUN 20, 1967	MAY	CRLD
	SOLUTION/DROPS; OPHTHALMIC					
	CHLORAMPHENICOL					
	@ AKORN	0.5%	N62042 001	AUG 31, 1981	FEB	WDRP
	@ ALCON	0.5%	N62628 001	SEP 25, 1985	MAY	DISC
	CHLOROPTIC					
	+ ALLERGAN	0.5%	N50091 001	MAR 20, 1968	MAY	CTEC
	CHLORDIAZEPOXIDE HYDROCHLORIDE					
	CAPSULE; ORAL					
	CHLORDIAZACHEL					
	@ RACHELLE	5MG	N85086 001	MAY 11, 1976	FEB	WDRP
	@	10MG	N84639 001	MAY 11, 1976	FEB	WDRP
	@	25MG	N85087 001	MAY 11, 1976	FEB	WDRP
	CHLORDIAZEPOXIDE HCL					
	@ FERRANTE	5MG	N85118 001	SEP 02, 1981	FEB	WDRP
	@	10MG	N85119 001	SEP 02, 1976	FEB	WDRP
	@	25MG	N85120 001	SEP 02, 1976	FEB	WDRP
	@ GENEVA PHARMS	5MG	N84678 001	JUN 15, 1976	JUL	DISC
	@	10MG	N84041 001	JUN 15, 1976	MAY	DISC
	@	25MG	N84679 002	SEP 07, 1976	MAY	DISC
	@ IMPAX LABS	5MG	N86213 001	JUL 10, 1979	JUL	DISC

@	25MG	N86212 001	JUL 10, 1979	JUL	DISC
@ ROSEMONT	5MG	N84644 001	FEB 24, 1976	MAY	DISC
@	25MG	N84645 001	FEB 24, 1976	JUL	DISC

CHLOROQUINE PHOSPHATE
TABLET; ORAL
CHLOROQUINE PHOSPHATE

@ TEVA	EQ 150MG BASE	N87504 001	JAN 13, 1982	JUL	DISC

CHLOROTHIAZIDE
TABLET; ORAL
CHLOROTHIAZIDE

@ ABC HOLDING	250MG	N85569 001	MAR 08, 1978	MAY	DISC
@ CHELSEA LABS	250MG	N86795 001	AUG 15, 1983	JUL	DISC
@ DANBURY PHARMA	250MG	N85173 001	NOV 04, 1977	MAY	DISC

CHLORPHENIRAMINE MALEATE
INJECTABLE; INJECTION
CHLORPHENIRAMINE MALEATE

@ STERIS	10MG/ML	N86096 001	OCT 09, 1979	JUL	DISC

TABLET; ORAL

@ GENEVA PHARMS	4MG	N80961 001	DEC 20, 1972	MAY	DISC
AA + ICN	4MG	N80598 001	FEB 11, 1972	MAY	CRLD
@ PHARMAVITE	4MG	N85104 001	FEB 11, 1977	FEB	WDRP
@ WEST WARD	4MG	N83787 001	OCT 18, 1973	FEB	WDRP

CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE
CAPSULE, EXTENDED RELEASE; ORAL
CHLORPHENIRAMINE MALEATE AND PHENYLPROPANOLAMINE HCL

@ GENEVA PHARMS	12MG;75MG	N88940 001	JAN 26, 1989	SEP	DISC

DRIZE

@ ASCHER	12MG;75MG	N88359 001	FEB 13, 1986	SEP	DISC

ORNADE

@ SMITHKLINE BEECHAM	12MG;75MG	N12152 004	JAN 06, 1981	SEP	DISC

CHLORPROMAZINE HYDROCHLORIDE
INJECTABLE; INJECTION
CHLORPROMAZINE HCL

@ STERIS	25MG/ML	N80365 001	FEB 13, 1974	MAY	DISC

CHLORTHALIDONE
TABLET; ORAL
CHLORTHALIDONE

@ GENEVA PHARMS	25MG	N87380 001	MAY 01, 1981	JUL	DISC

CHLORZOXAZONE
TABLET; ORAL
CHLORZOXAZONE

@ DANBURY PHARMA	500MG	N81019 001	JUL 29, 1991	MAY	DISC

CIMETIDINE

TABLET; ORAL

CIMETIDINE

AB	GENEVA PHARMS TECH	200MG	N74506 001	JAN 24, 1996	JAN	CAHN
AB		300MG	N74506 002	JAN 24, 1996	JAN	CAHN
AB		400MG	N74506 003	JAN 24, 1996	JAN	CAHN
AB		800MG	N74506 004	JAN 24, 1996	JAN	CAHN

CINOXACIN

CAPSULE; ORAL

CINOBAC

	LILLY	250MG	N18067 001	JUN 13, 1980	JUL	CTEC
+		500MG	N18067 002	JUN 13, 1980	JUL	CTEC

CINOXACIN

	@ TEVA	250MG	N73005 001	FEB 28, 1992	JUL	DISC
	@	500MG	N73006 001	FEB 28, 1992	JUL	DISC

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL

CLEOCIN HCL

AB +	PHARMACIA AND UPJOHN	EQ 300MG BASE	N50162 003	APR 14, 1988	FEB	CFTG

CLINDAMYCIN HCL

AB	RANBAXY	EQ 150MG BASE	N65061 001	FEB 02, 2001	FEB	NEWA
AB		EQ 300MG BASE	N65061 002	FEB 02, 2001	FEB	NEWA

CLINDAMYCIN PHOSPHATE

GEL; TOPICAL

CLINDAMYCIN PHOSPHATE

BT	GALDERMA LABS LP	EQ 1% BASE	N50782 001	NOV 27, 2000	SEP	CAHN

INJECTABLE; INJECTION

CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP +	PHARMACIA AND UPJOHN	EQ 18MG BASE/ML	N50639 003	APR 10, 1991	JUN	CFTG

CLINDAMYCIN PHOSPHATE

	@ ABBOTT	EQ 150MG BASE/ML	N62943 001	SEP 29, 1988	MAY	DISC
	@ ELKINS SINN	EQ 150MG BASE/ML	N62806 001	OCT 15, 1987	MAY	DISC
	@	EQ 150MG BASE/ML	N62953 001	APR 21, 1988	MAY	DISC
	@ GENSIA SICOR PHARMS	EQ 150MG BASE/ML	N63041 001	DEC 29, 1989	APR	DISC
	@	EQ 150MG BASE/ML	N63282 001	MAY 29, 1992	APR	DISC
	@ LEDERLE	EQ 150MG BASE/ML	N63068 001	AUG 28, 1989	MAY	DISC

CLINDAMYCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	ABBOTT	EQ 6MG BASE/ML	N65027 001	JUN 29, 2001	JUN	NEWA
AP		EQ 12MG BASE/ML	N65027 002	JUN 29, 2001	JUN	NEWA
AP		EQ 18MG BASE/ML	N65027 003	JUN 29, 2001	JUN	NEWA

SOLUTION; TOPICAL

CLINDAMYCIN PHOSPHATE

	@ COPLEY PHARM	EQ 1% BASE	N62944 001	JAN 11, 1989	MAY	DISC
	@ TEVA	EQ 1% BASE	N62930 001	JUN 28, 1989	MAY	DISC

CLOBETASOL PROPIONATE

CREAM; TOPICAL

CLOBETASOL PROPIONATE

AB1	STIEFEL	0.05%	N75338 001	FEB 09, 2001	FEB	NEWA

AB2		0.05%	N75733 001	AUG 22, 2001	AUG	NEWA

CLOMIPRAMINE HYDROCHLORIDE
CAPSULE; ORAL
ANAFRANIL

AB	TYCO HLTHCARE	25MG	N19906 001	DEC 29, 1989	JUN	CAHN
AB +		50MG	N19906 002	DEC 29, 1989	JUN	CAHN
AB		75MG	N19906 003	DEC 29, 1989	JUN	CAHN

CLONAZEPAM
TABLET; ORAL
CLONAZEPAM

AB	CARACO	0.5MG	N75423 001	APR 27, 2001	APR	NEWA
AB		1MG	N75423 002	APR 27, 2001	APR	NEWA
AB		2MG	N75423 003	APR 27, 2001	APR	NEWA

CLONIDINE HYDROCHLORIDE
INJECTABLE; INJECTION
DURACLON

+	ELAN PHARMS	0.1MG/ML	N20615 001	OCT 02, 1996	SEP	CAHN

CLORAZEPATE DIPOTASSIUM
CAPSULE; ORAL
CLORAZEPATE DIPOTASSIUM

@ ABLE		3.75MG	N71777 001	JUL 14, 1987	JAN	DISC
@		7.5MG	N71778 001	JUL 14, 1987	JAN	DISC
@		15MG	N71779 001	JUL 14, 1987	JAN	DISC

TABLET; ORAL

@ GENEVA PHARMS		3.75MG	N72512 001	MAY 11, 1990	JUL	DISC

COLCHICINE; PROBENECID
TABLET; ORAL
PROBENECID AND COLCHICINE

>D>	BP	IMPAX LABS	0.5MG;500MG	N83720 002	SEP 06, 1977	OCT	DISC
>A>		@	0.5MG;500MG	N83720 002	SEP 06, 1977	OCT	DISC

CORTICOTROPIN
INJECTABLE; INJECTION
H.P. ACTHAR GEL

BC +	QUESTCOR PHARMS	40 UNITS/ML	N08372 006	FEB 06, 1956	AUG	CAHN
BC +		80 UNITS/ML	N08372 008	FEB 06, 1956	AUG	CAHN

CORTISONE ACETATE
TABLET; ORAL
CORTISONE ACETATE

@ CHELSEA LABS		25MG	N85884 001	MAY 15, 1978	MAY	DISC

CROMOLYN SODIUM
AEROSOL, METERED; INHALATION
INTAL

+	AVENTIS	0.8MG/INH	N18887 001	DEC 05, 1985	SEP	CAHN

SOLUTION/DROPS; OPHTHALMIC
CROMOLYN SODIUM

CROMOLYN SODIUM
SOLUTION/DROPS; OPHTHALMIC
CROMOLYN SODIUM
AT NOVEX 4% N75615 001 JAN 26, 2001 JAN NEWA

CYCLACILLIN
TABLET; ORAL
CYCLACILLIN
@ TEVA 250MG N62895 001 AUG 04, 1988 MAY DISC
@ 500MG N62895 002 AUG 04, 1988 MAY DISC

CYPROHEPTADINE HYDROCHLORIDE
TABLET; ORAL
CYPROHEPTADINE HCL
@ GENEVA PHARMS 4MG N86808 001 FEB 24, 1981 JUL DISC

DACARBAZINE
INJECTABLE; INJECTION
DACARBAZINE
AP BEDFORD 200MG/VIAL N75812 001 JUN 15, 2001 JUN NEWA
>A> AP FAULDING 200MG/VIAL N75940 001 OCT 18, 2001 OCT NEWA

DELAVIRDINE MESYLATE
TABLET; ORAL
RESCRIPTOR
AGOURON 100MG N20705 001 APR 04, 1997 AUG CRLD
+ 200MG N20705 002 JUL 14, 1999 AUG NEWA

DESERPIDINE; HYDROCHLOROTHIAZIDE
TABLET; ORAL
ORETICYL 25
@ ABBOTT 0.125MG;25MG N12148 001 DEC 14, 1959 MAR DISC
ORETICYL 50
@ ABBOTT 0.125MG;50MG N12148 003 DEC 14, 1959 MAR DISC
ORETICYL FORTE
@ ABBOTT 0.25MG;25MG N12148 002 DEC 14, 1959 MAR DISC

DESONIDE
OINTMENT; TOPICAL
DESONIDE
AB ALTANA 0.05% N75751 001 MAR 12, 2001 MAR NEWA

DEXAMETHASONE
TABLET; ORAL
DEXAMETHASONE
@ DANBURY PHARMA 0.75MG N80968 001 MAY 03, 1973 MAY DISC

DEXAMETHASONE SODIUM PHOSPHATE
INJECTABLE; INJECTION
DEXAMETHASONE SODIUM PHOSPHATE
@ DELL LABS EQ 4MG PHOSPHATE/ML N83161 001 JUN 06, 1978 FEB WDRP
@ GENSIA SICOR PHARMS EQ 4MG PHOSPHATE/ML N81125 001 AUG 31, 1990 MAY DISC
OINTMENT; OPHTHALMIC

DEXAMETHASONE SODIUM PHOSPHATE

OINTMENT; OPHTHALMIC

DECADRON

@ MERCK — EQ 0.05% PHOSPHATE — N11977 001 — SEP 02, 1959 — MAY — DISC

MAXIDEX

\+ ALCON — EQ 0.05% PHOSPHATE — N83342 001 — OCT 23, 1973 — MAY — CTEC

SOLUTION/DROPS; OTIC

DEXAMETHASONE SODIUM PHOSPHATE

@ AKORN — EQ 0.1% PHOSPHATE — N84855 001 — JUN 29, 1976 — FEB — WDRP

DEXAMETHASONE SODIUM PHOSPHATE; NEOMYCIN SULFATE

SOLUTION/DROPS; OPHTHALMIC

NEODECADRON

\+ MERCK — EQ 0.1% PHOSPHATE;EQ 3.5MG BASE/ML — N50322 001 — JUL 06, 1959 — MAY — CTEC

NEOMYCIN SULFATE-DEXAMETHASONE SODIUM PHOSPHATE

@ ALCON UNIVERSAL — EQ 0.1% PHOSPHATE;EQ 3.5MG BASE/ML — N62714 001 — JUL 21, 1986 — MAY — DISC

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

DEXACIDIN

AT NOVARTIS — 0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM — N62566 001 — FEB 22, 1985 — FEB — CAHN

@ — 0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM — N62566 001 — FEB 22, 1985 — MAY — DISC

SUSPENSION/DROPS; OPHTHALMIC

AT NOVARTIS — 0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML — N62544 001 — OCT 29, 1984 — FEB — CAHN

DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

DEXTROAMPHETAMINE SULFATE

AA BARR — 5MG — N40361 001 — JAN 31, 2001 — JAN — NEWA

AA — 10MG — N40361 002 — JAN 31, 2001 — JAN — NEWA

DEXTROSTAT

AA \+ SHIRE RICHWOOD — 10MG — N84051 002 — MAY 29, 1975 — JAN — CFTG

DIAZEPAM

GEL; RECTAL

DIASTAT

\+ XCEL PHARMS — 2.5MG/0.5ML — N20648 001 — JUL 29, 1997 — JUL — CAHN

5MG/ML — N20648 002 — JUL 29, 1997 — JUL — CAHN

10MG/2ML — N20648 003 — JUL 29, 1997 — JUL — CAHN

15MG/3ML — N20648 004 — JUL 29, 1997 — JUL — CAHN

\+ — 20MG/4ML — N20648 005 — JUL 29, 1997 — JUL — CAHN

DICLOFENAC POTASSIUM

TABLET; ORAL

DICLOFENAC POTASSIUM

AB EON — 50MG — N75582 001 — FEB 23, 2001 — FEB — NEWA

DICLOFENAC SODIUM
GEL; TOPICAL
SOLARAZE
\+ BIOGLAN PHARMA PLC 3% N21005 001 OCT 16, 2000 MAR CAHN

DICLOXACILLIN SODIUM
CAPSULE; ORAL
DYCILL
@ SMITHKLINE BEECHAM EQ 250MG BASE N62238 001 DEC 31, 1979 APR DISC
@ EQ 500MG BASE N62238 002 DEC 31, 1979 APR DISC

DICYCLOMINE HYDROCHLORIDE
CAPSULE; ORAL
DICYCLOMINE HCL
@ HALSEY 10MG N84505 001 OCT 21, 1986 MAY DISC
INJECTABLE; INJECTION
@ STERIS 10MG/ML N80614 001 FEB 11, 1986 JUL DISC

DIETHYLPROPION HYDROCHLORIDE
TABLET, EXTENDED RELEASE; ORAL
TENUATE DOSPAN
\+ AVENTIS PHARMS 75MG N12546 001 NOV 07, 1960 JUL CTEC
TEPANIL TEN-TAB
@ 3M 75MG N17956 001 MAY 25, 1977 JUL DISC

DILTIAZEM HYDROCHLORIDE
CAPSULE, EXTENDED RELEASE; ORAL
DILTIAZEM HCL
AB2 MYLAN 120MG N75124 002 MAR 18, 1998 MAR CTEC

DIPHENHYDRAMINE HYDROCHLORIDE
CAPSULE; ORAL
DIPHENHYDRAMINE HCL
@ CHELSEA LABS 50MG N85083 001 JUN 29, 1976 MAY DISC
@ NEWTRON PHARMS 25MG N86543 001 FEB 08, 1979 FEB WDRP
@ 50MG N86544 001 FEB 08, 1979 FEB WDRP
INJECTABLE; INJECTION
DIPHENHYDRAMINE HCL PRESERVATIVE FREE
@ AM PHARM PARTNERS 50MG/ML N80586 002 JAN 10, 1973 JUL DISC

DISULFIRAM
TABLET; ORAL
ANTABUSE
ODYSSEY PHARMS 250MG N88482 001 DEC 08, 1983 JAN CAHN
\+ 500MG N88483 001 DEC 08, 1983 JAN CAHN
@ SIDMAK LABS 250MG N07883 003 NOV 03, 1970 MAR CAHN
@ 500MG N07883 002 JUN 01, 1953 MAR CAHN

DOXAZOSIN MESYLATE
TABLET; ORAL
DOXAZOSIN MESYLATE
AB SIDMAK LABS EQ 1MG BASE N75750 001 JUN 08, 2001 JUN NEWA

AB		EQ 2MG BASE	N75750 002	JUN 08, 2001	JUN	NEWA
AB		EQ 4MG BASE	N75750 003	JUN 08, 2001	JUN	NEWA
AB		EQ 8MG BASE	N75750 004	JUN 08, 2001	JUN	NEWA
AB	TEVA	EQ 1MG BASE	N75353 001	JAN 12, 2001	JAN	NEWA
AB		EQ 2MG BASE	N75353 002	JAN 12, 2001	JAN	NEWA
AB		EQ 4MG BASE	N75353 003	JAN 12, 2001	JAN	NEWA
AB		EQ 8MG BASE	N75353 004	JAN 12, 2001	JAN	NEWA

DOXYCYCLINE

FOR SUSPENSION; ORAL

	DOXYCHEL					
	@ RACHELLE	EQ 25MG BASE/5ML	N61720 001	JUN 18, 1973	FEB	WDRP
	VIBRAMYCIN					
+	PFIZER	EQ 25MG BASE/5ML	N50006 001	DEC 06, 1967	FEB	CTEC

DOXYCYCLINE HYCLATE

CAPSULE; ORAL

	DOXY-LEMMON					
	@ TEVA	EQ 50MG BASE	N62497 001	AUG 23, 1984	APR	DISC
	@	EQ 100MG BASE	N62497 002	JUN 15, 1984	APR	DISC
	DOXYCYCLINE HYCLATE					
	@ CHELSEA LABS	EQ 50MG BASE	N62142 001	AUG 12, 1981	APR	DISC
	@	EQ 100MG BASE	N62142 002	AUG 12, 1981	APR	DISC
AB	HALSEY	EQ 50MG BASE	N61717 001	JUL 17, 1973	JUN	CAHN
	@	EQ 50MG BASE	N62418 001	JAN 28, 1983	APR	DISC
AB		EQ 100MG BASE	N61717 002	JUL 17, 1973	JUN	CAHN
	@	EQ 100MG BASE	N62418 002	JAN 28, 1983	APR	DISC

CAPSULE, COATED PELLETS; ORAL

	@ SIDMAK LABS NJ	EQ 100MG BASE	N63187 001	JUN 30, 1992	MAY	DISC

INJECTABLE; INJECTION

	DOXYCHEL HYCLATE					
	@ RACHELLE	EQ 100MG BASE/VIAL	N61953 001	SEP 10, 1980	FEB	WDRP
	DOXYCYCLINE					
	@ BEDFORD	EQ 100MG BASE/VIAL	N62569 001	MAR 09, 1988	MAY	DISC
	@	EQ 200MG BASE/VIAL	N62569 002	MAR 09, 1988	MAY	DISC
	@ ELKINS SINN	EQ 100MG BASE/VIAL	N62450 001	OCT 27, 1983	APR	DISC
	@	EQ 200MG BASE/VIAL	N62450 002	OCT 27, 1983	APR	DISC
	DOXYCYCLINE HYCLATE					
	@ LEDERLE	EQ 100MG BASE/VIAL	N62992 001	FEB 16, 1989	MAY	DISC
	@	EQ 200MG BASE/VIAL	N62992 002	FEB 16, 1989	MAY	DISC

TABLET; ORAL

	DOXY-LEMMON					
	@ TEVA	EQ 100MG BASE	N62581 001	MAR 15, 1985	MAY	DISC
	DOXYCYCLINE HYCLATE					
AB	HALSEY	EQ 100MG BASE	N62269 001	SEP 03, 1980	JUN	CAHN
AB		EQ 100MG BASE	N62269 002	NOV 08, 1982	JUN	CAHN
	@	EQ 100MG BASE	N62391 001	SEP 30, 1982	APR	DISC
	DOXYCYCLINE HYLATE					
	@ HALSEY	EQ 50MG BASE	N62269 003	SEP 03, 1980	JUN	CAHN
	PERIOSTAT					
+	COLLAGENEX PHARMS	20MG	N50783 001	FEB 02, 2001	FEB	NEWA

DROPERIDOL; FENTANYL CITRATE
INJECTABLE; INJECTION
FENTANYL CITRATE AND DROPERIDOL

	@ ASTRAZENECA	2.5MG/ML;EQ 0.05MG BASE/ML	N72027 001	APR 13, 1989	JUL	DISC	

DROSPIRENONE; ETHINYL ESTRADIOL
TABLET; ORAL-28
YASMIN

+	BERLEX LABS	3MG;0.03MG	N21098 001	MAY 11, 2001	MAY	NEWA	

DYCLONINE HYDROCHLORIDE
SOLUTION; TOPICAL
DYCLONE

	@ ASTRAZENECA	0.5%	N09925 002	JUN 13, 1974	AUG	DISC	
	@	1%	N09925 001	AUG 03, 1955	AUG	DISC	

ENALAPRIL MALEATE
TABLET; ORAL
ENALAPRIL MALEATE

AB	TARO	2.5MG	N75657 001	JAN 23, 2001	JAN	NEWA	
AB		5MG	N75657 002	JAN 23, 2001	JAN	NEWA	
AB		10MG	N75657 003	JAN 23, 2001	JAN	NEWA	
AB		20MG	N75657 004	JAN 23, 2001	JAN	NEWA	
AB	TORPHARM	2.5MG	N75178 002	MAR 23, 2001	MAR	NEWA	
AB		5MG	N75178 001	MAR 23, 2001	MAR	NEWA	
AB		10MG	N75178 003	MAR 23, 2001	MAR	NEWA	
AB		20MG	N75178 004	MAR 23, 2001	MAR	NEWA	

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE
TABLET; ORAL
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

>A> AB	DR REDDYS LABS LTD	5MG;12.5MG	N75909 001	OCT 15, 2001	OCT	NEWA	
>A> AB		10MG;25MG	N75909 002	OCT 15, 2001	OCT	NEWA	
AB	EON	5MG;12.5MG	N76116 001	SEP 19, 2001	SEP	NEWA	
AB		10MG;25MG	N76116 002	SEP 19, 2001	SEP	NEWA	
AB	MYLAN	5MG;12.5MG	N75624 001	SEP 18, 2001	SEP	NEWA	
AB		10MG;25MG	N75624 002	SEP 18, 2001	SEP	NEWA	
AB	TARO PHARM INDS	5MG;12.5MG	N75788 001	SEP 18, 2001	SEP	NEWA	
AB		10MG;25MG	N75788 002	SEP 18, 2001	SEP	NEWA	
AB	TEVA	5MG;12.5MG	N75727 001	SEP 18, 2001	SEP	NEWA	
AB		10MG;25MG	N75727 002	SEP 18, 2001	SEP	NEWA	

VASERETIC

AB	MERCK RES LABS	5MG;12.5MG	N19221 003	JUL 12, 1995	SEP	CFTG	
AB +		10MG;25MG	N19221 001	OCT 31, 1986	SEP	CFTG	

ENFLURANE
LIQUID; INHALATION
ENFLURANE

AN	MINRAD	99.9%	N74396 001	JUL 29, 1994	FEB	CAHN	

ENOXAPARIN SODIUM
INJECTABLE; SUBCUTANEOUS
LOVENOX

+	AVENTIS	30MG/0.3ML	N20164	001	MAR 29, 1993	APR	CAHN
+		40MG/0.4ML	N20164	002	JAN 30, 1998	APR	CAHN
+		60MG/0.6ML	N20164	003	MAR 27, 1998	APR	CAHN
+		80MG/0.8ML	N20164	004	MAR 27, 1998	APR	CAHN
+		90MG/0.6ML	N20164	006	JUN 02, 2000	APR	CAHN
+		100MG/ML	N20164	005	MAR 27, 1998	APR	CAHN
+		120MG/0.8ML	N20164	007	JUN 02, 2000	APR	CAHN
+		150MG/ML	N20164	008	JUN 02, 2000	APR	CAHN

EPINEPHRINE BITARTRATE; ETIDOCAINE HYDROCHLORIDE
INJECTABLE; INJECTION
DURANEST

@	ASTRAZENECA	0.005MG/ML;1.5%	N17751	007	AUG 30, 1976	SEP	DISC
+	DENTSPLY PHARM	0.005MG/ML;1%	N17751	006	AUG 30, 1976	APR	CAHN
+		0.005MG/ML;1.5%	N17751	007	AUG 30, 1976	APR	CAHN
+		0.005MG/ML;1.5%	N21384	001	AUG 30, 1976	SEP	NEWA

EPINEPHRINE BITARTRATE; PRILOCAINE HYDROCHLORIDE
INJECTABLE; INJECTION
CITANEST FORTE

@	ASTRAZENECA	0.005MG/ML;4%	N14763	008	JUN 29, 1970	SEP	DISC
+	DENTSPLY PHARM	0.005MG/ML;4%	N21383	001	JUN 29, 1970	SEP	NEWA

EPINEPHRINE; ETIDOCAINE HYDROCHLORIDE
INJECTABLE; INJECTION
DURANEST

@	DENTSPLY PHARM	0.005MG/ML;0.5%	N17751	004	AUG 30, 1976	APR	CAHN

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE
INJECTABLE; INJECTION
LIDOCAINE HCL W/ EPINEPHRINE

@	INTL MEDICATION	0.01MG/ML;1%	N86402	001	FEB 04, 1980	JUL	DISC
@	STERIS	0.01MG/ML;1%	N80377	003	FEB 20, 1974	JUL	DISC
@		0.01MG/ML;2%	N80377	004	FEB 20, 1974	JUL	DISC

LIDOCATON

@	PHARMATON	0.02MG/ML;2%	N84728	001	AUG 17, 1983	FEB	WDRP

XYLOCAINE W/ EPINEPHRINE

@	ASTRAZENECA	0.01MG/ML;2%	N06488	003	NOV 19, 1948	SEP	DISC
+	DENTSPLY PHARM	0.01MG/ML;2%	N21381	001	NOV 19, 1948	SEP	NEWA
		0.02MG/ML;2%	N21381	002	NOV 19, 1948	SEP	NEWA

ERGOCALCIFEROL
CAPSULE; ORAL
VITAMIN D

@	IMPAX LABS	50,000 IU	N80951	001	JUL 13, 1973	FEB	DISC

ERGOLOID MESYLATES
TABLET; ORAL
ERGOLOID MESYLATES
@ DANBURY PHARMA 1MG N87244 001 AUG 16, 1982 JUL DISC
TABLET; SUBLINGUAL
@ DANBURY PHARMA 1MG N87183 001 APR 16, 1981 JUL DISC

ERYTHROMYCIN
SOLUTION; TOPICAL
ERYTHROMYCIN
@ CLAY PARK 2% N63038 001 JAN 11, 1991 APR DISC
AT 2% N63038 001 JAN 11, 1991 MAY CMFD
TABLET, DELAYED RELEASE; ORAL
E-BASE
@ BARR 333MG N63028 001 MAY 15, 1990 APR DISC
ILOTYCIN
@ DISTA 250MG N61910 001 FEB 27, 1975 MAY DISC

ERYTHROMYCIN ESTOLATE
CAPSULE; ORAL
ERYTHROMYCIN ESTOLATE
+ BARR EQ 250MG BASE N62162 002 JUN 15, 1981 MAY CTEC
@ DANBURY PHARMA EQ 250MG BASE N62087 001 JUN 14, 1979 APR DISC
ILOSONE
@ LILLY EQ 125MG BASE N61897 001 JAN 06, 1975 MAY DISC
@ EQ 250MG BASE N61897 002 JAN 06, 1975 MAY DISC
FOR SUSPENSION; ORAL
@ DISTA EQ 125MG BASE/5ML N61893 001 JAN 06, 1975 MAY DISC
SUSPENSION/DROPS; ORAL
@ LILLY EQ 100MG BASE/ML N61894 003 JAN 07, 1975 APR DISC
TABLET; ORAL
@ LILLY EQ 500MG BASE N61896 001 JAN 03, 1975 APR DISC
TABLET, CHEWABLE; ORAL
@ DISTA EQ 125MG BASE N61895 001 JAN 03, 1975 MAY DISC
@ EQ 250MG BASE N61895 002 JAN 03, 1975 MAY DISC

ERYTHROMYCIN ETHYLSUCCINATE
TABLET; ORAL
ERYTHROMYCIN ETHYLSUCCINATE
@ BARR EQ 400MG BASE N62256 001 APR 28, 1980 MAY DISC

ERYTHROMYCIN GLUCEPTATE
INJECTABLE; INJECTION
ILOTYCIN GLUCEPTATE
@ DISTA EQ 250MG BASE/VIAL N50370 001 JUN 23, 1964 JUL DISC
@ EQ 500MG BASE/VIAL N50370 002 JUN 23, 1964 JUL DISC
@ EQ 1GM BASE/VIAL N50370 003 JUN 23, 1964 JUL DISC

ERYTHROMYCIN STEARATE
TABLET; ORAL
ERYTHROMYCIN STEARATE
@ BARR EQ 500MG BASE N63179 001 MAY 15, 1990 MAY DISC

	@ ZENITH GOLDLINE	EQ 250MG BASE	N61461 001	SEP 04, 1971	MAY	DISC
	@	EQ 500MG BASE	N61461 002	APR 11, 1980	MAY	DISC
	WYAMYCIN S					
	@ WYETH AYERST	EQ 250MG BASE	N61675 001	OCT 06, 1972	APR	DISC
	@	EQ 500MG BASE	N61675 002	JUL 13, 1973	APR	DISC
	ESOMEPRAZOLE MAGNESIUM					
	CAPSULE, DELAYED REL PELLETS; ORAL					
	NEXIUM					
	+ ASTRAZENECA	EQ 20MG BASE	N21153 001	FEB 20, 2001	FEB	NEWA
	+	EQ 40MG BASE	N21153 002	FEB 20, 2001	FEB	NEWA
	ESTRADIOL VALERATE					
	INJECTABLE; INJECTION					
	DELESTROGEN					
	+ KING PHARMS	10MG/ML	N09402 002	AUG 18, 1962	AUG	CAHN
AO	+	20MG/ML	N09402 004	JUN 23, 1961	AUG	CAHN
AO	+	40MG/ML	N09402 003	FEB 24, 1961	AUG	CAHN
	ESTRADIOL; NORETHINDRONE ACETATE					
	FILM, EXTENDED RELEASE; TRANSDERMAL					
	COMBIPATCH					
	NOVARTIS	0.05MG/24HR;0.14MG/24HR	N20870 001	AUG 07, 1998	MAR	CAHN
	+	0.05MG/24HR;0.25MG/24HR	N20870 002	AUG 07, 1998	MAR	CAHN
	ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE					
	TABLET; ORAL-28					
	PREMPRO					
	+ WYETH AYERST	0.625MG;0.625MG;2.5MG;2.5M G	N20527 001	NOV 17, 1995	JAN	CTNA
	+	0.625MG;0.625MG;5MG;5MG	N20527 003	JAN 09, 1998	JAN	CTNA
	PREMPRO (PREMARIN;CYCRIN)					
	+ WYETH AYERST	0.625MG;0.625MG;2.5MG;2.5M G	N20303 001	DEC 30, 1994	JAN	CTNA
	ESTROGENS, ESTERIFIED					
	TABLET; ORAL					
	ESTRATAB					
	@ SOLVAY	0.3MG	N86715 001	APR 08, 1981	JUL	DISC
	@	0.625MG	N83209 001	JUN 17, 1977	JUL	DISC
	MENEST					
	+ MONARCH PHARMS	0.3MG	N84951 001	SEP 28, 1977	JUL	CTEC
		0.625MG	N84948 001	SEP 28, 1977	JUL	CTEC
	ESTROPIPATE					
	TABLET; ORAL					
	ORTHO-EST					
AB	WOMEN FIRST HLTHCARE	0.75MG	N89567 001	FEB 27, 1991	JAN	CAHN
AB		1.5MG	N89582 001	JUL 17, 1991	JAN	CAHN

>A>		ETHINYL ESTRADIOL; ETONOGESTREL					
>A>		RING; VAGINAL					
>A>		NUVARING					
>A>	+	ORGANON INC	0.015MG;0.12MG	N21187 001	OCT 03, 2001	OCT	NEWA
		ETHINYL ESTRADIOL; LEVONORGESTREL					
		TABLET; ORAL-21					
		ALESSE					
AB	+	WYETH AYERST	0.02MG;0.1MG	N20683 001	MAR 27, 1997	APR	CTEC
		AVIANE-21					
AB		DURAMED	0.02MG;0.1MG	N75796 002	APR 30, 2001	APR	NEWA
		ENPRESSE-21					
AB		DURAMED	0.03MG,0.04MG;0.03MG;0.05MG 0.075MG;0.125MG	N75809 001	JUL 16, 2001	JUL	NEWA
		TABLET; ORAL-28					
		ALESSE					
AB		WYETH AYERST	0.02MG;0.1MG	N20683 002	MAR 27, 1997	APR	CTEC
		AVIANE-28					
AB		DURAMED	0.02MG;0.1MG	N75796 001	APR 30, 2001	APR	NEWA
		ENPRESSE-28					
AB		DURAMED	0.03MG,0.04MG;0.03MG;0.05MG 0.075MG;0.125MG	N75809 002	JUL 16, 2001	JUL	NEWA
		ETHINYL ESTRADIOL; NORETHINDRONE ACETATE					
		TABLET; ORAL-28					
		LOESTRIN FE 1.5/30					
AB	+	PARKE DAVIS	0.03MG;1.5MG	N17355 001	APR 30, 1973	FEB	CFTG
		LOESTRIN FE 1/20					
AB	+	PARKE DAVIS	0.02MG;1MG	N17354 001	APR 30, 1973	FEB	CFTG
		MICROGESTIN FE 1.5/30					
AB		WATSON LABS	0.03MG;1.5MG	N75548 001	FEB 05, 2001	FEB	NEWA
		MICROGESTIN FE 1/20					
AB		WATSON LABS	0.02MG;1MG	N75647 001	FEB 05, 2001	FEB	NEWA
		ETHOSUXIMIDE					
		SYRUP; ORAL					
		ZARONTIN					
AA	+	PARKE DAVIS	250MG/5ML	N80258 001	FEB 13, 1974	JAN	CRLD
		ETIDOCAINE HYDROCHLORIDE					
		INJECTABLE; INJECTION					
		DURANEST					
	@	DENTSPLY PHARM	0.5%	N17751 003	AUG 30, 1976	APR	CAHN
	+		1%	N17751 005	AUG 30, 1976	APR	CAHN
		ETODOLAC					
		TABLET, EXTENDED RELEASE; ORAL					
		ETODOLAC					
AB		TEVA	400MG	N75665 003	FEB 05, 2001	FEB	NEWA

	ETOPOSIDE						
	CAPSULE; ORAL						
	ETOPOSIDE						
AB	GENPHARM	50MG	N75635	001	SEP 19, 2001	SEP	NEWA
	VEPESID						
AB +	BRISTOL	50MG	N19557	001	DEC 30, 1986	SEP	CFTG
	INJECTABLE; INJECTION						
	ETOPOSIDE						
	@ PIERRE FABRE	20MG/ML	N74813	001	JUL 09, 1997	SEP	WDAG
	ETOPOSIDE PHOSPHATE						
	INJECTABLE; INJECTION						
	ETOPOPHOS PRESERVATIVE FREE						
	@ BRISTOL MYERS SQUIBB	EQ 500MG BASE/VIAL	N20906	001	FEB 27, 1998	JUN	DISC
	@	EQ 1GM BASE/VIAL	N20906	002	FEB 27, 1998	JUN	NEWA
	FAMCICLOVIR						
	TABLET; ORAL						
	FAMVIR						
	NOVARTIS	125MG	N20363	003	DEC 11, 1995	JAN	CAHN
		250MG	N20363	001	APR 26, 1996	JAN	CAHN
+		500MG	N20363	002	JUN 29, 1994	JAN	CAHN
	FAMOTIDINE						
	INJECTABLE; INJECTION						
	FAMOTIDINE						
AP	AM PHARM PARTNERS	10MG/ML	N75709	001	APR 16, 2001	APR	NEWA
AP	APOTHECON	10MG/ML	N75707	001	APR 16, 2001	APR	NEWA
	@	10MG/ML	N75707	001	APR 16, 2001	MAY	DISC
AP	BEDFORD	10MG/ML	N75651	001	APR 16, 2001	APR	NEWA
AP		10MG/ML	N75684	001	APR 16, 2001	APR	NEWA
AP	ESI LEDERLE	10MG/ML	N75488	001	APR 16, 2001	APR	NEWA
AP	FAULDING	10MG/ML	N75705	001	APR 16, 2001	APR	NEWA
	FAMOTIDINE PRESERVATIVE FREE						
AP	AM PHARM PARTNERS	10MG/ML	N75813	001	APR 16, 2001	APR	NEWA
AP	APOTHECON	10MG/ML	N75708	001	APR 16, 2001	APR	NEWA
	@	10MG/ML	N75708	001	APR 16, 2001	MAY	DISC
AP	BEDFORD	10MG/ML	N75622	001	APR 16, 2001	APR	NEWA
AP	BEN VENUE	10MG/ML	N75825	001	APR 17, 2001	APR	NEWA
AP	ESI LEDERLE	10MG/ML	N75486	001	APR 16, 2001	APR	NEWA
AP	FAULDING	10MG/ML	N75669	001	APR 16, 2001	APR	NEWA
	FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER						
AP	BAXTER HLTHCARE	0.4MG/ML	N75591	001	MAY 10, 2001	MAY	NEWA
	PEPCID						
AP +	MERCK	10MG/ML	N19510	001	NOV 04, 1986	APR	CFTG
	PEPCID PRESERVATIVE FREE						
AP +	MERCK	10MG/ML	N19510	004	NOV 04, 1986	APR	CFTG
	PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER						
AP +	MERCK	0.4MG/ML	N20249	001	FEB 18, 1994	MAY	CFTG
	TABLET; ORAL						
	FAMOTIDINE						
AB	CARLSBAD	20MG	N75805	001	APR 16, 2001	APR	NEWA

AB			40MG	N75805 002	APR 16, 2001	APR	NEWA
AB		DANBURY PHARMA	20MG	N75062 002	APR 16, 2001	APR	NEWA
AB			40MG	N75062 001	APR 16, 2001	APR	NEWA
AB		DR REDDYS LABS LTD	20MG	N75718 001	APR 16, 2001	APR	NEWA
AB			40MG	N75718 002	APR 16, 2001	APR	NEWA
AB		EON	20MG	N75793 001	APR 16, 2001	APR	NEWA
AB			40MG	N75793 002	APR 16, 2001	APR	NEWA
AB		GENEVA PHARMS	20MG	N75302 001	APR 16, 2001	APR	NEWA
AB			40MG	N75302 002	APR 16, 2001	APR	NEWA
AB		GENPHARM	20MG	N75457 001	APR 18, 2001	APR	NEWA
AB			40MG	N75457 002	APR 18, 2001	APR	NEWA
AB		INVAMED	20MG	N75607 001	MAY 10, 2001	MAY	NEWA
AB			40MG	N75607 002	MAY 10, 2001	MAY	NEWA
AB		MYLAN	20MG	N75704 001	APR 16, 2001	APR	NEWA
AB			40MG	N75704 002	APR 16, 2001	APR	NEWA
AB		PUREPAC PHARM	20MG	N75650 001	SEP 14, 2001	SEP	NEWA
AB			40MG	N75650 002	SEP 14, 2001	SEP	NEWA
AB		TEVA	20MG	N75311 001	APR 16, 2001	APR	NEWA
AB			40MG	N75311 002	APR 16, 2001	APR	NEWA
AB		TORPHARM	20MG	N75611 001	JUL 23, 2001	JUL	NEWA
AB			40MG	N75611 002	JUL 23, 2001	JUL	NEWA
AB		WOCKHARDT	20MG	N75786 001	APR 16, 2001	APR	NEWA
AB			40MG	N75786 002	APR 16, 2001	APR	NEWA
AB		ZENITH GOLDLINE	20MG	N75511 001	APR 16, 2001	APR	NEWA
AB			40MG	N75511 002	APR 16, 2001	APR	NEWA
	PEPCID						
AB		MERCK	20MG	N19462 001	OCT 15, 1986	APR	CFTG
AB	+		40MG	N19462 002	OCT 15, 1986	APR	CFTG
	FELODIPINE						
	TABLET, EXTENDED RELEASE; ORAL						
	PLENDIL						
>D>	+	ASTRAZENECA	2.5MG	N19834 004	SEP 22, 1994	OCT	CRLD
>A>			2.5MG	N19834 004	SEP 22, 1994	OCT	CRLD
>D>	+		5MG	N19834 001	JUL 25, 1991	OCT	CRLD
>A>			5MG	N19834 001	JUL 25, 1991	OCT	CRLD
	FENOFIBRATE						
	TABLET; ORAL						
	TRICOR						
		ABBOTT	54MG	N21203 001	SEP 04, 2001	AUG	NEWA
	+		160MG	N21203 003	SEP 04, 2001	SEP	NEWA
	FENTANYL						
	FILM, EXTENDED RELEASE; TRANSDERMAL						
	DURAGESIC						
		ALZA	1.2MG/24HR	N19813 003	AUG 07, 1990	MAY	CTEC
			1.8MG/24HR	N19813 002	AUG 07, 1990	MAY	CTEC
			2.4MG/24HR	N19813 001	AUG 07, 1990	MAY	CTEC

FENTANYL CITRATE
INJECTABLE; INJECTION
FENTANYL CITRATE PRESERVATIVE FREE

	@ MARSAM	EQ 0.05MG BASE/ML	N74917 001	FEB 03, 1998	JAN	DISC

FLECAINIDE ACETATE
TABLET; ORAL
FLECAINIDE ACETATE

AB	ALPHAPHARM	50MG	N75442 001	JUL 31, 2001	JUL	NEWA
AB		100MG	N75442 002	JUL 31, 2001	JUL	NEWA
AB		150MG	N75442 003	JUL 31, 2001	JUL	NEWA
	TAMBOCOR					
AB	3M	50MG	N18830 004	AUG 23, 1988	JUL	CFTG
AB		100MG	N18830 001	OCT 31, 1985	JUL	CFTG
AB	+	150MG	N18830 003	JUN 03, 1988	JUL	CFTG

FLOXURIDINE
INJECTABLE; INJECTION
FLOXURIDINE

AP	AM PHARM PARTNERS	500MG/VIAL	N75837 001	FEB 22, 2001	FEB	NEWA

FLUDEOXYGLUCOSE, F-18
INJECTABLE; INJECTION
FLUDEOXYGLUCOSE F 18

	+ DOWNSTATE CLINCL	4-90mCi/ML	N20306 002	SEP 25, 2001	SEP	NEWA

FLUOCINOLONE ACETONIDE
CREAM; TOPICAL
FLUOCINOLONE ACETONIDE

	@ CLAY PARK	0.01%	N86810 001	MAR 04, 1982	APR	DISC
	@	0.025%	N86811 001	MAR 04, 1982	APR	DISC

FLUOCINOLONE ACETONIDE; NEOMYCIN SULFATE
CREAM; TOPICAL
NEO-SYNALAR

	@ MEDICIS	0.025%;EQ 3.5MG BASE/GM	N60700 001	JUN 11, 1963	MAY	DISC

FLUOROMETHOLONE
SUSPENSION/DROPS; OPHTHALMIC
FLUOR-OP

AB	NOVARTIS	0.1%	N70185 001	FEB 27, 1986	FEB	CAHN

FLUOROURACIL
CREAM; TOPICAL
CARAC

	+ DERMIK LABS	0.5%	N20985 001	OCT 27, 2000	MAY	CTNA

FLUOXETINE HYDROCHLORIDE
CAPSULE; ORAL
FLUOXETINE

AB	BARR	EQ 20MG BASE	N74803 001	AUG 02, 2001	AUG	NEWA
AB	DR REDDYS LABS LTD	EQ 40MG BASE	N75465 003	AUG 02, 2001	AUG	NEWA

AB	GENEVA PHARMS	EQ 10MG BASE	N75049 001	AUG 02, 2001	AUG	NEWA		
	PROZAC							
AB	LILLY	EQ 10MG BASE	N18936 006	DEC 23, 1992	AUG	CFTG		
AB		EQ 20MG BASE	N18936 001	DEC 29, 1987	AUG	CFTG		
AB +		EQ 40MG BASE	N18936 003	JUN 15, 1999	AUG	CFTG		
	CAPSULE, DELAYED REL PELLETS; ORAL							
	PROZAC WEEKLY							
	+ LILLY	EQ 90MG BASE	N21235 001	FEB 26, 2001	FEB	NEWA		
	SOLUTION; ORAL							
	FLUOXETINE							
AT	TEVA	EQ 20MG BASE/5ML	N75506 001	AUG 02, 2001	AUG	NEWA		
	PROZAC							
AT +	LILLY	EQ 20MG BASE/5ML	N20101 001	APR 24, 1991	AUG	CFTG		
	TABLET; ORAL							
	FLUOXETINE HCL							
AB	ALPHAPHARM	EQ 10MG BASE	N75755 001	AUG 02, 2001	AUG	NEWA		
+		EQ 20MG BASE	N75755 002	AUG 02, 2001	AUG	NEWA		
	PROZAC							
AB +	LILLY	EQ 10MG BASE	N20974 001	MAR 09, 1999	AUG	CFTG		
	FLUPHENAZINE DECANOATE							
	INJECTABLE; IM-SC							
	FLUPHENAZINE DECANOATE							
AO	APOTEX	25MG/ML	N75918 001	AUG 17, 2001	AUG	NEWA		
	FLUPHENAZINE HYDROCHLORIDE							
	TABLET; ORAL							
>D>	PERMITIL							
>D> BP	SCHERING	10MG	N12034 006	JAN 07, 1964	OCT	DISC		
>A>	@	10MG	N12034 006	JAN 07, 1964	OCT	DISC		
	FLURAZEPAM HYDROCHLORIDE							
	CAPSULE; ORAL							
	FLURAZEPAM HCL							
	@ CHELSEA LABS	15MG	N72368 001	MAR 30, 1989	JUL	DISC		
	@ PUREPAC PHARM	15MG	N71927 001	SEP 09, 1987	JUL	DISC		
	@	30MG	N71551 001	SEP 09, 1987	JUL	DISC		
	FLURBIPROFEN							
	TABLET; ORAL							
	FLURBIPROFEN							
AB	CARACO	50MG	N75058 001	APR 27, 2001	APR	NEWA		
AB		100MG	N75058 002	APR 27, 2001	APR	NEWA		
	FLUTAMIDE							
	CAPSULE; ORAL							
	EULEXIN							
AB +	SCHERING	125MG	N18554 001	JAN 27, 1989	SEP	CFTG		
	FLUTAMIDE							
AB	BARR	125MG	N75820 001	SEP 18, 2001	SEP	NEWA		
AB	EON	125MG	N75818 001	SEP 18, 2001	SEP	NEWA		
>A> AB	IVAX PHARMS	125MG	N75780 001	SEP 19, 2001	OCT	NEWA		
AB	TEVA	125MG	N75298 001	SEP 18, 2001	SEP	NEWA		

FLUVOXAMINE MALEATE
TABLET; ORAL
FLUVOXAMINE MALEATE

	AB	BARR	25MG	N75897 001	JAN 25, 2001	JAN	NEWA
	AB		50MG	N75897 002	JAN 25, 2001	JAN	NEWA
	AB		100MG	N75897 003	JAN 25, 2001	JAN	NEWA
>A>	AB	GENPHARM	50MG	N75950 001	OCT 15, 2001	OCT	NEWA
>A>	AB		100MG	N75950 002	OCT 15, 2001	OCT	NEWA
	AB	INVAMED	25MG	N75887 001	JAN 05, 2001	JAN	NEWA
	AB		50MG	N75887 002	JAN 05, 2001	JAN	NEWA
	AB		100MG	N75887 003	JAN 05, 2001	JAN	NEWA
	AB	SYNTHON PHARMS	25MG	N75899 001	JAN 17, 2001	JAN	NEWA
	AB		50MG	N75899 002	JAN 17, 2001	JAN	NEWA
	AB		100MG	N75899 003	JAN 17, 2001	JAN	NEWA
	AB	TORPHARM	25MG	N75902 001	MAY 07, 2001	MAY	NEWA
	AB		50MG	N75902 002	MAY 07, 2001	MAY	NEWA
	AB		100MG	N75902 003	MAY 07, 2001	MAY	NEWA
	AB	WATSON LABS	25MG	N75894 001	APR 18, 2001	APR	NEWA
	AB		50MG	N75894 002	APR 18, 2001	APR	NEWA
	AB		100MG	N75894 003	APR 18, 2001	APR	NEWA
	AB	ZENITH GOLDLINE	25MG	N75898 001	MAR 12, 2001	MAR	NEWA
	AB		50MG	N75898 002	MAR 12, 2001	MAR	NEWA
	AB		100MG	N75898 003	MAR 12, 2001	MAR	NEWA

FOLIC ACID
TABLET; ORAL
FOLIC ACID

>D>	AA	IMPAX LABS	1MG	N80686 001	JUL 20, 1973	OCT	DISC
>A>		@	1MG	N80686 001	JUL 20, 1973	OCT	DISC

FOLLITROPIN ALFA
INJECTABLE; INJECTION
GONAL-F

	+	SERONO	1,200 IU/VIAL	N20378 004	FEB 28, 2001	AUG	NEWA

FORMOTEROL FUMARATE
CAPSULE; INHALATION
FORADIL

	+	NOVARTIS	0.012MG/INH	N20831 001	FEB 16, 2001	FEB	NEWA

GABAPENTIN
CAPSULE; ORAL
NEURONTIN

		PFIZER	100MG	N20235 001	DEC 30, 1993	MAR	CAHN
			300MG	N20235 002	DEC 30, 1993	MAR	CAHN
	+		400MG	N20235 003	DEC 30, 1993	MAR	CAHN

SOLUTION; ORAL

>D>		@ PARKE DAVIS	250MG/5ML	N21129 001	MAR 02, 2000	OCT	CMFD
>A>		+	250MG/5ML	N21129 001	MAR 02, 2000	OCT	CMFD

GALANTAMINE HYDROBROMIDE
SOLUTION; ORAL
REMINYL
\+ JANSSEN — 4MG/ML — N21224 001 JUN 22, 2001 JUN NEWA
TABLET; ORAL
JANSSEN — EQ 4MG BASE — N21169 001 FEB 28, 2001 FEB NEWA
EQ 8MG BASE — N21169 002 FEB 28, 2001 FEB NEWA
\+ EQ 12MG BASE — N21169 003 FEB 28, 2001 FEB NEWA

GEMFIBROZIL
TABLET; ORAL
GEMFIBROZIL
AB GENEVA PHARMS TECH — 600MG — N74615 001 SEP 29, 1995 JAN CAHN

GENTAMICIN SULFATE
CREAM; TOPICAL
GENTAMICIN SULFATE
@ BAUSCH AND LOMB — EQ 0.1% BASE — N64056 001 APR 29, 1994 MAY DISC
INJECTABLE; INJECTION
@ GENSIA SICOR PHARMS — EQ 10MG BASE/ML — N63149 001 NOV 21, 1991 MAY DISC
@ — EQ 40MG BASE/ML — N63106 002 NOV 21, 1991 APR DISC
@ STERIS — EQ 10MG BASE/ML — N62318 002 AUG 20, 1981 APR DISC
@ — EQ 40MG BASE/ML — N62318 001 JUN 02, 1981 APR DISC
U-GENCIN
@ PHARMACIA AND UPJOHN — EQ 10MG BASE/ML — N62248 001 MAY 02, 1980 FEB WDRP
@ — EQ 40MG BASE/ML — N62248 002 MAY 02, 1980 FEB WDRP
INJECTABLE; INTRATHECAL
GARAMYCIN
@ SCHERING — EQ 2MG BASE/ML — N50505 001 OCT 01, 1979 APR DISC
OINTMENT; OPHTHALMIC
GENTACIDIN
AT NOVARTIS — EQ 0.3% BASE — N62501 001 JUL 26, 1984 FEB CAHN
@ — EQ 0.3% BASE — N62501 001 JUL 26, 1984 MAY DISC
OINTMENT; TOPICAL
GARAMYCIN
@ SCHERING — EQ 0.1% BASE — N60463 001 MAR 15, 1966 SEP DISC
GENTAMICIN
AT \+ CLAY PARK — EQ 0.1% BASE — N62351 001 FEB 18, 1982 SEP CTEC
GENTAMICIN SULFATE
@ BAUSCH AND LOMB — EQ 0.1% BASE — N64054 001 APR 29, 1994 MAY DISC
SOLUTION/DROPS; OPHTHALMIC
GENTACIDIN
AT NOVARTIS — EQ 0.3% BASE — N62480 001 MAR 30, 1984 FEB CAHN
>A> GENTAK
>A> AT AKORN — EQ 0.3% BASE — N64163 001 OCT 12, 2001 OCT NEWA
GENTAMICIN SULFATE
@ ALCON UNIVERSAL — EQ 0.3% BASE — N62523 001 NOV 25, 1985 APR DISC

GLIPIZIDE
TABLET; ORAL
GLIPIZIDE
AB GENEVA PHARMS TECH — 5MG — N74542 001 JUN 20, 1995 JAN CAHN

AB		10MG	N74542 002	JUN 20, 1995	JAN	CAHN
AB	TORPHARM	5MG	N75795 001	JUN 13, 2001	JUN	NEWA
AB		10MG	N75795 002	JUN 13, 2001	JUN	NEWA

GLUTETHIMIDE
TABLET; ORAL
GLUTETHIMIDE

@	CELLTECH PHARMS	500MG	N85171 001	DEC 22, 1976	SEP	DISC

GLYCOPYRROLATE
INJECTABLE; INJECTION
GLYCOPYRROLATE

@	GENSIA SICOR PHARMS	0.2MG/ML	N81169 001	SEP 10, 1991	MAY	DISC

TABLET; ORAL
ROBINUL

+	FIRST HORIZON	1MG	N12827 001	AUG 11, 1961	AUG	CAHN

ROBINUL FORTE

+	FIRST HORIZON	2MG	N12827 002	AUG 11, 1961	AUG	CAHN

GRANISETRON HYDROCHLORIDE
SOLUTION; ORAL
KYTRIL

+	ROCHE	EQ 2MG BASE/10ML	N21238 001	JUN 27, 2001	JUN	NEWA

GRISEOFULVIN, MICROCRYSTALLINE
SUSPENSION; ORAL
GRIFULVIN V

+	J AND J	125MG/5ML	N62483 001	JAN 26, 1984	MAR	CRLD
@	JOHNSON AND JOHNSON	125MG/5ML	N50448 001	MAY 19, 1972	MAR	DISC

GRISEOFULVIN, ULTRAMICROCRYSTALLINE
TABLET; ORAL
GRISACTIN ULTRA

@	WYETH AYERST	125MG	N62178 001	MAR 13, 1980	APR	DISC
@		250MG	N62178 002	MAR 13, 1980	APR	DISC

ULTRAGRIS-165

@	SIDMAK LABS NJ	165MG	N62645 001	JUN 30, 1992	MAY	DISC

ULTRAGRIS-330

@	SIDMAK LABS NJ	330MG	N62646 001	JUN 30, 1992	MAY	DISC

HALOPERIDOL
TABLET; ORAL
HALOPERIDOL

@	DANBURY PHARMA	1MG	N70982 001	MAR 06, 1987	JUL	DISC
@	ROXANE	0.5MG	N71128 001	FEB 17, 1987	AUG	DISC
@		1MG	N71129 001	FEB 17, 1987	AUG	DISC
@		2MG	N71130 001	FEB 17, 1987	AUG	DISC
@		5MG	N71131 001	FEB 17, 1987	AUG	DISC
@		20MG	N71133 001	MAY 12, 1987	AUG	DISC

HALOPERIDOL LACTATE
CONCENTRATE; ORAL
HALOPERIDOL INTENSOL
@ ROXANE — EQ 2MG BASE/ML — N72045 001 APR 12, 1988 AUG DISC
INJECTABLE; INJECTION
HALOPERIDOL
AP AM PHARM PARTNERS — EQ 5MG BASE/ML — N75689 001 MAR 09, 2001 JUN CTNA
AP BEDFORD — EQ 5MG BASE/ML — N75858 001 JUN 18, 2001 JUN NEWA
AP GENSIA SICOR PHARMS — EQ 5MG BASE/ML — N76035 001 AUG 29, 2001 AUG NEWA
HALOPERIDOL LACTATE
AP AM PHARM PARTNERS — EQ 5MG BASE/ML — N75689 001 MAR 09, 2001 MAR NEWA

HALOTHANE
LIQUID; INHALATION
HALOTHANE
@ BH — 99.99% — N84977 001 JUL 14, 1976 JAN DISC

HEPARIN SODIUM
INJECTABLE; INJECTION
HEPARIN SODIUM
@ ABBOTT — 10,000 UNITS/ML — N40095 001 JUL 26, 1996 MAY DISC
HEPARIN SODIUM PRESERVATIVE FREE
@ PHARMA SERVE NY — 1,000 UNITS/ML — N86129 001 FEB 22, 1980 FEB WDRP

HOMATROPINE METHYLBROMIDE
TABLET; ORAL
HOMAPIN-10
@ MISSION PHARMA — 10MG — N86308 001 APR 11, 1979 JUL DISC
HOMAPIN-5
@ MISSION PHARMA — 5MG — N86309 001 APR 11, 1979 JUL DISC

HYALURONIDASE
INJECTABLE; INJECTION
WYDASE
@ WYETH AYERST — 150 UNITS/ML — N06343 002 MAR 22, 1950 JUL DISC
@ — 150 UNITS/VIAL — N06343 006 MAR 06, 1951 JUL DISC
@ — 1,500 UNITS/VIAL — N06343 005 MAR 06, 1951 JUL DISC

HYDRALAZINE HYDROCHLORIDE
INJECTABLE; INJECTION
HYDRALAZINE HCL
AP AM PHARM PARTNERS — 20MG/ML — N40388 001 MAR 13, 2001 MAR NEWA

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE
TABLET; ORAL
RESERPINE, HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE
@ DANBURY PHARMA — 25MG;15MG;0.1MG — N85549 001 SEP 29, 1977 MAY DISC

HYDROCHLOROTHIAZIDE
TABLET; ORAL
HYDROCHLOROTHIAZIDE
@ DANBURY PHARMA — 50MG — N83232 001 JAN 24, 1975 MAY DISC

@ HALSEY	25MG	N83972 001	OCT 03, 1974	MAY	DISC	
@	50MG	N83972 002	OCT 03, 1974	MAY	DISC	
@ IMPAX LABS	25MG	N84029 001	JUL 05, 1977	MAY	DISC	
@	50MG	N83607 002	JUN 06, 1977	MAY	DISC	
@ PHARMERAL	25MG	N84325 001	JUN 24, 1976	MAY	DISC	
@	50MG	N84324 001	JUN 24, 1976	MAY	DISC	
@ PVT FORM	50MG	N86597 001	OCT 11, 1978	JUL	DISC	
@ WEST WARD	50MG	N84878 001	JAN 31, 1977	MAY	DISC	

HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

HYDRO-RESERP					
@ ABC HOLDING	50MG;0.125MG	N84714 002	JUN 29, 1982	MAY	DISC
HYDROCHLOROTHIAZIDE W/ RESERPINE					
@ DANBURY PHARMA	25MG;0.125MG	N84466 001	JAN 07, 1977	MAY	DISC
@	50MG;0.125MG	N84467 001	JAN 07, 1977	MAY	DISC
RESERPINE AND HYDROCHLOROTHIAZIDE-50					
@ WEST WARD	50MG;0.125MG	N88189 001	MAY 10, 1984	FEB	WDRP

HYDROCORTISONE

CREAM; TOPICAL

DERMACORT					
@ MONARCH PHARMS	1%	N83011 002	APR 26, 1973	SEP	WDAG
HC (HYDROCORTISONE)					
@ C AND M PHARMA	0.5%	N80482 003	MAR 20, 1973	FEB	WDRP
@	1%	N80482 004	MAR 20, 1973	FEB	WDRP
HYDROCORTISONE					
@ TOPIDERM	1%	N89273 001	FEB 17, 1989	FEB	WDRP
NUTRACORT					
@ HEALTHPOINT	1%	N80442 003	APR 04, 1972	JUL	DISC
PROCTOCORT					
@ MONARCH PHARMS	1%	N83011 001	APR 26, 1973	FEB	DISC

LOTION; TOPICAL

ACTICORT					
@ BAKER NORTON	1%	N86535 001	FEB 04, 1981	JUL	DISC
BETA-HC					
@ BETA DERMAC	1%	N89495 001	JAN 25, 1988	FEB	WDRP
GLYCORT					
@ HERAN	1%	N87489 001	OCT 03, 1983	FEB	WDRP
HYDROCORTISONE					
@ MERICON	0.5%	N85282 001	JUN 05, 1978	MAY	DISC
@	1%	N85282 002	FEB 26, 1987	MAY	DISC

OINTMENT; TOPICAL

HC (HYDROCORTISONE)					
@ C AND M PHARMA	1%	N80481 002	MAR 20, 1973	FEB	WDRP

POWDER; FOR RX COMPOUNDING

H-CORT					
@ TORCH	100%	N87834 001	MAR 29, 1982	FEB	WDRP

SOLUTION; TOPICAL

TEXACORT					
AT + SIRIUS LABS	1%	N80425 001	DEC 22, 1971	JUN	CAHN
+	2.5%	N81271 001	APR 17, 1992	MAY	CAHN

TABLET; ORAL

HYDROCORTISONE
TABLET; ORAL
HYDROCORTISONE

>D>	BP	IMPAX LABS	20MG	N80781	001	AUG 02, 1973	OCT	DISC
>A>		@	20MG	N80781	001	AUG 02, 1973	OCT	DISC
		@ LANNETT	20MG	N85070	001	MAY 07, 1976	MAY	DISC

HYDROCORTISONE ACETATE
CREAM; TOPICAL
MICORT-HC

		FERNDALE LABS	2.5%	N40396	001	FEB 27, 2001	FEB	NEWA

HYDROCORTISONE ACETATE; NEOMYCIN SULFATE
OINTMENT; TOPICAL
NEO-CORTEF

		@ PHARMACIA AND UPJOHN	1%;EQ 3.5MG BASE/GM	N60751	002	MAY 18, 1965	APR	DISC

SUSPENSION/DROPS; OPHTHALMIC
COR-OTICIN

		@ AKORN	1.5%;EQ 3.5MG BASE/ML	N60188	001	OCT 26, 1968	FEB	WDRP

HYDROCORTISONE VALERATE
OINTMENT; TOPICAL
HYDROCORTISONE VALERATE

	AB	ALTANA	0.2%	N75085	001	JUL 31, 2001	JUL	NEWA

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SOLUTION/DROPS; OTIC
NEO-OTOSOL-HC

		@ ALCON	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N62423	001	AUG 25, 1983	APR	DISC

SUSPENSION/DROPS; OPHTHALMIC
CORTISPORIN

	+	MONARCH PHARMS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N50169	001	DEC 18, 1964	MAY	CTEC

NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE

		@ ALCON UNIVERSAL	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N62874	001	MAY 11, 1988	MAY	DISC

SUSPENSION/DROPS; OTIC

		@ ALCON UNIVERSAL	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N62488	001	NOV 06, 1985	APR	DISC

HYDROXYZINE HYDROCHLORIDE
INJECTABLE; INJECTION
HYDROXYZINE HCL

		@ ABBOTT	50MG/ML	N86821	001	SEP 05, 1979	JUL	DISC
		@ AM PHARM PARTNERS	25MG/ML	N88184	001	MAR 31, 1983	JUL	DISC
		@	50MG/ML	N88185	001	MAR 31, 1983	JUL	DISC
		@ STERIS	25MG/ML	N85778	001	OCT 05, 1979	MAY	DISC

TABLET; ORAL

		@ PAR PHARM	10MG	N87602	001	JAN 22, 1982	JUL	DISC
		@	25MG	N87603	001	JAN 22, 1982	JUL	DISC
		@	50MG	N87604	001	JAN 22, 1982	JUL	DISC

HYDROXYZINE PAMOATE
CAPSULE; ORAL
HYDROXYZINE PAMOATE

		@ GENEVA PHARMS	EQ 50MG HCL	N81128 001	JUN 28, 1991	MAY	DISC
		@	EQ 100MG HCL	N81129 001	JUN 28, 1991	MAY	DISC
		@ VANGARD	EQ 50MG HCL	N88393 001	SEP 19, 1983	FEB	WDRP

IBUPROFEN
TABLET; ORAL
IBUPROFEN

>A>	AB	DR REDDYS LABS INC	400MG	N76112 001	OCT 31, 2001	OCT	NEWA
>A>	AB		600MG	N76112 002	OCT 31, 2001	OCT	NEWA
>A>	AB		800MG	N76112 003	OCT 31, 2001	OCT	NEWA
>D>	AB	LEDERLE	400MG	N70629 001	SEP 19, 1986	OCT	DISC
>A>		@	400MG	N70629 001	SEP 19, 1986	OCT	DISC
>D>	AB		600MG	N70630 001	SEP 19, 1986	OCT	DISC
>A>		@	600MG	N70630 001	SEP 19, 1986	OCT	DISC

IMATINIB MESYLATE
CAPSULE; ORAL
GLEEVEC

		NOVARTIS	50MG	N21335 001	MAY 10, 2001	MAY	NEWA
	+		100MG	N21335 002	MAY 10, 2001	MAY	NEWA

IMIPRAMINE HYDROCHLORIDE
TABLET; ORAL
IMIPRAMINE HCL

		@ ROXANE	25MG	N83799 002	AUG 05, 1977	SEP	DISC
		@	50MG	N83799 003	AUG 05, 1977	SEP	DISC
		TOFRANIL					
AB		TYCO HLTHCARE	10MG	N87844 001	MAY 22, 1984	JUN	CAHN
AB			25MG	N87845 001	MAY 22, 1984	JUN	CAHN
AB	+		50MG	N87846 001	MAY 22, 1984	JUN	CAHN

IMIPRAMINE PAMOATE
CAPSULE; ORAL
TOFRANIL-PM

		TYCO HLTHCARE	EQ 75MG HCL	N17090 001	MAR 15, 1973	JUN	CAHN
			EQ 100MG HCL	N17090 004	MAR 08, 1974	JUN	CAHN
			EQ 125MG HCL	N17090 003	MAR 08, 1974	JUN	CAHN
	+		EQ 150MG HCL	N17090 002	MAR 15, 1973	JUN	CAHN

INDAPAMIDE
TABLET; ORAL
INDAPAMIDE

AB		GENEVA PHARMS TECH	1.25MG	N74594 001	MAY 23, 1996	JAN	CAHN
AB			2.5MG	N74594 002	MAY 23, 1996	JAN	CAHN

INDINAVIR SULFATE
CAPSULE; ORAL
CRIXIVAN

		MERCK RES LABS	EQ 100MG BASE	N20685 006	APR 19, 2000	AUG	NEWA

IPRATROPIUM BROMIDE
SOLUTION; INHALATION
IPRATROPIUM BROMIDE

	AN	ASLUNG PHARM	0.02%	N75693 001	JAN 26, 2001	JAN	NEWA
>A>	AN	BAUSCH AND LOMB	0.02%	N75835 001	OCT 15, 2001	OCT	NEWA
	AN	NEPHRON	0.02%	N75562 001	SEP 27, 2001	SEP	NEWA
	AN	NOVEX	0.02%	N75441 001	MAR 28, 2001	MAR	NEWA
	AN	WARRICK PHARMS	0.02%	N75507 001	JAN 19, 2001	JAN	NEWA

ISOFLURANE
LIQUID; INHALATION
ISOFLURANE

AN	MINRAD	99.9%	N74416 001	SEP 30, 1994	FEB	CAHN

ISONIAZID
SYRUP; ORAL
ISONIAZID

+	CAROLINA MEDCL	50MG/5ML	N88235 001	NOV 10, 1983	MAY	CTEC
@	MIKART	50MG/5ML	N81118 001	JUL 21, 1997	MAY	DISC

TABLET; ORAL

@	HALSEY	100MG	N80136 001	NOV 13, 1970	MAY	DISC

ISOSORBIDE MONONITRATE
TABLET, EXTENDED RELEASE; ORAL
ISOSORBIDE MONONITRATE

AB	ZENITH GOLDLINE	30MG	N75448 002	AUG 07, 2001	AUG	NEWA
AB		120MG	N75448 003	AUG 07, 2001	AUG	NEWA

ISOTRETINOIN
CAPSULE; ORAL
ACCUTANE

+	HLR	20MG	N18662 004	MAR 28, 1983	APR	CTEC

KANAMYCIN SULFATE
INJECTABLE; INJECTION
KANAMYCIN SULFATE

@	LOCH	EQ 75MG BASE/2ML	N63021 001	JUL 31, 1992	MAY	DISC
@		EQ 500MG BASE/2ML	N63022 001	JUL 31, 1992	MAY	DISC
@		EQ 1GM BASE/3ML	N63025 001	JUL 31, 1992	APR	DISC
@	STERIS	EQ 1GM BASE/3ML	N62520 003	MAY 09, 1985	MAY	DISC

KANTREX

+	APOTHECON	EQ 75MG BASE/2ML	N61901 003	MAR 06, 1975	MAY	CTEC
+		EQ 500MG BASE/2ML	N61901 001	MAR 06, 1975	MAY	CTEC
+		EQ 1GM BASE/3ML	N61901 002	MAR 06, 1975	MAY	CTEC

KETOCONAZOLE
CREAM; TOPICAL
NIZORAL

AB	+	JANSSEN	2%	N19084 001	DEC 31, 1985	JUL	CAHN

KETOROLAC TROMETHAMINE
INJECTABLE; INJECTION
KETOROLAC TROMETHAMINE

AP	APOTEX	15MG/ML	N75631 002	JUN 29, 2001	JUN	NEWA	
AP		30MG/ML	N75626 001	JUL 24, 2001	JUL	NEWA	
AP		30MG/ML	N75631 001	JUN 29, 2001	JUN	NEWA	
	@ APOTHECON	15MG/ML	N75348 001	NOV 28, 2000	MAY	DISC	
	@	30MG/ML	N75348 002	NOV 28, 2000	MAY	DISC	
>D> AP	BEDFORD	15MG/ML	N75230 002	OCT 25, 1999	OCT	DISC	
>A>	@	15MG/ML	N75230 002	OCT 25, 1999	OCT	DISC	
>D> AP		30MG/ML	N75230 001	OCT 25, 1999	OCT	DISC	
>A>	@	30MG/ML	N75230 001	OCT 25, 1999	OCT	DISC	

LABETALOL HYDROCHLORIDE
INJECTABLE; INJECTION
LABETALOL HCL

	@ APOTHECON	5MG/ML	N75355 001	NOV 29, 1999	MAY	DISC	

TRANDATE

AP +	PROMETHEUS LABS	5MG/ML	N19425 001	DEC 31, 1985	MAY	CAHN	

LACTULOSE
SOLUTION; ORAL
LACTULOSE

AA	VINTAGE PHARMS	10GM/15ML	N75993 001	JUL 26, 2001	JUL	NEWA	

SOLUTION; ORAL, RECTAL

	@ ROXANE	10GM/15ML	N73590 001	MAY 29, 1992	SEP	DISC	

LAMOTRIGINE
TABLET, CHEWABLE; ORAL
LAMICTAL CD

	GLAXO WELLCOME	2MG	N20764 004	SEP 08, 2000	MAR	NEWA	

LANSOPRAZOLE
FOR SUSPENSION, EXTENDED RELEASE; ORAL
PREVACID

	TAP PHARM	15MG/PACKET	N21281 001	MAY 03, 2001	MAY	NEWA	
+		30MG/PACKET	N21281 002	MAY 03, 2001	MAY	NEWA	

>A> LATANOPROST; TIMOLOL MALEATE
>A> SOLUTION/DROPS; OPHTHALMIC
>A> XALCOM

>A> +	PHARMACIA AND UPJOHN	0.005%;0.5%	N21219 001	OCT 02, 2001	OCT	NEWA	

LEUCOVORIN CALCIUM
INJECTABLE; INJECTION
LEUCOVORIN CALCIUM PRESERVATIVE FREE

AP	LUITPOLD	EQ 50MG BASE/VIAL	N40338 001	JAN 31, 2001	JAN	NEWA	

LEVOCARNITINE
INJECTABLE; INJECTION
CARNITOR

AP +	SIGMA TAU	200MG/ML	N20182 001	DEC 16, 1992	MAR	CFTG	

LEVOCARNITINE
INJECTABLE; INJECTION
LEVOCARNITINE

AP	BEDFORD	200MG/ML	N75567 001	MAR 29, 2001	MAR	NEWA
AP	GENSIA SICOR PHARMS	200MG/ML	N75881 001	MAR 29, 2001	MAR	NEWA
AP	LUITPOLD	200MG/ML	N75861 001	JUN 22, 2001	JUN	NEWA

LEVODOPA
CAPSULE; ORAL
DOPAR

@	SHIRE LABS	250MG	N16913 001	JUN 04, 1970	MAY	DISC

TABLET; ORAL

@	SHIRE LABS	250MG	N16913 004	JUL 06, 1972	JUN	DISC
@		500MG	N16913 005	JUL 06, 1972	JUN	DISC

LARODOPA

	ROCHE	250MG	N16912 003	JUN 04, 1970	JUN	CRLD
+		500MG	N16912 004	JUN 04, 1970	JUN	CRLD

LEVONORDEFRIN; MEPIVACAINE HYDROCHLORIDE
INJECTABLE; INJECTION
POLOCAINE W/ LEVONORDEFRIN

AP	DENTSPLY PHARM	0.05MG/ML;2%	N89517 001	APR 14, 1988	JUL	CAHN

LEVOTHYROXINE SODIUM
TABLET; ORAL
LEVOXYL

BX	+ JONES PHARMA	0.025MG	N21301 001	MAY 25, 2001	MAY	NEWA
BX		0.025MG	N21301 001	MAY 25, 2001	JUL	CRLD
BX		0.05MG	N21301 002	MAY 25, 2001	MAY	NEWA
BX		0.075MG	N21301 003	MAY 25, 2001	MAY	NEWA
BX		0.088MG	N21301 004	MAY 25, 2001	MAY	NEWA
BX		0.1MG	N21301 005	MAY 25, 2001	MAY	NEWA
BX		0.112MG	N21301 006	MAY 25, 2001	MAY	NEWA
BX		0.125MG	N21301 007	MAY 25, 2001	MAY	NEWA
BX		0.137MG	N21301 008	MAY 25, 2001	MAY	NEWA
BX		0.15MG	N21301 009	MAY 25, 2001	MAY	NEWA
BX		0.175MG	N21301 010	MAY 25, 2001	MAY	NEWA
BX		0.2MG	N21301 011	MAY 25, 2001	MAY	NEWA
BX		0.3MG	N21301 012	MAY 25, 2001	MAY	NEWA
BX	+	0.3MG	N21301 012	MAY 25, 2001	JUL	CRLD

UNITHROID

BX	STEVENS J	0.025MG	N21210 001	AUG 21, 2000	MAY	CTEC
BX		0.05MG	N21210 002	AUG 21, 2000	MAY	CTEC
BX		0.075MG	N21210 003	AUG 21, 2000	MAY	CTEC
BX		0.088MG	N21210 004	AUG 21, 2000	MAY	CTEC
BX		0.1MG	N21210 005	AUG 21, 2000	MAY	CTEC
BX		0.112MG	N21210 006	AUG 21, 2000	MAY	CTEC
BX		0.125MG	N21210 007	AUG 21, 2000	MAY	CTEC
BX		0.15MG	N21210 008	AUG 21, 2000	MAY	CTEC
BX		0.175MG	N21210 009	AUG 21, 2000	MAY	CTEC
BX		0.2MG	N21210 010	AUG 21, 2000	MAY	CTEC
BX	+	0.3MG	N21210 011	AUG 21, 2000	MAY	CTEC

	LIDOCAINE HYDROCHLORIDE						
	INJECTABLE; INJECTION						
	LIDOCAINE HCL						
	@ STERIS	1%	N80377 001	FEB 20, 1974	JUL	DISC
	@	2%	N80377 002	FEB 20, 1974	JUL	DISC
	LIDOCATON						
	@ PHARMATON	2%	N84727 001	AUG 17, 1983	FEB	WDRP
	XYLOCAINE						
	@ ASTRAZENECA	2%	N06488 002	NOV 19, 1948	SEP	DISC
AP	+ DENTSPLY PHARM	2%	N21380 001	NOV 19, 1948	SEP	NEWA
	LINCOMYCIN HYDROCHLORIDE						
	INJECTABLE; INJECTION						
	LINCOCIN						
	+ PHARMACIA AND UPJOHN	EQ 300MG BASE/ML	N50317 001	DEC 29, 1964	MAY	CTEC
	LINCOMYCIN HCL						
	@ STERIS	EQ 300MG BASE/ML	N63180 001	APR 16, 1991	MAY	DISC
	LISINOPRIL						
	TABLET; ORAL						
	ZESTRIL						
AB	ASTRAZENECA	10MG	N19777 002	MAY 19, 1988	APR	CTEC
	LITHIUM CARBONATE						
	CAPSULE; ORAL						
	ESKALITH						
AB	SMITHKLINE BEECHAM	300MG	N16860 001	APR 06, 1970	JUN	CRLD
	LITHIUM CARBONATE						
AB	ABLE	300MG	N76121 001	SEP 27, 2001	SEP	NEWA
	+ ROXANE	600MG	N17812 003	JAN 28, 1987	JUN	CRLD
	LOMEFLOXACIN HYDROCHLORIDE						
	TABLET; ORAL						
	MAXAQUIN						
	+ UNIMED PHARMS	EQ 400MG BASE	N20013 001	FEB 21, 1992	SEP	CAHN
	LOPERAMIDE HYDROCHLORIDE						
	CAPSULE; ORAL						
	LOPERAMIDE HCL						
	@ ROXANE	2MG	N73080 001	NOV 27, 1991	JUL	DISC
	LORATADINE						
	TABLET; ORAL						
	CLARITIN						
AB	+ SCHERING	10MG	N19658 001	APR 12, 1993	SEP	CFTG
	LORAZEPAM						
	TABLET; ORAL						
	LORAZEPAM						
AB	RANBAXY	0.5MG	N76045 001	AUG 29, 2001	AUG	NEWA
AB		1MG	N76045 002	AUG 29, 2001	AUG	NEWA
AB		2MG	N76045 003	AUG 29, 2001	AUG	NEWA

		@ WATSON LABS	0.5MG	N71086 001	MAR 23, 1987	JUL	DISC
		LOSARTAN POTASSIUM					
		TABLET; ORAL					
		COZAAR					
		MERCK RES LABS	50MG	N20386 002	APR 14, 1995	AUG	CRLD
		+	100MG	N20386 003	OCT 13, 1998	AUG	NEWA
		LOTEPREDNOL ETABONATE					
		SUSPENSION/DROPS; OPHTHALMIC					
		ALREX					
>A>		+ BAUSCH AND LOMB	0.2%	N20803 001	MAR 09, 1998	OCT	CAHN
>D>		+ PHARMOS	0.2%	N20803 001	MAR 09, 1998	OCT	CAHN
		LOTEMAX					
>A>		+ BAUSCH AND LOMB	0.5%	N20583 001	MAR 09, 1998	OCT	CAHN
>D>		+ PHARMOS	0.5%	N20583 001	MAR 09, 1998	OCT	CAHN
		MANNITOL					
		INJECTABLE; INJECTION					
		MANNITOL 25%					
		@ ASTRAZENECA	12.5GM/50ML	N89240 001	MAY 06, 1987	SEP	DISC
		MECLIZINE HYDROCHLORIDE					
		TABLET; ORAL					
		MECLIZINE HCL					
		@ CHELSEA LABS	12.5MG	N85269 001	NOV 11, 1976	MAY	DISC
		MEGESTROL ACETATE					
		SUSPENSION; ORAL					
		MEGACE					
	AB	+ BRISTOL MYERS SQUIBB	40MG/ML	N20264 001	SEP 10, 1993	JUL	CFTG
		MEGESTROL ACETATE					
	AB	PAR PHARM	40MG/ML	N75671 001	JUL 25, 2001	JUL	NEWA
		MELOXICAM					
		TABLET; ORAL					
		MOBIC					
		BOEHRINGER INGELHEIM	7.5MG	N20938 001	APR 13, 2000	JUL	CRLD
		+	15MG	N20938 002	AUG 23, 2000	JUL	NEWA
		MENOTROPINS (FSH;LH)					
		INJECTABLE; INJECTION					
>D>		HUMEGON					
>D>	AB	ORGANON	75 IU/VIAL;75 IU/VIAL	N20328 001	SEP 01, 1994	OCT	DISC
>A>		@	75 IU/VIAL;75 IU/VIAL	N20328 001	SEP 01, 1994	OCT	DISC
>D>	AB		150 IU/VIAL;150 IU/VIAL	N20328 002	SEP 01, 1994	OCT	DISC
>A>		@	150 IU/VIAL;150 IU/VIAL	N20328 002	SEP 01, 1994	OCT	DISC
		PERGONAL					
>D>	AB +	SERONO	75 IU/AMP;75 IU/AMP	N17646 001	AUG 22, 1975	OCT	CTEC
>A>	BX +		75 IU/AMP;75 IU/AMP	N17646 001	AUG 22, 1975	OCT	CTEC
>D>	AB +		150 IU/AMP;150 IU/AMP	N17646 002	MAY 20, 1985	OCT	CTEC
>A>	BX +		150 IU/AMP;150 IU/AMP	N17646 002	MAY 20, 1985	OCT	CTEC

MEPERIDINE HYDROCHLORIDE
INJECTABLE; INJECTION
MEPERIDINE HCL

	@ ASTRAZENECA	50MG/ML	N89784 001	MAR 31, 1989	JUN	DISC
	@	100MG/ML	N89788 001	MAR 31, 1989	JUN	DISC

MEPIVACAINE HYDROCHLORIDE
INJECTABLE; INJECTION
MEPIVACAINE HCL

	@ INTL MEDICATION	1%	N87509 001	OCT 05, 1982	JUL	DISC
	POLOCAINE					
AP	DENTSPLY PHARM	3%	N88653 001	AUG 21, 1984	JUL	CAHN

MEPROBAMATE
TABLET; ORAL
AMOSENE

	@ FERNDALE LABS	400MG	N84030 001	MAY 10, 1974	FEB	WDRP
	MEPROBAMATE					
	@ HALSEY	400MG	N80699 002	OCT 16, 1972	MAY	DISC
	@ IMPAX LABS	200MG	N14322 002	JUL 23, 1973	AUG	DISC
	@	400MG	N14322 001	JUL 15, 1963	AUG	DISC

MEQUINOL; TRETINOIN
SOLUTION; TOPICAL
SOLAGE

+	WESTWOOD SQUIBB	2%;0.01%	N20922 001	DEC 10, 1999	JUN	CAHN

MESALAMINE
SUPPOSITORY; RECTAL
CANASA

+	AXCAN SCANDIPHARM	500MG	N21252 001	JAN 05, 2001	JAN	NEWA

MESNA
INJECTABLE; INTRAVENOUS
MESNA

AP	AM PHARM PARTNERS	100MG/ML	N75811 001	APR 26, 2001	APR	NEWA
AP	GENSIA SICOR PHARMS	100MG/ML	N75764 001	APR 27, 2001	APR	NEWA
	MESNEX					
AP +	ASTA	100MG/ML	N19884 001	DEC 30, 1988	APR	CFTG

METAPROTERENOL SULFATE
SOLUTION; INHALATION
METAPROTERENOL SULFATE

AN	NEPHRON	0.4%	N71855 001	JUL 14, 1988	AUG	CAHN
AN		0.6%	N71726 001	JUL 14, 1988	AUG	CAHN
AN	NOVEX	0.4%	N75402 001	FEB 28, 2001	FEB	NEWA
AN		0.6%	N75403 001	FEB 28, 2001	FEB	NEWA

METHAMPHETAMINE HYDROCHLORIDE
TABLET; ORAL
DESOXYN

+	ABBOTT	5MG	N05378 002	DEC 31, 1943	JUL	CTEC

METHAMPHETAMINE HYDROCHLORIDE
TABLET; ORAL
METHAMPHETAMINE HCL

@	REXAR	5MG	N84931 001	JAN 19, 1976	JUL	DISC
@		10MG	N84931 002	AUG 22, 1977	JUL	DISC

METHAZOLAMIDE
TABLET; ORAL
METHAZOLAMIDE

@	APPLIED ANAL	25MG	N40011 001	JUL 17, 1997	MAY	DISC
@		50MG	N40011 002	JUL 17, 1997	MAY	DISC

METHIMAZOLE
TABLET; ORAL
METHIMAZOLE

AB	EON	5MG	N40411 001	MAR 27, 2001	MAR	NEWA
AB		10MG	N40411 002	MAR 27, 2001	MAR	NEWA
+	GENPHARM	20MG	N40350 003	JUN 07, 2001	JUN	NEWA

METHOTREXATE SODIUM
TABLET; ORAL
TREXALL

	BARR	EQ 5MG BASE	N40385 001	MAR 21, 2001	MAR	NEWA
		EQ 7.5MG BASE	N40385 002	MAR 21, 2001	MAR	NEWA
		EQ 10MG BASE	N40385 003	MAR 21, 2001	MAR	NEWA
+		EQ 15MG BASE	N40385 004	MAR 21, 2001	MAR	NEWA

METHOXAMINE HYDROCHLORIDE
INJECTABLE; INJECTION
VASOXYL

@	GLAXO WELLCOME	20MG/ML	N06772 001	MAR 28, 1949	SEP	WDAG

METHSCOPOLAMINE BROMIDE
TABLET; ORAL
METHSCOPOLAMINE BROMIDE

@	PVT FORM PAMINE	2.5MG	N80970 001	OCT 18, 1976	MAY	DISC
+	BRADLEY PHARMS	2.5MG	N08848 001	APR 09, 1953	MAY	CTEC

METHYCLOTHIAZIDE
TABLET; ORAL
METHYCLOTHIAZIDE

@	PAR PHARM	2.5MG	N89135 001	FEB 12, 1986	JUL	DISC
@		5MG	N89136 001	FEB 12, 1986	JUL	DISC

METHYLDOPA
TABLET; ORAL
METHYLDOPA

@	LEDERLE	125MG	N70070 003	OCT 15, 1985	MAY	DISC

METHYLPHENIDATE HYDROCHLORIDE							
CAPSULE, EXTENDED RELEASE; ORAL							
METADATE CD							
+ CELLTECH PHARMS	20MG		N21259 001	APR 03, 2001	APR	NEWA
TABLET; ORAL							
METHYLPHENIDATE HCL							
AB ABLE	5MG		N40404 001	MAR 29, 2001	MAR	NEWA
AB	10MG		N40404 002	MAR 29, 2001	MAR	NEWA
AB	20MG		N40404 003	MAR 29, 2001	MAR	NEWA
TABLET, EXTENDED RELEASE; ORAL							
METADATE ER							
AB CELLTECH PHARMS	10MG		N40306 001	OCT 20, 1999	APR	CTEC
METHYLPHENIDATE HCL							
AB ABLE	20MG		N76032 001	MAY 09, 2001	MAY	NEWA
AB DANBURY PHARMA	20MG		N40410 001	FEB 09, 2001	FEB	NEWA
METHYLPREDNISOLONE ACETATE							
INJECTABLE; INJECTION							
DEPO-MEDROL							
PHARMACIA AND UPJOHN	40MG/ML		N11757 001	APR 27, 1959	MAY	CTEC
METHYLPREDNISOLONE ACETATE							
@ STERIS	40MG/ML		N85600 001	MAR 14, 1979	MAY	DISC
METHYLPREDNISOLONE ACETATE; NEOMYCIN SULFATE							
CREAM; TOPICAL							
NEO-MEDROL ACETATE							
@ PHARMACIA AND UPJOHN	0.25%;EQ 3.5MG BASE/GM		N60611 002	DEC 07, 1964	MAY	DISC
@	1%;EQ 3.5MG BASE/GM		N60611 001	DEC 07, 1964	MAY	DISC
METHYLPREDNISOLONE SODIUM SUCCINATE							
INJECTABLE; INJECTION							
METHYLPREDNISOLONE SODIUM SUCCINATE							
@ GENSIA SICOR PHARMS	EQ 500MG BASE/VIAL		N81267 001	NOV 30, 1992	MAY	DISC
@	EQ 1GM BASE/VIAL		N81268 001	NOV 30, 1992	MAY	DISC
METHYLTESTOSTERONE							
TABLET; BUCCAL							
ORETON							
@ SCHERING	10MG		N80281 001	AUG 03, 1979	FEB	DISC
TABLET; BUCCAL/SUBLINGUAL							
METHYLTESTOSTERONE							
@ IMPAX LABS	10MG		N84287 001	JUL 16, 1974	JUL	DISC
@ LILLY	10MG		N80256 001	DEC 22, 1971	JUL	DISC
TABLET; ORAL							
@ LILLY	25MG		N80256 002	DEC 22, 1971	JUL	DISC
METIPRANOLOL HYDROCHLORIDE							
SOLUTION/DROPS; OPHTHALMIC							
METIPRANOLOL							
AT FALCON PHARMS	0.3%		N75720 001	AUG 06, 2001	AUG	NEWA
OPTIPRANOLOL							
AT + BAUSCH AND LOMB	0.3%		N19907 001	DEC 29, 1989	AUG	CFTG

METOCLOPRAMIDE HYDROCHLORIDE							
INJECTABLE; INJECTION							
METOCLOPRAMIDE HCL							
@ ABBOTT	EQ 5MG BASE/ML	N70506 001	JUN 22, 1989	MAY	DISC		
SOLUTION; INJECTION							
METOCLOPRAMIDE							
AA UDL	EQ 5MG BASE/5ML	N75051 001	JAN 26, 2001	JAN	NEWA		
SOLUTION; ORAL							
AA UDL	EQ 5MG BASE/5ML	N75051 001	JAN 26, 2001	MAY	CDFR		
TABLET; ORAL							
METOCLOPRAMIDE HCL							
AB GENEVA PHARMS TECH	EQ 5MG BASE	N74478 001	OCT 05, 1995	JAN	CAHN		
AB	EQ 10MG BASE	N74478 002	OCT 05, 1995	JAN	CAHN		
@ MUTUAL PHARM	EQ 5MG BASE	N71536 002	JAN 16, 1997	JUL	DISC		
@	EQ 10MG BASE	N71536 001	APR 28, 1993	JUL	DISC		
METOCURINE IODIDE							
INJECTABLE; INJECTION							
METUBINE IODIDE							
@ LILLY	2MG/ML	N06632 003	FEB 15, 1952	SEP	WDAG		
METOPROLOL SUCCINATE							
TABLET, EXTENDED RELEASE; ORAL							
TOPROL-XL							
+ ASTRAZENECA	EQ 25MG TARTRATE	N19962 004	FEB 05, 2001	FEB	NEWA		
	EQ 25MG TARTRATE	N19962 004	FEB 05, 2001	JUL	CRLD		
	EQ 100MG TARTRATE	N19962 002	JAN 10, 1992	JUL	CRLD		
METRONIDAZOLE							
INJECTABLE; INJECTION							
METRO I.V.							
@ B BRAUN	500MG/100ML	N18674 001	AUG 31, 1982	MAY	DISC		
METRONIDAZOLE							
@ ABBOTT	500MG/100ML	N18889 001	NOV 18, 1983	MAY	DISC		
@ ELKINS SINN	500MG/100ML	N18907 001	MAR 30, 1984	MAY	DISC		
TABLET; ORAL							
PROTOSTAT							
@ JOHNSON RW	250MG	N18871 001	MAR 02, 1983	MAR	DISC		
@	500MG	N18871 002	MAR 02, 1983	MAR	DISC		
MEZLOCILLIN SODIUM MONOHYDRATE							
INJECTABLE; INJECTION							
MEZLIN							
@ BAYER	EQ 1GM BASE/VIAL	N62372 005	JAN 13, 1983	MAY	DISC		
@	EQ 2GM BASE/VIAL	N62372 001	MAY 13, 1982	MAY	DISC		
@	EQ 3GM BASE/VIAL	N62372 002	MAY 13, 1982	MAY	DISC		
@	EQ 4GM BASE/VIAL	N62372 003	MAY 13, 1982	MAY	DISC		
@	EQ 20GM BASE/VIAL	N62372 004	MAR 02, 1988	MAY	DISC		

MIDAZOLAM HYDROCHLORIDE
INJECTABLE; INJECTION
MIDAZOLAM HCL

>D>	AP	AESGEN	EQ 1MG BASE/ML	N75154 002	JUN 20, 2000	OCT	CAHN
>D>	AP		EQ 5MG BASE/ML	N75154 001	JUN 20, 2000	OCT	CAHN
>A>	AP	AM PHARM PARTNERS	EQ 1MG BASE/ML	N75154 002	JUN 20, 2000	OCT	CAHN
>A>	AP		EQ 5MG BASE/ML	N75154 001	JUN 20, 2000	OCT	CAHN
		@ APOTHECON	EQ 1MG BASE/ML	N75620 001	NOV 01, 2000	MAY	DISC
		@	EQ 5MG BASE/ML	N75620 002	NOV 01, 2000	MAY	DISC
		@	EQ 5MG BASE/ML	N75641 001	OCT 19, 2000	MAY	DISC
		@ ASTRAZENECA	EQ 5MG BASE/ML	N75263 001	JUN 26, 2000	MAY	DISC
		@ BEDFORD	EQ 5MG BASE/ML	N75249 001	JUN 23, 2000	SEP	DISC
		@ BEN VENUE	EQ 5MG BASE/ML	N75455 001	JUN 20, 2000	SEP	DISC

MINOCYCLINE HYDROCHLORIDE
CAPSULE; ORAL
MINOCIN

AB		LEDERLE	EQ 75MG BASE	N50649 003	FEB 12, 2001	MAR	NEWA
AB	+		EQ 100MG BASE	N50649 002	MAY 31, 1990	MAR	CRLD

MINOCYCLINE HCL

AB		DANBURY PHARMA	EQ 100MG BASE	N63065 001	DEC 30, 1991	MAR	CRLD
AB		IMPAX LABS	EQ 75MG BASE	N65005 003	APR 18, 2001	APR	NEWA

VECTRIN

		@ MEDICIS	EQ 75MG BASE	N63067 002	SEP 15, 1999	MAY	DISC
		@	EQ 100MG BASE	N63067 001	JUL 31, 1990	MAY	DISC

POWDER, EXTENDED RELEASE; DENTAL
ARESTIN

	+	ORAPHARMA	EQ 1MG BASE	N50781 001	FEB 16, 2001	FEB	NEWA

MIRTAZAPINE
TABLET, ORALLY DISINTEGRATING; ORAL
REMERON SOLTAB

	+	ORGANON INC	15MG	N21208 001	JAN 12, 2001	JAN	NEWA
			30MG	N21208 002	JAN 12, 2001	JAN	NEWA
			45MG	N21208 003	JAN 12, 2001	JAN	NEWA

MORPHINE SULFATE
CAPSULE, EXTENDED RELEASE; ORAL
KADIAN

	+	FAULDING PHARMS	20MG	N20616 001	JUL 03, 1996	JUN	CAHN
	+		30MG	N20616 004	MAR 09, 2001	JUN	NEWA
	+		50MG	N20616 002	JUL 03, 1996	JUN	CAHN
	+		60MG	N20616 005	MAR 09, 2001	JUN	NEWA
	+		100MG	N20616 003	JUL 03, 1996	JUN	CAHN

TABLET, EXTENDED RELEASE; ORAL
MORPHINE SULFATE

AB		WATSON LABS	100MG	N75656 001	JAN 30, 2001	JAN	NEWA

ORAMORPH SR

BC		ELAN PHARMS	15MG	N19977 004	NOV 23, 1994	SEP	CAHN
BC			30MG	N19977 001	AUG 15, 1991	SEP	CAHN
BC			60MG	N19977 002	AUG 15, 1991	SEP	CAHN
BC			100MG	N19977 003	AUG 15, 1991	SEP	CAHN

NABUMETONE							
TABLET; ORAL							
NABUMETONE							
AB	TEVA	750MG	N75189 002	SEP 24, 2001	SEP	NEWA	
NADOLOL							
TABLET; ORAL							
CORGARD							
AB	APOTHECON	40MG	N18063 001	DEC 10, 1979	AUG	CRLD	
NADOLOL							
AB	GENEVA PHARMS TECH	20MG	N74501 001	NOV 09, 1995	JAN	CAHN	
AB		40MG	N74501 002	NOV 09, 1995	JAN	CAHN	
AB		80MG	N74501 003	NOV 09, 1995	JAN	CAHN	
NAFCILLIN SODIUM							
INJECTABLE; INJECTION							
NAFCILLIN SODIUM							
@	APOTHECON	EQ 500MG BASE/VIAL	N61984 001	APR 29, 1976	MAY	DISC	
+		EQ 500MG BASE/VIAL	N62527 001	AUG 02, 1984	MAY	CRLD	
@		EQ 1GM BASE/VIAL	N61984 002	APR 29, 1976	MAY	DISC	
@		EQ 2GM BASE/VIAL	N61984 003	APR 29, 1976	MAY	DISC	
@		EQ 4GM BASE/VIAL	N61984 005	APR 29, 1976	MAY	DISC	
@	MARSAM	EQ 500MG BASE/VIAL	N62844 001	OCT 26, 1988	MAY	DISC	
@		EQ 1GM BASE/VIAL	N62844 002	OCT 26, 1988	MAY	DISN	
@		EQ 1.5GM BASE/VIAL	N62844 003	OCT 26, 1988	MAY	DISC	
@		EQ 2GM BASE/VIAL	N62844 004	OCT 26, 1988	MAY	DISC	
@		EQ 4GM BASE/VIAL	N62844 005	OCT 26, 1988	MAY	DISC	
@		EQ 10GM BASE/VIAL	N63008 001	SEP 29, 1988	MAY	DISC	
NALLPEN							
@	SMITHKLINE BEECHAM	EQ 500MG BASE/VIAL	N61999 001	JUL 10, 1978	MAY	DISC	
@		EQ 1GM BASE/VIAL	N61999 002	JUL 10, 1978	MAY	DISC	
@		EQ 2GM BASE/VIAL	N61999 003	JUL 10, 1978	MAY	DISC	
@		EQ 10GM BASE/VIAL	N61999 004	JUL 17, 1978	MAY	DISC	
UNIPEN							
@	WYETH AYERST	EQ 500MG BASE/VIAL	N50320 001	JUN 23, 1970	MAY	DISC	
@		EQ 500MG BASE/VIAL	N62717 001	DEC 16, 1986	MAY	DISC	
@		EQ 1GM BASE/VIAL	N62717 002	DEC 16, 1986	MAY	DISC	
@		EQ 2GM BASE/VIAL	N50320 003	JUN 23, 1970	MAY	DISC	
@		EQ 2GM BASE/VIAL	N62717 004	DEC 16, 1986	MAY	DISC	
@		EQ 4GM BASE/VIAL	N50320 004	JUN 23, 1970	MAY	DISC	
@		EQ 10GM BASE/VIAL	N50320 005	DEC 21, 1978	MAY	DISC	
UNIPEN IN PLASTIC CONTAINER							
@	WYETH AYERST	EQ 1GM BASE/VIAL	N50320 002	JUN 23, 1970	MAY	DISC	
NALBUPHINE HYDROCHLORIDE							
INJECTABLE; INJECTION							
NALBUPHINE HCL							
@	ASTRAZENECA	10MG/ML	N72070 001	APR 10, 1989	JUN	DISC	
@		20MG/ML	N72073 001	APR 10, 1989	JUN	DISC	

NALOXONE HYDROCHLORIDE
INJECTABLE; INJECTION
NALOXONE

	@ WYETH AYERST	0.02MG/ML	N70188 001	SEP 24, 1986	JAN	DISC
	@	0.02MG/ML	N70189 001	SEP 24, 1986	JAN	DISC
	@	0.4MG/ML	N70190 001	SEP 24, 1986	JAN	DISC
	@	0.4MG/ML	N70191 001	SEP 24, 1986	JAN	DISC

NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE
TABLET; ORAL
NALOXONE HCL AND PENTAZOCAINE

AB	AMIDE PHARM	EQ 0.5MG BASE;EQ 50MG BASE	N75735 001	JUL 11, 2001	JUL	NEWA

NAPHAZOLINE HYDROCHLORIDE
SOLUTION/DROPS; OPHTHALMIC
ALBALON

AT	ALLERGAN	0.1%	N80248 001	MAR 24, 1972	JUL	CRLD
AT +		0.1%	N80248 001	MAR 24, 1972	AUG	CRLD

NAPHCON FORTE

	@ ALCON	0.1%	N80229 001	MAR 06, 1974	JUL	DISC

OPCON

	@ BAUSCH AND LOMB	0.1%	N87506 001	DEC 01, 1981	JUL	DISC

VASOCON

AT	NOVARTIS	0.1%	N80235 002	MAR 24, 1983	FEB	CAHN

NAPROXEN
TABLET, EXTENDED RELEASE; ORAL
NAPROXEN

AB +	ALPHAPHARM	375MG	N75390 001	APR 19, 2001	APR	NEWA
AB +		500MG	N75390 002	APR 19, 2001	APR	NEWA

NAPROXEN SODIUM
TABLET; ORAL
NAPROXEN SODIUM

AB	GENEVA PHARMS TECH	EQ 250MG BASE	N74495 001	DEC 05, 1994	JAN	CAHN
AB		EQ 500MG BASE	N74495 002	DEC 05, 1994	JAN	CAHN

NEDOCROMIL SODIUM
AEROSOL, METERED; INHALATION
TILADE

+	AVENTIS	1.75MG/INH	N19660 001	DEC 30, 1992	SEP	CAHN

NEFAZODONE HYDROCHLORIDE
TABLET; ORAL
SERZONE

	BRISTOL MYERS SQUIBB	50MG	N20152 001	DEC 22, 1994	APR	CTEC

NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SOLUTION; IRRIGATION
NEOMYCIN AND POLYMYXIN B SULFATES

	@ STERIS	EQ 40MG BASE/ML;200,000 UNITS/ML	N62664 001	APR 08, 1986	MAY	DISC

NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION; IRRIGATION

NEOSPORIN G.U. IRRIGANT

MONARCH PHARMS — EQ 40MG BASE/ML;200,000 UNITS/ML — N60707 001 JUN 28, 1966 MAY CTEC

SOLUTION/DROPS; OPHTHALMIC

STATROL

@ ALCON — EQ 3.5MG BASE/ML;16,250 UNITS/ML — N62339 001 NOV 30, 1984 JUL DISC

NESIRITIDE

FOR SOLUTION; INTRAVENOUS

NATRECOR

\+ SCIOS — 1.5MG/VIAL — N20920 001 AUG 10, 2001 AUG NEWA

NETILMICIN SULFATE

INJECTABLE; INJECTION

NETROMYCIN

@ SCHERING — EQ 100MG BASE/ML — N50544 003 FEB 28, 1983 MAY DISC

NIFEDIPINE

CAPSULE; ORAL

NIFEDIPINE

@ CHASE LABS NJ — 10MG — N72409 001 JUL 04, 1990 FEB WDRP

@ — 20MG — N73421 001 JUN 19, 1991 FEB WDRP

TABLET, EXTENDED RELEASE; ORAL

ADALAT CC

AB1 BAYER — 30MG — N20198 001 APR 21, 1993 APR CTEC

NIFEDIPINE

AB2 BIOVAIL — 30MG — N75289 002 FEB 06, 2001 FEB NEWA

>A> AB1 ELAN PHARM — 60MG — N75659 001 OCT 26, 2001 OCT NEWA

PROCARDIA XL

AB2 + PFIZER — 30MG — N19684 001 SEP 06, 1989 FEB CTEC

NITROFURAZONE

OINTMENT; TOPICAL

NITROFURAZONE

@ CLAY PARK — 0.2% — N84968 001 JAN 25, 1978 MAY DISC

POWDER; TOPICAL

FURACIN

@ ROBERTS LABS — 0.2% — N83791 001 OCT 17, 1975 FEB WDRP

SOLUTION; TOPICAL

NITROFURAZONE

@ CLAY PARK — 0.2% — N85130 001 NOV 02, 1978 MAY DISC

\+ WENDT — 0.2% — N87081 001 JUL 22, 1981 MAY CTEC

NITROGLYCERIN

AEROSOL; SUBLINGUAL

NITROLINGUAL

@ POHL BOSKAMP — 0.4MG/SPRAY — N18705 001 OCT 31, 1985 APR DISC

NOREPINEPHRINE BITARTRATE; PROCAINE HYDROCHLORIDE; PROPOXYCAINE HYDROCHLORIDE

	INJECTABLE; INJECTION						
	RAVOCAINE AND NOVOCAIN W/ LEVOPHED						
	@ EASTMAN KODAK	EQ 0.033MG BASE/ML;2%;0.4%	N08592	003	MAR 11, 1955	SEP	WDAG

NORETHINDRONE ACETATE

	TABLET; ORAL						
	NORETHINDRONE ACETATE						
AB	BARR	5MG	N75951	001	MAY 25, 2001	MAY	NEWA

NORTRIPTYLINE HYDROCHLORIDE

	CAPSULE; ORAL						
	PAMELOR						
AB	TYCO HLTHCARE	EQ 10MG BASE	N18013	001	AUG 01, 1977	JUN	CAHN
AB		EQ 25MG BASE	N18013	002	AUG 01, 1977	JUN	CAHN
AB		EQ 50MG BASE	N18013	004	JUN 14, 1979	JUN	CAHN
AB	+	EQ 75MG BASE	N18013	003	JUN 14, 1979	JUN	CAHN
	SOLUTION; ORAL						
AA	TYCO HLTHCARE	EQ 10MG BASE/5ML	N18012	001	AUG 01, 1977	JUN	CAHN

NYSTATIN

	CREAM; TOPICAL						
	NILSTAT						
	@ LEDERLE	100,000 UNITS/GM	N61445	001	APR 02, 1971	MAY	DISC
	NYSTATIN						
	@ TEVA	100,000 UNITS/GM	N61966	001	MAY 25, 1976	MAY	DISC
	OINTMENT; TOPICAL						
	NILSTAT						
	@ LEDERLE	100,000 UNITS/GM	N61444	001	MAR 29, 1971	MAY	DISC
	NYSTATIN						
AT	+ ALTANA	100,000 UNITS/GM	N62124	002	SEP 23, 1982	MAY	CTEC
	SUSPENSION; ORAL						
	@ ROXANE	100,000 UNITS/ML	N62832	001	DEC 27, 1991	MAY	DISC
	@ TEVA	100,000 UNITS/ML	N62670	001	JUN 18, 1987	MAY	DISC
	@	100,000 UNITS/ML	N62776	001	DEC 17, 1987	MAY	DISC
	@ THAMES	100,000 UNITS/ML	N62876	001	FEB 29, 1988	JUL	DISC
	TABLET; ORAL						
	@ EON	500,000 UNITS	N62065	001	JUL 22, 1977	MAY	DISC
	@ ROSEMONT	500,000 UNITS	N62524	001	NOV 26, 1985	MAY	DISC
	TABLET; VAGINAL						
	KOROSTATIN						
	@ HOLLAND RANTOS	100,000 UNITS	N61718	001	SEP 30, 1974	FEB	WDRP

NYSTATIN; TRIAMCINOLONE ACETONIDE

	OINTMENT; TOPICAL						
	MYCO-TRIACET II						
	@ TEVA	100,000 UNITS/GM;0.1%	N62045	002	NOV 26, 1985	MAY	DISC
	NYSTATIN AND TRIAMCINOLONE ACETONIDE						
	@ CLAY PARK	100,000 UNITS/GM;0.1%	N62280	002	OCT 10, 1985	MAY	DISC

		OLANZAPINE					
		TABLET; ORAL					
		ZYPREXA					
		LILLY	15MG	N20592 005	SEP 09, 1997	JUN	CRLD
	+		20MG	N20592 006	SEP 09, 1997	JUN	CMFD
		OXACILLIN SODIUM					
		INJECTABLE; INJECTION					
		BACTOCILL					
		@ SMITHKLINE BEECHAM	EQ 1GM BASE/VIAL	N62736 001	DEC 19, 1986	FEB	DISC
		@	EQ 2GM BASE/VIAL	N62736 002	DEC 19, 1986	FEB	DISC
		OXACILLIN SODIUM					
AP	+	APOTHECON	EQ 1GM BASE/VIAL	N61490 003	APR 08, 1971	FEB	CRLD
AP	+		EQ 2GM BASE/VIAL	N62737 002	DEC 23, 1986	FEB	CRLD
		@ IBI	EQ 125MG BASE/VIAL	N62798 003	DEC 11, 1995	MAY	DISC
		@	EQ 250MG BASE/VIAL	N62798 004	DEC 11, 1995	MAY	DISC
		@	EQ 500MG BASE/VIAL	N62798 005	DEC 11, 1995	MAY	DISC
		@	EQ 1GM BASE/VIAL	N62798 001	DEC 11, 1995	MAY	DISC
		@	EQ 2GM BASE/VIAL	N62798 002	DEC 11, 1995	MAY	DISC
		OXAPROZIN					
		TABLET; ORAL					
		DAYPRO					
AB	+	SEARLE	600MG	N18841 004	OCT 29, 1992	JAN	CFTG
		OXAPROZIN					
AB		DR REDDYS LABS LTD	600MG	N75855 001	JAN 31, 2001	JAN	NEWA
AB		EON	600MG	N75845 001	JAN 31, 2001	JAN	NEWA
AB		GENEVA PHARMS	600MG	N75850 001	APR 27, 2001	APR	NEWA
AB		GENPHARM	600MG	N75847 001	FEB 28, 2001	FEB	NEWA
AB		INVAMED	600MG	N75842 001	APR 12, 2001	APR	NEWA
AB		MYLAN	600MG	N75851 001	AUG 17, 2001	AUG	NEWA
>A> AB		PUREPAC PHARM	600MG	N75843 001	OCT 03, 2001	OCT	NEWA
AB		WATSON LABS	600MG	N75848 001	FEB 09, 2001	FEB	NEWA
		OXAZEPAM					
		CAPSULE; ORAL					
		SERAX					
AB		FAULDING PHARMS	10MG	N15539 002	SEP 29, 1966	JUN	CAHN
AB			15MG	N15539 004	SEP 29, 1966	JUN	CAHN
AB	+		30MG	N15539 006	SEP 29, 1966	JUN	CAHN
		TABLET; ORAL					
	+	FAULDING PHARMS	15MG	N15539 008	NOV 16, 1967	JUN	CAHN
		OXCARBAZEPINE					
		SUSPENSION; ORAL					
		TRILEPTAL					
	+	NOVARTIS	300MG/5ML	N21285 001	MAY 25, 2001	MAY	NEWA
		OXYCODONE HYDROCHLORIDE					
		TABLET; ORAL					
		ROXICODONE					
		ELAN PHARMS	15MG	N21011 001	AUG 31, 2000	SEP	CAHN

	+	30MG	N21011 002	AUG 31, 2000	SEP	CAHN
	TABLET, EXTENDED RELEASE; ORAL					
	OXYCONTIN					
	@ PURDUE PHARMA LP	160MG	N20553 005	MAR 15, 2000	JUN	DISC
	OXYTETRACYCLINE HYDROCHLORIDE					
	CAPSULE; ORAL					
	OXYTETRACYCLINE HCL					
	@ IMPAX LABS	EQ 250MG BASE	N60760 001	AUG 09, 1967	FEB	DISC
	@ PROTER	EQ 250MG BASE	N60869 001	JAN 29, 1964	FEB	WDRP
	@ WEST WARD	EQ 250MG BASE	N60770 001	SEP 29, 1967	MAY	DISC
	TERRAMYCIN					
	+ PFIZER	EQ 250MG BASE	N50286 002	SEP 08, 1964	MAY	CTEC
	PACLITAXEL					
	INJECTABLE; INJECTION					
	PACLITAXEL					
AP	BEDFORD	6MG/ML	N75190 001	JUL 27, 2001	JUL	NEWA
AP	MYLAN	6MG/ML	N75278 001	JUL 23, 2001	JUL	NEWA
AP	ZENITH GOLDLINE	6MG/ML	N75297 001	MAR 27, 2001	MAR	NEWA
	PAMIDRONATE DISODIUM					
	INJECTABLE; INJECTION					
	AREDIA					
AP	+ NOVARTIS	30MG/VIAL	N20036 001	OCT 31, 1991	APR	CFTG
AP	+	90MG/VIAL	N20036 004	MAY 06, 1993	APR	CFTG
	PAMIDRONATE DISODIUM					
AP	BEDFORD	30MG/VIAL	N75290 001	APR 30, 2001	APR	NEWA
AP		90MG/VIAL	N75290 003	APR 30, 2001	APR	NEWA
	PANCURONIUM BROMIDE					
	INJECTABLE; INJECTION					
	PANCURONIUM BROMIDE					
	@ ASTRAZENECA	1MG/ML	N72210 001	MAR 31, 1988	JUL	DISC
	@	2MG/ML	N72211 001	MAR 31, 1988	JUL	DISC
	@	2MG/ML	N72213 001	MAR 31, 1988	JUL	DISC
	PANTOPRAZOLE SODIUM					
	INJECTABLE; IV (INFUSION)					
	PROTONIX IV					
	+ WYETH AYERST	EQ 40MG BASE/VIAL	N20988 001	MAR 22, 2001	MAR	NEWA
	TABLET, DELAYED RELEASE; ORAL					
	PROTONIX					
	+ WYETH AYERST	EQ 20MG BASE	N20987 002	JUN 12, 2001	JUN	NEWA
	PEMOLINE					
	TABLET; ORAL					
	PEMOLINE					
AB	MALLINCKRODT	18.75MG	N75726 003	MAR 30, 2001	MAR	NEWA
AB		37.5MG	N75726 002	MAR 30, 2001	MAR	NEWA
AB		75MG	N75726 001	MAR 30, 2001	MAR	NEWA
AB	WATSON LABS	18.75MG	N75287 001	JUN 13, 2001	JUN	NEWA

PENCICLOVIR SODIUM						
CREAM; TOPICAL						
DENAVIR						
+ NOVARTIS	1%	N20629 001	SEP 24, 1996	JUL	CAHN	
PENICILLIN G POTASSIUM						
FOR SOLUTION; ORAL						
PENICILLIN						
@ TEVA	200,000 UNITS/5ML	N60307 002	MAY 27, 1964	JUL	DISC	
@	400,000 UNITS/5ML	N60307 004	MAY 27, 1964	JUL	DISC	
PENICILLIN-2						
@ TEVA	250,000 UNITS/5ML	N60307 003	MAY 27, 1964	JUL	DISC	
TABLET; ORAL						
PENICILLIN G POTASSIUM						
@ TEVA	200,000 UNITS	N60306 001	JUN 01, 1964	MAY	DISC	
@	250,000 UNITS	N60306 002	JUN 01, 1964	MAY	DISC	
@	400,000 UNITS	N60306 003	JUN 01, 1964	MAY	DISC	
@	500,000 UNITS	N60306 004	JUN 26, 1979	MAY	DISC	
PENICILLIN G PROCAINE						
INJECTABLE; INJECTION						
PENICILLIN G PROCAINE						
@ PFIZER	300,000 UNITS/VIAL	N60099 001	NOV 10, 1948	MAY	DISC	
@	1,500,000 UNITS/VIAL	N60099 002	NOV 10, 1948	MAY	DISC	
PFIZERPEN-AS						
@ PFIZER	300,000 UNITS/ML	N60286 001	NOV 01, 1950	MAY	DISC	
@	600,000 UNITS/ML	N60286 002	NOV 01, 1950	MAY	DISC	
WYCILLIN						
+ KING PHARMS	300,000 UNITS/ML	N60101 002	APR 26, 1948	MAY	CTEC	
+	600,000 UNITS/ML	N60101 001	APR 26, 1948	MAY	CTEC	
PENICILLIN G SODIUM						
INJECTABLE; IM-IV						
PENICILLIN G SODIUM						
+ BIOCHEMIE	5,000,000 UNITS/VIAL	N65068 001	FEB 26, 2001	FEB	NEWA	
@ MARSAM	5,000,000 UNITS/VIAL	N63014 001	SEP 13, 1988	FEB	DISC	
PENICILLIN V POTASSIUM						
FOR SOLUTION; ORAL						
PENICILLIN V POTASSIUM						
@ MYLAN	EQ 125MG BASE/5ML	N61624 002	AUG 07, 1972	MAY	DISC	
@	EQ 250MG BASE/5ML	N61624 001	JUN 05, 1972	MAY	DISC	
V-CILLIN K						
@ LILLY	EQ 125MG BASE/5ML	N60004 001	AUG 21, 1958	MAY	DISC	
@	EQ 250MG BASE/5ML	N60004 002	APR 07, 1967	MAY	DISC	
TABLET; ORAL						
PEN-VEE K						
AB + WYETH AYERST	EQ 500MG BASE	N60006 003	JAN 13, 1958	MAY	CRLD	
PENICILLIN V POTASSIUM						
AB + BIOCHEMIE	EQ 500MG BASE	N64071 002	NOV 30, 1995	MAY	CTEC	
@ MYLAN	EQ 250MG BASE	N61530 001	NOV 18, 1971	MAY	DISC	
@	EQ 500MG BASE	N61530 002	MAR 20, 1972	MAY	DISC	

PENICILLIN V POTASSIUM
TABLET; ORAL
V-CILLIN K

@ LILLY	EQ 125MG BASE	N60003 001	SEP 17, 1957	MAY	DISC
@	EQ 250MG BASE	N60003 002	SEP 17, 1957	MAY	DISC
@	EQ 500MG BASE	N60003 003	SEP 17, 1957	MAY	DISC

PENTOBARBITAL
ELIXIR; ORAL
NEMBUTAL

@ ABBOTT	18.2MG/5ML	N83244 001	JAN 08, 1975	JUL	DISC

PENTOBARBITAL SODIUM
CAPSULE; ORAL
NEMBUTAL SODIUM

@ ABBOTT	50MG	N84093 001	JAN 14, 1975	JUL	DISC

SUPPOSITORY; RECTAL
NEMBUTAL

@ ABBOTT	30MG	N83247 001	JAN 25, 1982	JUL	DISC
@	60MG	N83247 002	JAN 25, 1982	JUL	DISC
@	120MG	N83247 003	JAN 25, 1982	JUL	DISC
@	200MG	N83247 004	JAN 25, 1982	JUL	DISC

PERFLUTREN
INJECTABLE; INTRAVENOUS
DEFINITY

+ DUPONT PHARMS	6.52MG/ML	N21064 001	JUL 31, 2001	JUL	NEWA

PERPHENAZINE
CONCENTRATE; ORAL
PERPHENAZINE

+ PHARM ASSOC	16MG/5ML	N40360 001	MAY 25, 2001	MAY	NEWA

TRILAFON

@ SCHERING	16MG/5ML	N11557 001	DEC 12, 1958	MAR	DISC

PHENAZOPYRIDINE HYDROCHLORIDE; SULFAMETHOXAZOLE; TRIMETHOPRIM
TABLET; ORAL
SULFAMETHOXAZOLE AND TRIMETHOPRIM AND PENAZOPYRIDINE HCL

+ ABLE	200MG;800MG;160MG	N21105 001	JUN 26, 2001	JUN	NEWA

PHENDIMETRAZINE TARTRATE
CAPSULE; ORAL
PHENDIMETRAZINE TARTRATE

	@ EON	35MG	N85633 001	JUL 13, 1978	JUL	DISC
	@	35MG	N85694 001	JUN 05, 1978	MAY	DISC
AA	+	35MG	N85695 001	JUN 05, 1978	JUL	CRLD
	@	35MG	N85702 001	JUN 07, 1978	JUL	DISC

CAPSULE, EXTENDED RELEASE; ORAL

BC	+ EON	105MG	N18074 001	APR 16, 1979	JUL	CRLD
	@ GENEVA PHARMS	105MG	N87378 001	NOV 03, 1981	JUL	DISC

TABLET; ORAL
PHENAZINE-35

@ ABC HOLDING	35MG	N85512 001	MAY 06, 1977	MAY	DISC

PHENDIMETRAZINE TARTRATE						
TABLET; ORAL						
PHENDIMETRAZINE TARTRATE						
@ EON	35MG	N85402 001	MAY 19, 1978	MAY	DISC	
@	35MG	N85497 001	AUG 19, 1977	MAY	DISC	
@ MIKART	35MG	N89452 001	OCT 30, 1991	JUL	DISC	
@ ROSEMONT	35MG	N84399 001	MAY 28, 1981	MAY	DISC	
STATOBEX						
@ TEVA	35MG	N86013 001	DEC 16, 1977	JUL	DISC	
X-TROZINE						
@ SHIRE RICHWOOD	35MG	N86550 001	SEP 16, 1981	JUL	DISC	
@	35MG	N86551 001	SEP 16, 1981	JUL	DISC	
@	35MG	N86552 001	SEP 16, 1981	JUL	DISC	
PHENTERMINE HYDROCHLORIDE						
CAPSULE; ORAL						
OBY-TRIM						
@ SHIRE RICHWOOD	30MG	N87764 001	MAR 18, 1982	JUL	DISC	
PHENTERMINE HCL						
@ ABC HOLDING	30MG	N85411 001	SEP 10, 1980	MAY	DISC	
AA ABLE	30MG	N40403 001	AUG 30, 2001	AUG	NEWA	
AA	30MG	N40427 001	AUG 30, 2001	AUG	NEWA	
@ ROSEMONT	30MG	N84487 001	APR 09, 1982	MAY	DISC	
TABLET; ORAL						
AA ABLE	37.5MG	N40402 001	AUG 30, 2001	AUG	NEWA	
+ EON	30MG	N88605 001	SEP 28, 1987	MAY	CMFD	
PHENYTOIN						
SUSPENSION; ORAL						
PHENYTOIN						
AB UDL	125MG/5ML	N40342 001	JAN 31, 2001	JAN	NEWA	
PIPERAZINE CITRATE						
SYRUP; ORAL						
PIPERAZINE CITRATE						
@ LANNETT	EQ 500MG BASE/5ML	N80963 001	JUL 25, 1974	MAY	DISC	
TABLET; ORAL						
@ IMPAX LABS	EQ 250MG BASE	N80874 001	JUL 19, 1973	MAY	DISC	
PIPOBROMAN						
TABLET; ORAL						
VERCYTE						
@ ABBOTT	25MG	N16245 002	JUL 01, 1966	JUL	DISC	
PORACTANT ALFA						
SUSPENSION; INTRATRACHEAL						
CUROSURF						
+ DEY	80MG/ML	N20744 001	NOV 18, 1999	SEP	CAIN	
POTASSIUM CHLORIDE						
TABLET, EXTENDED RELEASE; ORAL						
K-DUR 10						
AB KEY PHARMS	10MEQ	N19439 002	JUN 13, 1986	APR	CTEC	

PRAZOSIN HYDROCHLORIDE
CAPSULE; ORAL
PRAZOSIN HCL

		@ PUREPAC PHARM	EQ 1MG BASE	N72991	001	MAY 16, 1989	JUL	DISC
		@	EQ 2MG BASE	N72921	001	MAY 16, 1989	JUL	DISC
		@	EQ 5MG BASE	N72992	001	MAY 16, 1989	JUL	DISC

PREDNICARBATE
OINTMENT; TOPICAL
DERMATOP

	+	AVENTIS PHARMS	0.1%	N19568	001	SEP 23, 1991	MAR	CMFD

PREDNISOLONE
SYRUP; ORAL
PREDNISOLONE

>A>	AA	KV PHARM	5MG/5ML	N40423	001	OCT 22, 2001	OCT	NEWA

PRELONE

>D>	+	MURO	5MG/5ML	N89654	001	JAN 17, 1989	OCT	CFTG
>A>	AA +		5MG/5ML	N89654	001	JAN 17, 1989	OCT	CFTG

TABLET; ORAL
PREDNISOLONE

		@ CHELSEA LABS	5MG	N85085	002	FEB 23, 1977	MAY	DISC

PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM
OINTMENT; OPHTHALMIC
VASOCIDIN

AT		NOVARTIS	0.5%;10%	N88791	001	OCT 05, 1984	FEB	CAHN

SUSPENSION/DROPS; OPHTHALMIC
METIMYD

	+	SCHERING	0.5%;10%	N10210	001	FEB 24, 1956	FEB	CTEC

PREDAMIDE

		@ AKORN	0.5%;10%	N88059	001	JUL 29, 1983	FEB	WDRP

SULPHRIN

		@ BAUSCH AND LOMB	0.5%;10%	N88089	001	DEC 28, 1982	FEB	WDRP

PREDNISOLONE SODIUM PHOSPHATE
SOLUTION/DROPS; OPHTHALMIC
INFLAMASE FORTE

AT	+	NOVARTIS	EQ 0.9% PHOSPHATE	N80751	002	DEC 19, 1973	FEB	CAHN

INFLAMASE MILD

AT	+	NOVARTIS	EQ 0.11% PHOSPHATE	N80751	001	DEC 19, 1973	FEB	CAHN

PREDNISOLONE SODIUM PHOSPHATE

		@ AKORN	EQ 0.11% PHOSPHATE	N83358	001	AUG 21, 1974	FEB	WDRP
		@	EQ 0.9% PHOSPHATE	N83358	002	AUG 21, 1974	FEB	WDRP
		@ ALCON UNIVERSAL	EQ 0.11% PHOSPHATE	N81043	001	OCT 24, 1991	MAY	DISC
		@	EQ 0.9% PHOSPHATE	N81044	001	OCT 24, 1991	MAY	DISC

PREDNISONE
TABLET; ORAL
PREDNISONE

		@ CHELSEA LABS	5MG	N85084	002	DEC 15, 1981	MAY	DISC
		@ GENEVA PHARMS	5MG	N80336	002	JUL 29, 1976	MAY	DISC

	@ HALSEY	10MG	N86595 001	APR 10, 1979	JUL	DISC
	@ LANNETT	20MG	N84275 001	JUN 27, 1974	MAY	DISC
AB	TRIGEN	5MG	N40362 002	AUG 29, 2001	AUG	NEWA
AB		10MG	N40362 001	AUG 29, 2001	AUG	NEWA

PRILOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CITANEST PLAIN

	@ ASTRAZENECA	4%	N14763 007	NOV 18, 1965	SEP	DISC
+	DENTSPLY PHARM	4%	N21382 001	NOV 18, 1965	SEP	NEWA

PRIMIDONE

SUSPENSION; ORAL

MYSOLINE

+	XCEL PHARMS	250MG/5ML	N10401 001	JUL 05, 1956	JUL	CAHN

TABLET; ORAL

AB	ELAN PHARMA	50MG	N09170 003	MAR 08, 1954	MAY	CFTG
AB	XCEL PHARMS	50MG	N09170 003	MAR 08, 1954	JUL	CAHN
AB +		250MG	N09170 002	MAR 08, 1954	JUL	CAHN

PRIMIDONE

AB	LANNETT	50MG	N84903 002	MAY 24, 2001	MAY	NEWA

PROCHLORPERAZINE

SUPPOSITORY; RECTAL

COMPAZINE

AB	SMITHKLINE BEECHAM	2.5MG	N11127 003	FEB 09, 1959	JUL	CFTG
AB		5MG	N11127 001	SEP 27, 1957	JUL	CFTG

PROCHLORPERAZINE

AB	ABLE	2.5MG	N40407 001	JUL 11, 2001	JUL	NEWA
AB		5MG	N40407 002	JUL 11, 2001	JUL	NEWA
AB		25MG	N40407 003	JUL 11, 2001	JUL	NEWA

PROCHLORPERAZINE EDISYLATE

INJECTABLE; INJECTION

PROCHLORPERAZINE EDISYLATE

	@ WYETH AYERST	EQ 5MG BASE/ML	N86348 001	JUL 05, 1979	JUL	DISC

PROCHLORPERAZINE MALEATE

TABLET; ORAL

PROCHLORPERAZINE MALEATE

AB	GENEVA PHARMS TECH	EQ 5MG BASE	N40101 001	JUL 19, 1996	JAN	CAHN
AB		EQ 10MG BASE	N40101 002	JUL 19, 1996	JAN	CAHN
AB		EQ 25MG BASE	N40101 003	JUL 19, 1996	JAN	CAHN

PROGESTERONE

INJECTABLE; INJECTION

PROGESTERONE

AO	AM PHARM PARTNERS	50MG/ML	N75906 001	APR 25, 2001	APR	NEWA
>A> AO +	SCHEIN	50MG/ML	N17362 002	MAY 08, 1978	OCT	CAHN
>D> AO +	STERIS	50MG/ML	N17362 002	MAY 08, 1978	OCT	CAHN
AO +		50MG/ML	N17362 002	MAY 08, 1978	APR	CFTG

		PROMETHAZINE HYDROCHLORIDE						
		SUPPOSITORY; RECTAL						
		PROMETHACON						
		@ POLYMEDICA	50MG	N84902	001	OCT 05, 1981	MAY	DISC
		TABLET; ORAL						
		PHENERGAN						
		WYETH AYERST	12.5MG	N07935	002	MAR 29, 1951	MAY	CTEC
		PROMETHAZINE HCL						
		@ LANNETT	12.5MG	N80949	001	JUL 28, 1976	MAY	DISC
		@	25MG	N80949	002	JUN 28, 1976	MAY	DISC
		@	50MG	N80949	003	JUN 28, 1976	MAY	DISC
		@ PVT FORM	25MG	N83658	001	OCT 01, 1976	MAY	DISC
		PROPOXYPHENE HYDROCHLORIDE						
		CAPSULE; ORAL						
		PROPOXYPHENE HCL						
		@ GENEVA PHARMS	65MG	N83125	002	APR 14, 1976	MAY	DISC
		@ IMPAX LABS	65MG	N83317	001	OCT 23, 1973	MAY	DISC
		PROPRANOLOL HYDROCHLORIDE						
		CAPSULE, EXTENDED RELEASE; ORAL						
		INDERAL LA						
		WYETH AYERST LABS	60MG	N18553	004	MAR 18, 1987	AUG	CRLD
			80MG	N18553	002	APR 19, 1983	AUG	CRLD
			120MG	N18553	003	APR 19, 1983	AUG	CRLD
		TABLET; ORAL						
		PROPRANOLOL HCL						
		@ LEDERLE	10MG	N70125	001	JUL 30, 1985	MAY	DISC
>D>	AB		20MG	N70126	001	JUL 30, 1985	OCT	DISC
>A>		@	20MG	N70126	001	JUL 30, 1985	OCT	DISC
		@	40MG	N70127	001	JUL 30, 1985	SEP	DISC
		@ WATSON LABS	20MG	N70549	001	APR 11, 1986	MAY	DISC
		PROTRIPTYLINE HYDROCHLORIDE						
		TABLET; ORAL						
		PROTRIPTYLINE HCL						
	AB	ODYSSEY PHARMS	5MG	N73644	001	AUG 24, 1995	JAN	CAHN
	AB		10MG	N73645	001	AUG 24, 1995	JAN	CAHN
		VIVACTIL						
	AB	ODYSSEY PHARMS	5MG	N73644	001	AUG 24, 1995	MAR	CTNA
	AB	+	10MG	N73645	001	AUG 24, 1995	MAR	CTNA
		@ SIDMAK LABS	5MG	N16012	001	SEP 27, 1967	MAR	DISC
		@	10MG	N16012	002	SEP 27, 1967	MAR	DISC
		PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE						
		SYRUP; ORAL						
		TRILITRON						
		@ NEWTRON PHARMS	30MG/5ML;1.25MG/5ML	N88474	001	FEB 12, 1985	FEB	WDRP

QUINIDINE GLUCONATE
TABLET, EXTENDED RELEASE; ORAL
QUINAGLUTE

BX	+ BERLEX LABS	324MG	N16647 001	DEC 08, 1969	MAR	CTEC
	QUINIDINE GLUCONATE					
BX	DANBURY PHARMA	324MG	N87810 001	SEP 29, 1982	MAR	CTEC
	@ GENEVA PHARMS	324MG	N89894 001	DEC 15, 1988	MAR	DISC
BX	MUTUAL PHARM	324MG	N89338 001	FEB 11, 1987	MAR	CTEC

QUINIDINE SULFATE
TABLET; ORAL
QUINIDINE SULFATE

@ IMPAX LABS	200MG	N83347 001	DEC 08, 1976	FEB	DISC
@ MUTUAL PHARM	300MG	N81031 001	APR 14, 1989	MAY	DISC
@ WEST WARD	200MG	N83862 001	SEP 02, 1976	MAY	DISC

RANITIDINE HYDROCHLORIDE
CAPSULE; ORAL
ZANTAC 150

@ GLAXO WELLCOME	EQ 150MG BASE	N20095 001	MAR 08, 1994	AUG	DISC

TABLET; ORAL
RANITIDINE HCL

@ BOEHRINGER INGELHEIM	EQ 150MG BASE	N74662 001	AUG 29, 1997	SEP	DISC
@	EQ 300MG BASE	N74662 002	AUG 29, 1997	SEP	DISC

RIBAVIRIN
CAPSULE; ORAL
REBETOL

+ SCHERING PLOUGH RES	200MG	N20903 002	JUL 25, 2001	AUG	NEWA

RIFAMPIN
CAPSULE; ORAL
RIFAMPIN

AB	VERSAPHARM	150MG	N65028 001	MAR 14, 2001	MAR	NEWA
AB		300MG	N65028 002	MAR 14, 2001	MAR	NEWA

RISPERIDONE
TABLET; ORAL
RISPERDAL

	JANSSEN	0.5MG	N20272 007	JAN 27, 1999	APR	CRLD
+		1MG	N20272 001	DEC 29, 1993	APR	CRLD
		4MG	N20272 004	DEC 29, 1993	APR	CRLD

SECOBARBITAL SODIUM
CAPSULE; ORAL
SECOBARBITAL SODIUM

@ ICN	100MG	N85477 001	DEC 10, 1981	FEB	WDRP

SECRETIN
INJECTABLE; INJECTION
SECRETIN-FERRING

@ FERRING	75CU/VIAL	N18290 001	MAY 29, 1981	JUN	DISC

	SILVER SULFADIAZINE						
	DRESSING; TOPICAL						
	SILDAFLO						
	@ QUESTCOR PHARMS	1%	N19608 001	NOV 30, 1989	MAY	CTNA
	SIMVASTATIN						
	TABLET; ORAL						
	ZOCOR						
	MERCK	5MG	N19766 001	DEC 23, 1991	APR	CTEC
	SODIUM IODIDE, I-131						
	CAPSULE; ORAL						
	SODIUM IODIDE I 131						
>D>	+ CIS	100uCi	N17316 002	NOV 10, 1976	OCT	DISC
>A>	@	100uCi	N17316 002	NOV 10, 1976	OCT	DISC
	SODIUM POLYSTYRENE SULFONATE						
	SUSPENSION; ORAL, RECTAL						
	SPS						
AA	+ CAROLINA MEDCL	15GM/60ML	N87859 001	DEC 08, 1982	MAY	CRLD
	SODIUM TETRADECYL SULFATE						
	INJECTABLE; INJECTION						
	SOTRADECOL						
	@ ELKINS SINN	1%	N05970 004	AUG 13, 1946	JUL	DISC
	@	3%	N05970 005	AUG 13, 1946	JUL	DISC
	SOMATROPIN RECOMBINANT						
	INJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS						
	SAIZEN						
	+ SERONO	8.8MG/VIAL	N19764 003	AUG 29, 2000	AUG	NEWA
	SOTALOL HYDROCHLORIDE						
	TABLET; ORAL						
	SORINE						
AB	UPSHER SMITH	80MG	N75500 001	APR 27, 2001	APR	NEWA
AB		120MG	N75500 004	APR 27, 2001	APR	NEWA
AB		160MG	N75500 002	APR 27, 2001	APR	NEWA
AB		240MG	N75500 003	APR 27, 2001	APR	NEWA
	SOTALOL HCL						
>A> AB	MUTUAL PHARM	80MG	N75515 001	OCT 15, 2001	OCT	NEWA
>A> AB		120MG	N75515 004	OCT 15, 2001	OCT	NEWA
>A> AB		160MG	N75515 002	OCT 15, 2001	OCT	NEWA
>A> AB		240MG	N75515 003	OCT 15, 2001	OCT	NEWA
	SPIRONOLACTONE						
	TABLET; ORAL						
	SPIRONOLACTONE						
AB	MYLAN	25MG	N40424 001	AUG 20, 2001	AUG	NEWA
AB		50MG	N40424 002	AUG 20, 2001	AUG	NEWA
AB		100MG	N40424 003	AUG 20, 2001	AUG	NEWA

STREPTOMYCIN SULFATE
INJECTABLE; INJECTION
STREPTOMYCIN SULFATE

@ PFIZER		EQ 1GM BASE/VIAL	N60076 001	FEB 18, 1946	MAY	DISC
@		EQ 5GM BASE/VIAL	N60076 002	FEB 18, 1946	MAY	DISC
+ PHARMA TEK		EQ 1GM BASE/VIAL	N64210 001	JUN 30, 1998	MAY	CTEC

SULFACETAMIDE SODIUM
OINTMENT; OPHTHALMIC
BLEPH-10

@ ALLERGAN		10%	N84015 001	JAN 07, 1975	MAY	DISC
CETAMIDE							
AT + ALCON		10%	N80021 001	SEP 27, 1972	MAY	CTEC
SODIUM SULAMYD							
@ SCHERING		10%	N05963 002	NOV 26, 1947	MAY	DISC

SOLUTION/DROPS; OPHTHALMIC
BLEPH-10

AT + ALLERGAN		10%	N80028 001	MAY 25, 1971	MAY	CRLD
BLEPH-30							
AT + ALLERGAN		30%	N80028 002	MAY 25, 1971	MAY	CRLD
SODIUM SULAMYD							
@ SCHERING		10%	N05963 001	AUG 01, 1946	MAY	DISC
@		30%	N05963 003	NOV 26, 1947	MAY	DISC
SULF-10							
@ NOVARTIS		10%	N80025 001	JUN 03, 1971	FEB	CAHN
AT		10%	N80025 001	JUN 03, 1971	SEP	CMFD
SULF-15							
AT NOVARTIS		15%	N89047 001	OCT 31, 1995	FEB	CAHN
SULTEN-10							
@ BAUSCH AND LOMB		10%	N87818 001	FEB 03, 1983	FEB	WDRP

SULFAMETHOXAZOLE
TABLET; ORAL
GANTANOL

+ ROCHE		500MG	N12715 002	NOV 17, 1961	MAY	CTEC
SULFAMETHOXAZOLE							
@ GENEVA PHARMS		500MG	N85844 001	MAR 23, 1978	MAY	DISC

SULFAMETHOXAZOLE; TRIMETHOPRIM
INJECTABLE; INJECTION
BACTRIM

>D>	AP	+ ROCHE	80MG/ML;16MG/ML	N18374 001	JUN 23, 1981	OCT	CAHN
>A>	AP	+ WOMEN FIRST HLTHCARE	80MG/ML;16MG/ML	N18374 001	JUN 23, 1981	OCT	CAHN

SUSPENSION; ORAL

>D>	@ ROCHE	200MG/5ML;40MG/5ML	N17560 001	APR 16, 1975	OCT	CAHN
>A>	@ WOMEN FIRST HLTHCARE	200MG/5ML;40MG/5ML	N17560 001	APR 16, 1975	OCT	CAHN

BACTRIM PEDIATRIC

>D>	AB	+ ROCHE	200MG/5ML;40MG/5ML	N17560 002	DEC 10, 1979	OCT	CAHN
>A>	AB	+ WOMEN FIRST HLTHCARE	200MG/5ML;40MG/5ML	N17560 002	DEC 10, 1979	OCT	CAHN

TRIMETH/SULFA

@ NASKA			200MG/5ML;40MG/5ML	N72399 001	MAY 23, 1988	FEB	WDRP

TABLET; ORAL

		SULFAMETHOXAZOLE; TRIMETHOPRIM						
		TABLET; ORAL						
		BACTRIM						
>D>	AB	ROCHE	400MG;80MG	N17377 001	JUL 30, 1973	OCT	CAHN	
>A>	AB	WOMEN FIRST HLTHCARE	400MG;80MG	N17377 001	JUL 30, 1973	OCT	CAHN	
		BACTRIM DS						
>D>	AB +	ROCHE	800MG;160MG	N17377 002	MAR 01, 1978	OCT	CAHN	
>A>	AB +	WOMEN FIRST HLTHCARE	800MG;160MG	N17377 002	MAR 01, 1978	OCT	CAHN	
		SULFAMETHOXAZOLE AND TRIMETHOPRIM						
>D>	AB	ROXANE	400MG;80MG	N72768 001	AUG 30, 1991	OCT	DISC	
>A>		@	400MG;80MG	N72768 001	AUG 30, 1991	OCT	DISC	
		@ TEVA	400MG;80MG	N18242 001	MAY 19, 1981	MAY	DISC	
		@	800MG;160MG	N18242 002	MAY 19, 1981	MAY	DISC	
		SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH						
>D>	AB	PLANTEX	800MG;160MG	N70037 001	JUN 02, 1987	OCT	CAHN	
		@ ROXANE	800MG;160MG	N72769 001	AUG 30, 1991	SEP	DISC	
>A>	AB	TEVA	800MG;160MG	N70037 001	JUN 02, 1987	OCT	CAHN	
		SULFANILAMIDE						
		CREAM; VAGINAL						
		AVC						
	AT +	NOVAVAX	15%	N06530 003	JAN 27, 1987	JAN	CAHN	
		SUPPOSITORY; VAGINAL						
		+ NOVAVAX	1.05GM	N06530 004	JAN 27, 1987	JAN	CAHN	
		SULFISOXAZOLE						
		TABLET; ORAL						
		SULFISOXAZOLE						
		@ GENEVA PHARMS	500MG	N85628 001	JUN 13, 1977	JUL	DISC	
		TECHNETIUM TC-99M APCITIDE						
		INJECTABLE; INJECTION						
		ACUTECT						
		BERLEX LABS	N/A	N20887 001	SEP 14, 1998	MAY	CAHN	
		DIATIDE RES LABS	N/A	N20887 001	SEP 14, 1998	APR	CAHN	
			N/A	N20887 001	SEP 14, 1998	JUL	CAHN	
		TECHNETIUM TC-99M PENTETATE KIT						
		INJECTABLE; INJECTION						
		MPI DTPA KIT - CHELATE						
		@ NYCOMED AMERSHAM	N/A	N17255 001	APR 15, 1976	SEP	WDAG	
		TEMAZEPAM						
		CAPSULE; ORAL						
		RESTORIL						
		TYCO HLTHCARE	7.5MG	N18163 003	OCT 25, 1991	JUN	CAHN	
	AB		15MG	N18163 001	FEB 27, 1981	JUN	CAHN	
	AB +		30MG	N18163 002	FEB 27, 1981	JUN	CAHN	
>A>		TENOFOVIR DISOPROXIL FUMARATE						
>A>		TABLET; ORAL						
>A>		VIREAD						
>A>		+ GILEAD	300MG	N21356 001	OCT 26, 2001	OCT	NEWA	

TERAZOSIN HYDROCHLORIDE
CAPSULE; ORAL
TERAZOSIN HCL

AB	TORPHARM	EQ 1MG BASE	N75498 001	APR 12, 2001	APR	NEWA
AB		EQ 2MG BASE	N75498 002	APR 12, 2001	APR	NEWA
AB		EQ 5MG BASE	N75498 003	APR 12, 2001	APR	NEWA
AB		EQ 10MG BASE	N75498 004	APR 12, 2001	APR	NEWA
AB	ZENITH GOLDLINE	EQ 1MG BASE	N75614 002	JAN 30, 2001	JAN	NEWA
AB		EQ 2MG BASE	N75614 001	JAN 30, 2001	JAN	NEWA
AB		EQ 5MG BASE	N75614 003	JAN 30, 2001	JAN	NEWA
AB		EQ 10MG BASE	N75614 004	JAN 30, 2001	JAN	NEWA

TERBUTALINE SULFATE
TABLET; ORAL
BRETHINE

AB	NOVARTIS	2.5MG	N17849 001	MAY 17, 1976	JUN	CFTG
AB +		5MG	N17849 002	MAY 17, 1976	JUN	CFTG
	TERBUTALINE SULFATE					
AB	IMPAX LABS	2.5MG	N75877 001	JUN 26, 2001	JUN	NEWA
AB		5MG	N75877 002	JUN 26, 2001	JUN	NEWA

TETRACYCLINE HYDROCHLORIDE
CAPSULE; ORAL
PANMYCIN

	@ PHARMACIA AND UPJOHN	250MG	N60347 001	SEP 28, 1954	MAY	DISC
	ROBITET					
	@ WYETH AYERST	250MG	N61734 001	JUN 06, 1973	MAY	DISC
	@	500MG	N61734 002	JUN 06, 1973	MAY	DISC
	TETRACYCLINE HCL					
	@ DANBURY PHARMA	250MG	N62343 001	OCT 02, 1981	MAY	DISC
	@	500MG	N62343 002	OCT 02, 1981	MAY	DISC
	@ EON	250MG	N61471 001	OCT 28, 1971	MAY	DISC
	@ WEST WARD	250MG	N60768 001	AUG 24, 1964	MAY	DISC
	@	500MG	N60768 002	NOV 07, 1977	MAY	DISC
	@ WYETH AYERST	250MG	N61685 001	DEC 11, 1972	JUL	DISC
	@	500MG	N61685 002	DEC 11, 1972	JUL	DISC

THIORIDAZINE HYDROCHLORIDE
TABLET; ORAL
THIORIDAZINE HCL

	@ CHELSEA LABS	10MG	N88561 001	MAY 11, 1984	JUL	DISC
	@ TEVA	10MG	N88493 001	MAY 17, 1985	JUL	DISC
	@ ZENITH GOLDLINE	50MG	N88194 001	APR 14, 1983	JUL	DISC

THIOTEPA
INJECTABLE; INJECTION
THIOPLEX

AP +	IMMUNEX	15MG/VIAL	N20058 001	DEC 22, 1994	APR	CFTG
	THIOTEPA					
AP	AAIPHARMA	15MG/VIAL	N75698 001	SEP 20, 2001	SEP	NEWA
AP	BEDFORD	15MG/VIAL	N75547 001	APR 02, 2001	APR	NEWA
AP	GENSIA SICOR PHARMS	15MG/VIAL	N75730 001	APR 20, 2001	APR	NEWA

+		30MG/VIAL	N75730 002	APR 20, 2001	APR	NEWA
@ IMMUNEX		15MG/VIAL	N11683 001	FEB 19, 1959	APR	DISC
THYROGLOBULIN						
TABLET; ORAL						
THYROGLOBULIN						
@ IMPAX LABS		64.8MG	N80151 001	AUG 07, 1973	FEB	DISC
TICARCILLIN DISODIUM						
INJECTABLE; INJECTION						
TICAR						
@ SMITHKLINE BEECHAM		EQ 3GM BASE/VIAL	N62690 001	DEC 19, 1986	MAY	DISC
TOBRAMYCIN						
SOLUTION; INHALATION						
TOBI						
+ CHIRON		300MG/5ML	N50753 001	DEC 22, 1997	SEP	CAHN
SOLUTION/DROPS; OPHTHALMIC						
TOBRAMYCIN						
@ ALCON UNIVERSAL		0.3%	N63176 001	MAY 25, 1994	MAY	DISC
AT ALTANA		0.3%	N65026 001	SEP 11, 2001	SEP	NEWA
TOBRAMYCIN SULFATE						
INJECTABLE; INJECTION						
NEBCIN						
AP + LILLY		EQ 1.2GM BASE/VIAL	N50519 001	JUN 11, 1979	AUG	CFTG
TOBRAMYCIN						
AP PHARMA TEK		EQ 1.2GM BASE/VIAL	N65013 001	AUG 17, 2001	AUG	NEWA
TOBRAMYCIN SULFATE						
@ ASTRAZENECA		EQ 10MG BASE/ML	N63119 001	OCT 31, 1994	AUG	DISC
@		EQ 40MG BASE/ML	N63121 001	OCT 31, 1994	MAY	DISC
@ ELKINS SINN		EQ 10MG BASE/ML	N63128 001	NOV 27, 1991	MAY	DISC
@		EQ 40MG BASE/ML	N63127 001	NOV 27, 1991	MAY	DISC
@ LEDERLE		EQ 10MG BASE/ML	N63113 001	APR 26, 1991	MAY	DISC
TOLMETIN SODIUM						
CAPSULE; ORAL						
TOLMETIN SODIUM						
@ GENEVA PHARMS		EQ 400MG BASE	N73462 001	APR 30, 1992	JUL	DISC
TOPIRAMATE						
TABLET; ORAL						
TOPAMAX						
+ JOHNSON RW		25MG	N20505 004	DEC 24, 1996	MAR	CRLD
		200MG	N20505 002	DEC 24, 1996	MAR	CRLD
TRAVOPROST						
SOLUTION/DROPS; OPHTHALMIC						
TRAVATAN						
+ ALCON UNIVERSAL		0.004%	N21257 001	MAR 16, 2001	MAR	NEWA

		TRIAMCINOLONE						
		TABLET; ORAL						
		TRIAMCINOLONE						
		@ IMPAX LABS	4MG	N84340 001	APR 22, 1975	FEB	DISC	
		TRIAMCINOLONE ACETONIDE						
		AEROSOL, METERED; INHALATION						
		AZMACORT						
		+ AVENTIS	0.1MG/INH	N18117 001	APR 23, 1982	SEP	CAHN	
		AEROSOL, METERED; NASAL						
		NASACORT						
		+ AVENTIS	0.055MG/INH	N19798 001	JUL 11, 1991	SEP	CAHN	
		CREAM; TOPICAL						
		TRIAMCINOLONE ACETONIDE						
		@ TARO	0.025%	N40038 001	OCT 26, 1994	MAY	DISC	
		@ TOPIDERM	0.025%	N89274 001	FEB 21, 1989	FEB	WDRP	
		@	0.1%	N89275 001	FEB 21, 1989	FEB	WDRP	
		@	0.5%	N89276 001	FEB 21, 1989	FEB	WDRP	
		OINTMENT; TOPICAL						
		ARISTOCORT						
		@ FUJISAWA HLTHCARE	0.5%	N80745 002	MAY 28, 1974	JUL	DISC	
		ARISTOCORT A						
		@ FUJISAWA HLTHCARE	0.5%	N80745 003	SEP 23, 1975	JUL	DISC	
		TRIAMCINOLONE ACETONIDE						
		@ G AND W LABS	0.025%	N89795 001	DEC 23, 1988	JUL	DISC	
		@	0.1%	N89796 001	DEC 23, 1988	JUL	DISC	
	AT	THAMES	0.025%	N40374 001	JUN 05, 2001	JUN	NEWA	
	AT		0.5%	N40386 001	JUN 05, 2001	JUN	NEWA	
		SPRAY; TOPICAL						
		KENALOG						
		+ APOTHECON	0.147MG/GM	N12104 001	DEC 24, 1959	JUL	CDFR	
		SPRAY, METERED; NASAL						
		NASACORT AQ						
		+ AVENTIS	0.055MG/SPRAY	N20468 001	MAY 20, 1996	SEP	CAHN	
		TRICHLORMETHIAZIDE						
		TABLET; ORAL						
		TRICHLOREX						
		@ LANNETT	4MG	N83436 001	AUG 11, 1980	MAY	DISC	
		@	4MG	N85630 001	MAY 16, 1977	FEB	WDRP	
		TRICHLORMETHIAZIDE						
>D>	BP	IMPAX LABS	4MG	N83967 001	JAN 17, 1978	OCT	DISC	
>A>		@	4MG	N83967 001	JAN 17, 1978	OCT	DISC	
		TRIFLUOPERAZINE HYDROCHLORIDE						
		CONCENTRATE; ORAL						
		TRIFLUOPERAZINE HCL						
		@ GENEVA PHARMS	EQ 10MG BASE/ML	N85787 001	APR 15, 1982	MAY	DISC	
		TABLET; ORAL						
	AB	GENEVA PHARMS TECH	EQ 1MG BASE	N40153 001	OCT 25, 1996	JAN	CAHN	
	AB		EQ 2MG BASE	N40153 002	OCT 25, 1996	JAN	CAHN	
	AB		EQ 5MG BASE	N40153 003	OCT 25, 1996	JAN	CAHN	

AB		EQ 10MG BASE	N40153 004	OCT 25, 1996	JAN	CAHN

TRIMETHOBENZAMIDE HYDROCHLORIDE
INJECTABLE; INJECTION
TRIMETHOBENZAMIDE HCL

	@ STERIS	100MG/ML	N86577 001	OCT 19, 1982	JUL	DISC

TRIMETHOPRIM HYDROCHLORIDE
SOLUTION; ORAL
PRIMSOL

	@ ASCENT PEDS	EQ 25MG BASE/5ML	N74374 001	JUN 23, 1995	JUN	DISC

TRIMIPRAMINE MALEATE
CAPSULE; ORAL
SURMONTIL

	SIDMAK LABS	EQ 25MG BASE	N16792 001	JUN 12, 1979	AUG	CAHN
		EQ 50MG BASE	N16792 002	JUN 12, 1979	AUG	CAHN
	+	EQ 100MG BASE	N16792 003	SEP 15, 1982	AUG	CAHN

TRIPELENNAMINE HYDROCHLORIDE
TABLET; ORAL
TRIPELENNAMINE HCL

>D>	AA IMPAX LABS	50MG	N80785 001	AUG 07, 1973	OCT	DISC
>A>	@	50MG	N80785 001	AUG 07, 1973	OCT	DISC

TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE;SULFATHIAZOLE)
CREAM; VAGINAL
TRIPLE SULFA

	@ FOUGERA	3.7%;2.86%;3.42%	N86424 001	MAY 31, 1979	JUN	DISC

TRIPTORELIN PAMOATE
INJECTABLE; INTRAMUSCULAR
TRELSTAR

	+ DEBIO RECHERCHE	11.25MG/VIAL	N21288 001	JUN 29, 2001	JUN	NEWA
	+ PHARMACIA AND UPJOHN	11.25MG/VIAL	N21288 001	JUN 29, 2001	SEP	CAHN

TRELSTAR DEPOT

	+ DEBIO RECHERCHE	EQ 3.75MG BASE/VIAL	N20715 001	JUN 15, 2000	JUN	CDFR
	+ PHARMACIA AND UPJOHN	EQ 3.75MG BASE/VIAL	N20715 001	JUN 15, 2000	SEP	CAHN

TUBOCURARINE CHLORIDE
INJECTABLE; INJECTION
TUBOCURARINE CHLORIDE

	@ LILLY	3MG/ML	N06325 001	NOV 28, 1947	SEP	WDAG

URACIL MUSTARD
CAPSULE; ORAL
URACIL MUSTARD

	@ SHIRE PHARM	1MG	N12892 001	SEP 13, 1962	JUN	DISC

UREA, C-13
FOR SOLUTION; ORAL
BREATHTEK UBT FOR H-PYLORI

	+ MERETEK	EQ 75MG /POUCHE	N20586 002	MAY 10, 2001	AUG	NEWA

UREA, C-13
FOR SOLUTION; ORAL
MERETEK UBT KIT (W/ PRANACTIN)
@ MERETEK — 125MG/VIAL — N20586 001 SEP 17, 1996 AUG DISC

VALGANCICLOVIR HYDROCHLORIDE
TABLET; ORAL
VALCYTE
\+ SYNTEX (USA) INC LLC — EQ 450MG BASE — N21304 001 MAR 29, 2001 MAR NEWA

VALPROIC ACID
CAPSULE; ORAL
VALPROIC ACID
@ PAR PHARM — 250MG — N70431 001 FEB 28, 1986 MAY DISC
@ SCHERER RP — 250MG — N70195 001 JUL 02, 1987 JUL DISC

VALSARTAN
TABLET; ORAL
DIOVAN
NOVARTIS — 80MG — N21283 001 JUL 18, 2001 JUL NEWA
\+ — 160MG — N21283 002 JUL 18, 2001 JUL NEWA
320MG — N21283 003 JUL 18, 2001 JUL NEWA

VANCOMYCIN HYDROCHLORIDE
INJECTABLE; INJECTION
VANCOMYCIN HCL
@ ELKINS SINN — EQ 500MG BASE/VIAL — N62879 001 AUG 02, 1988 MAY DISC
@ — EQ 1GM BASE/VIAL — N62879 002 AUG 02, 1988 MAY DISC

VECURONIUM BROMIDE
INJECTABLE; INJECTION
VECURONIUM BROMIDE
\+ ABBOTT — 4MG/VIAL — N75558 001 SEP 11, 2001 SEP NEWA

VINBLASTINE SULFATE
INJECTABLE; INJECTION
VELBAN
@ LILLY — 10MG/VIAL — N12665 001 MAR 06, 1961 MAY DISC
VINBLASTINE SULFATE
AP \+ BEDFORD — 10MG/VIAL — N89395 001 APR 09, 1987 MAY CRLD

VITAMIN A PALMITATE
CAPSULE; ORAL
VITAMIN A
@ WEST WARD — EQ 50,000 UNITS BASE — N80967 001 MAY 04, 1973 FEB WDRP
INJECTABLE; INJECTION
AQUASOL A
\+ NEOSAN PHARMS — EQ 50,000 UNITS BASE/ML — N06823 001 MAY 18, 1949 AUG CAHN

WARFARIN SODIUM
TABLET; ORAL
COUMADIN

AB		DUPONT MERCK	2.5MG	N09218 018	NOV 29, 1961	JUL	CRLD
AB	+		5MG	N09218 007	FEB 17, 1964	JUL	CRLD
AB			5MG	N09218 007	FEB 17, 1964	AUG	CRLD

ZIPRASIDONE HYDROCHLORIDE
CAPSULE; ORAL
GEODON

		PFIZER	20MG	N20825 001	FEB 05, 2001	FEB	NEWA
			40MG	N20825 002	FEB 05, 2001	FEB	NEWA
			60MG	N20825 003	FEB 05, 2001	FEB	NEWA
	+		80MG	N20825 004	FEB 05, 2001	FEB	NEWA

ZOLEDRONIC ACID
INJECTABLE; IV (INFUSION)
ZOMETA

	+	NOVARTIS	EQ 4MG BASE/VIAL	N21223 001	AUG 20, 2001	SEP	CPOT
	+		4.264MG/VIAL	N21223 001	AUG 20, 2001	AUG	NEWA

ZOLMITRIPTAN
TABLET, ORALLY DISINTEGRATING; ORAL
ZOMIG-ZMT

		ASTRAZENECA	2.5MG	N21231 001	FEB 13, 2001	FEB	NEWA

ACETAMINOPHEN
SUPPOSITORY; RECTAL
ACETAMINOPHEN

@ ABLE	120MG	N73106 001	FEB 27, 1995	SEP	WDAG
@	325MG	N73107 001	FEB 27, 1995	SEP	WDAG
@	650MG	N73108 001	FEB 27, 1995	SEP	WDAG
ALPHARMA US PHARM	120MG	N18337 003	SEP 12, 1983	MAR	CAHN
	325MG	N18337 002	AUG 21, 1981	MAR	CAHN
+	650MG	N18337 001	APR 22, 1980	MAR	CAHN

INFANTS' FEVERALL

ALPHARMA US PHARM	80MG	N18337 004	AUG 26, 1992	MAR	CAHN

ACETAMINOPHEN; CLEMASTINE FUMARATE; PSEUDOEPHEDRINE HYDROCHLORIDE
TABLET; ORAL
TAVIST ALLERGY/SINUS/HEADACHE

+ NOVARTIS	500MG;EQ 0.25MG BASE;30MG	N21082 001	MAR 01, 2001	MAR	NEWA

ALCOHOL; CHLORHEXIDINE GLUCONATE
SOLUTION; TOPICAL
AVAGARD

+ 3M	61%;1%	N21074 001	JUN 07, 2001	JUN	NEWA

>A> ASPIRIN
>A> TABLET; ORAL
>A> BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN

>A> + BAYER	500MG	N21317 001	OCT 18, 2001	OCT	NEWA

BROMPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE
TABLET, EXTENDED RELEASE; ORAL
BROMATAPP

@ COPLEY PHARM	12MG;75MG	N71099 001	JUL 02, 1987	JUL	DISC

CLEMASTINE FUMARATE; PHENYLPROPANOLAMINE HYDROCHLORIDE
TABLET, EXTENDED RELEASE; ORAL
TAVIST-D

@ NOVARTIS	1.34MG;75MG	N18298 002	AUG 21, 1992	JAN	DISC
@	1.34MG;75MG	N20640 001	AUG 09, 1996	JAN	DISC

CLOTRIMAZOLE
CREAM; VAGINAL
TRIVAGIZOLE 3

TARO	2%	N21143 001	APR 12, 2000	JUL	CRLD

CROMOLYN SODIUM
SPRAY, METERED; NASAL
CROMOLYN SODIUM

ALPHARMA	5.2MG/INH	N74800 001	JUL 26, 2001	JUL	NEWA
BAUSCH AND LOMB	5.2MG/SPRAY	N75702 001	JUL 03, 2001	JUL	NEWA

FAMOTIDINE
TABLET; ORAL
FAMOTIDINE

DR REDDYS LABS LTD	10MG	N75758 001	AUG 17, 2001	AUG	NEWA
TEVA	10MG	N75312 001	MAY 31, 2001	MAY	NEWA
ZENITH GOLDLINE	10MG	N75512 001	JUL 26, 2001	JUL	NEWA

IBUPROFEN
TABLET; ORAL
ACHES-N-PAIN

>D> LEDERLE	200MG	N71065 001	MAY 28, 1987	OCT	DISC
>D> @	200MG	N71065 001	MAY 28, 1987	OCT	DISC

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE
TABLET; ORAL
IBUPROHM COLD AND SINUS

OHM LABS	200MG;30MG	N74567 001	APR 17, 2001	APR	NEWA

INSULIN PURIFIED PORK
INJECTABLE; INJECTION
REGULAR PURIFIED PORK INSULIN

+ NOVO NORDISK	100 UNITS/ML	N18381 001	MAR 17, 1980	MAY	CTEC

INSULIN RECOMBINANT HUMAN
INJECTABLE; INJECTION
NOVOLIN R

+ NOVO NORDISK	100 UNITS/ML	N19938 001	JUN 25, 1991	MAY	CTEC

INSULIN RECOMBINANT HUMAN; INSULIN SUSP ISOPHANE RECOMBINANT HUMAN
INJECTABLE; INJECTION
HUMULIN 50/50

+ LILLY	50 UNITS/ML;50 UNITS/ML	N20100 001	APR 29, 1992	MAY	CTEC
NOVOLIN 70/30					
+ NOVO NORDISK	30 UNITS/ML;70 UNITS/ML	N19991 001	JUN 25, 1991	MAY	CTEC

INSULIN RECOMBINANT PURIFIED HUMAN
INJECTABLE; INJECTION
VELOSULIN BR HUMAN

@ NOVO NORDISK	100 UNITS/ML	N19450 001	MAY 30, 1986	SEP	WDAG

MICONAZOLE NITRATE
CREAM; TOPICAL
MONISTAT 3 COMBINATION PACK

+ PERSONAL PRODS	2%;4%	N21261 001	FEB 02, 2001	FEB	NEWA
CREAM; TOPICAL, VAGINAL					
+ PERSONAL PRODS	2%;4%	N21261 001	FEB 02, 2001	MAY	CDFR

CREAM; VAGINAL

MINOXIDIL
SOLUTION; TOPICAL
MINOXIDIL EXTRA STRENGTH (FOR MEN)

PERRIGO	5%	N75598 001	JUN 13, 2001	JUN	NEWA

MINOXIDIL

SOLUTION; TOPICAL

MINOXIDIL EXTRA STRENGTH FOR MEN

>A>	NOVEX	5%	N75839 001	OCT 01, 2001	OCT	NEWA	

NICOTINE POLACRILEX

GUM, CHEWING; BUCCAL

>A>	NICORETTE (ORANGE)						
>A>	+ SMITHKLINE BEECHAM	EQ 4MG BASE	N20066 004	SEP 25, 2000	OCT	NEWA	
>A>	NICORETTE (ORANGE)						
>A>	+ SMITHKLINE BEECHAM	EQ 2MG BASE	N18612 004	SEP 25, 2000	OCT	NEWA	

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

CUMULATIVE SUPPLEMENT NUMBER 10 OCTOBER '01

NO OCTOBER 2001 APPROVALS

This data is provided to the Division of Data Management and Services from the Office of Orphan Products Development and it is not edited prior to publication.

Orphan Products Designations and Approvals List

October 2001

Name: Generic Name TN=Trade Name	Indication Designafed:	Sponsor & Address DD=Date Designated MA=Marketing Approval
(R)-N-[2-(6-chloro-5-methoxy-1H-indol-3-yl)propyl]acetamide TN=	Treatment of circadian rhythm sleep disorders in blind people with no light perception	Phase 2 Discovery, Inc. 3130 Highland Avenue, Third Floor Cincinnati OH 45219-2374 DD= 10/3/01 MA=
2-chloroethyl-3-sarcosinamide-1-nitrosourea TN=	Treatment for malignant gliomas	Lawrence Panasci, MD Professor of Medicine, McGill 3755 Cote Ste Catherine Montreal, Quebec H3T 1E2 DD= 8/3/01 MA=
2-methoxyestradiol TN=Panzem	Treatment of multiple myeloma	EntreMed, Inc. 9640 Medical Center Drive Rockville MD 20850 DD= 7/10/01 MA=
3-(4'aminoisoindoline-1'-one)-1-piperidine-2,6-dione TN=Revimid (proposed)	Treatment for multiple myeloma	Celegene Corporation 7 Powder Horn Drive Warren NJ 07059 DD= 9/20/01 MA=
9-nitro-20-(S)-camptothecin TN=Camvirex	Treatment of pediatric HIV infection/AIDS	NovoMed Pharmaceuticals, Inc. P.O. Box 900 Germantown MD 20875-0900 DD= 5/15/01 MA=
acetylcysteine TN=Acetadote	For the intravenous treatment of moderate to severe acetaminophen overdose	Cumberland Pharmaceuticals Inc. 209 10th Street South Suite 332 Nashville TN 37203 DD= 10/19/01 MA=

Orphan Products Designations and Approvals List
October 2001

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Adeno-associated viral vector containing the gene for human coagulation factor IX TN=Coagulin-B	Intrahepatic treatment of patients with moderate to severe hemophilia	Avigen, Inc. 1301 Harbor Bay Parkway Alameda CA 94502 DD= 6/13/01 MA=
Adeno-associated viral vector containing the gene for human coagulation factor IX TN=Coagulin-B	Intramuscular treatment of patients with moderate to severe hemophilia	Avigen, Inc. 1301 Harbor Bay Parkway Alameda CA 94502 DD= 6/13/01 MA=
adenovirus-mediated herpes simplex virus-thymidine kinase TN=	Use with gancyclovir in the treatment of malignant glioma	Ark Therapeutics Ltd 6 Warren Mews London W1T6AR UK DD= 7/31/01 MA=
Alendronate disodium TN=Fosamax	Treatment of the bone manifestations of Gaucher disease	Richard J. Wenstrup, M.D. Division of Human Genetics Children's Hospital Research Cincinnati OH 45229-3039 DD= 2/13/01 MA=
Angiotensin 1-7 TN=MARstem	Treatment of myelodysplastic syndrome	Maret Pharmaceutical Corporation 4041 MacArthur Boulevard, Suite Newport Beach CA 92660 DD= 8/3/01 MA=
arsenic trioxide TN=Trisenox	Treatment of chronic myeloid leukemia	Cell Therapeutics, Inc. 201 Elliott Avenue West Suite 400 Seattle WA 98119 DD= 10/18/01 MA=

Orphan Products Designations and Approvals List
October 2001

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
augmerosen TN=Genasense	Treatment of multiple myeloma	Genta Incorporated Two Oak Way Berkeley Heights NJ 07922 DD= 8/28/01 MA=
augmerosen TN=Genasense	Treatment of chronic lymphocytic leukemia	Genta Incorporated Two Oak Way Berkeley Heights NJ 07922 DD= 8/28/01 MA=
augmerosen TN=Genasense	Treatment of acute myelocytic leukemia	Genta Incorporated Two Oak Way Berkeley Heights NJ 07922 DD= 8/28/01 MA=
B Lymphocyte Stimulator TN=BLyS	Treatment of common variable immunodeficiency (CVID)	Human Genome Sciences, Inc. 9410 Key West Avenue Rockville MD 20850 DD= 2/21/01 MA=
Beclomethasone 17,21-dipropionate TN=	Prevention of gastrointestinal graft-versus-host disease	Enteron Pharmaceuticals, Inc. 1680 Michigan Ave. Suite 700 Miami FL 33139 DD= 8/28/01 MA=
Benzophenone-3, octylmethoxycinnamate, avobenzone, titanium TN= Total Block VL SPF 75	For the prevention of visible light induced skin photosensitivity as a result of porfimer sodium dioxide, zinc oxidephotodynamic therapy	Fallien Cosmeceuticals Ltd. 677 W. Dekalb Pike King of Prussia PA 19406 DD= 8/13/01 MA=

Orphan Products Designations and Approvals List
October 2001

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Busulfan TN=Spartajet-Busulfan	Intrathecal therapy for neoplastic meningitis	SuperGen, Inc. 4140 Dublin Boulevard Dublin CA 94568 DD= 3/5/01 MA=
Coenzyme Q10 TN=	For the treatrment of Huntington's disease	Vitaline Corporation 385 Williamson Way Ashland OR 97520 DD= 3/5/01 MA=
DHA-paclitaxel TN=Taxoprexin	Treatment of pancreatic cancer	Protarga, Inc. 2200 Renaissance Blvd. Suite 450 King of Prussia PA 19406 DD= 9/25/01 MA=
digitoxin TN=	Treatment of soft tissue sarcomas	PrimeCyte, Inc. 130 Fifth Ave., N. Seattle WA 98109-4933 DD= 10/18/01 MA=
docosahexanoic acid-paclitaxel TN=Taxoprexin	Treatment of hormone-refractory prostate cancer.	Protarga, Inc. 1100 East Hector Street Suite 450 Conshohocken PA 19428-2377 DD= 3/5/01 MA=
Glatiramer acetate for Injection TN=Copaxone	Treatment of primary-progressive multiple sclerosis	TEVA Pharmaceuticals, USA 1090 Horsham Road North Wales PA 19454 DD= 6/5/01 MA=

Orphan Products Designations and Approvals List
October 2001

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
h5G1.1mAb TN=	Idiopathic membranous glomerular nephropathy	Alexion Pharmaceuticals, Inc. 352 Knotter Drive Cheshire CT 06410 DD= 3/5/01 MA=
Hsp E7 TN=	Treatment of recurrent respiratory papillomatosis (RRP)	StressGen Biotechnologies, Inc. 409 2nd Avenue Suite 201 Collegeville PA 19426-2655 DD= 3/19/01 MA=
human gammaglobulin TN=	Treatment for juvenile rheumatoid arthritis	Protein Therapeutics, Inc 9040 S. Rita Rd., Suite 1100 Tucson AZ 84747 DD= 5/25/01 MA=
humanized monoclonal antibody against Shiga-like toxin II TN=	To prevent the development of or to decrease the incidence and severity of hemolytic uremic syndrome and associated sequelae of Shiga-like toxin-producing E. coli.	Teijin America, Inc. 600 Alexander Park Suite 304 Princeton NJ 08540 DD= 9/12/01 MA=
Imatinib TN=Gleevec	Treatment of chronic myelogenous leukemia	Novartis Pharmaceuticals 59 Route 10 East Hanover NJ 07936-1080 DD= 1/31/01 MA= 5/10/01
Imexon TN= n/a	Treatment of metastatic malignant melanoma	AmpliMed Corporation 2321 Camino La Zorrela Tucson AZ 85718 DD= 8/3/01 MA=

Orphan Products Designations and Approvals List
October 2001

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
INH-A00021 TN=	Reduction (prevention) of nosocomial bacteremia caused by staphylococci in very low birth weight infants.	Inhibitex, Inc. 8995 Westside Parkway Suite 150 Alpharetta GA 30004 DD= 6/13/01 MA=
Interferon-alfa-1b TN=	Treatment of multiple myeloma	Ernest C.Borden Center for Cancer Drud Discovery 9500 Euclid Avenue Clevland OH 44195 DD= 4/17/01 MA=
Intraoral fluoride releasing system TN=IFRS	Prevention of dental caries due to radiation-induced xerostomia in patients with head and neck cancer	Digestive Care, Inc. 1120 Win Drive Bethlehem PA 18017 DD= 7/31/01 MA=
L-glutamine TN=	Treatment of sickle cell disease	Orphan Drugs International, LLC PO Box 0401 Montrose CA 91021-0401 DD= 8/1/01 MA=
Latrodectus immune F(ab)2 TN=Aracmyn	Treatment of black widow spider envenomations	Rare Disease Therapeutics, Inc. 1101 Kermit Drive, Suite 608 Nashville TN 37217 DD= 6/18/01 MA=
Medroxyprogesterone acetate TN=Hematrol	Treatment of immune thrombocytopenic purpura.	InKine Pharmaceutical Company, 1787 Sentry Parkway West Building 18, Suite 440 Blue Bell PA 19422 DD= 2/22/01 MA=
metreleptin TN=	Treatment of metabolic disorders secondary to lipodystrophy	Amgen, Inc., One Amgen Center Drive Thousand Oaks CA 91320-1799 DD= 8/22/01 MA=

Orphan Products Designations and Approvals List
October 2001

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
metreleptin TN=	Treatment of leptin deficiency secondary to generalized lipodystrophy and partial familial lipodystrophy	Amgen, Inc. One Amgen Center Drive Thousand Oaks CA 91320-1799 DD= 8/22/01 MA=
MTC-DOX for Injection TN=	Treatment of hepatocellular carcinoma	FeRx Incorporated 4330 La Jolla Village Drive Suite #250 San Diego CA 92122 DD= 1/3/01 MA=
muramyltripeptide, phosphatidyl-ethanolamine encased in multi-lamellar liposomes TN=	Treatment of children and adolescent osteosarcoma	Jenner Biotherapies, Inc. 541 Kenosa Street Walworth WI 53184 DD= 6/5/01 MA=
nitazoxanide TN=Cryptaz	Treatment for intestinal amebiasis	Romark Laboratories, L.C. 6200 Courtney Campbell Causeway Suite 880 Tampa FL 33607 DD= 10/23/01 MA=
Nitisinone TN=Orfadin	Treatment of alkaptonuria	Swedish Orphan AB Kungsgatan 37, 7th Floor SE-111 56 Stockholm, Sweden DD= 10/19/01 MA=
Nitroprusside TN=	Treatment and prevention of cerebral vasospasm following subarachnoid hemorrhage.	Thomas, MD, Jeffrey Evan Thomas Jefferson University 834 Walnut Street, Suite 650 Philadelphia PA 19107-5102 DD= 2/21/01 MA=

Orphan Products Designations and Approvals List
October 2001

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Nolatrexed TN=THYMITAQ	Treatment of hepatocellular carcinoma	Zarix, Inc. 1055 Westlakes Drive Suite 200 Berwyn PA 19312 DD= 10/18/01 MA=
Novel Acting Thrombolytic (NAT) TN=	Treatment of peripheral arterial occlusion (PAO)	Amgen, Inc. One Amgen Center Drive Thousand Oaks CA 91320-1799 DD= 1/26/01 MA=
NZ-1002 TN=	Enzyme replacement therapy in patients with all subtypes of Mucopolysaccharidosis I.	Novazyme Pharmaceuticals, Inc. 800 Research Parkway Suite 200 Oklahoma City OK 73104 DD= 4/11/01 MA=
oglufanide disodium TN=	Treatment of ovarian cancer	Cytran, Inc. 10230 NE Points Dr., NE Suite 530 Kirkland WA 98033-7869 DD= 9/24/01 MA=
p1-(uridine 5'-)-p4-(2'-deoxycytidine 5'-) tetraphosphate, tetrasodium salt TN=	For the treatment of cystic fibrosis	Inspire Pharmaceuticals, Inc. 4222 Emperor Blvd. Suite 470 Durham NC 27703 DD= 3/7/01 MA=
pemetrexed disodium TN=Alimta	Treatment of malignant pleural mesothelioma	Eli Lilly and Company Lilly Corporate Center Indianapolis IN 46285 DD= 8/28/01 MA=

Orphan Products Designations and Approvals List
October 2001

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Perflubron TN=LiquiVent	Treatment of acute respiratory distress disease (ARDS) in adults	Alliance Pharmaceutical Corp. 3040 Science Park Road San Diego CA 92191 DD= 4/26/01 MA=
Polyethylene glycol (PEG)-uricase TN=	To control the clinical consequences of hyperuricemia in patients with severe gout in whom conventional therapy is contraindicated or has been ineffective.	Bio-Technology General Corporation 70 Wood Avenue South Iselin NJ 08830 DD= 2/21/01 MA=
porfimer TN= Photofrin	For the ablation of High-Grade Dysplasia in Barrett's Esophagus in patients who are not considered to be candidates for esophagectomy	Axcan Scandipharm Inc. 22 Inverness Parkway Suite 310 Birmingham AL 35242 DD= 10/19/01 MA=
Pyruvate TN=	Treatment of interstitial lung disease.	Cellular Sciences, Inc 84 park Avenue P.O. Box 968 Flemington NJ 08822 DD= 2/21/01 MA=
recombinant human alpha-1 antitrypsin (rAAT) TN=	To delay progression of chronic obstructive pulmonary disease resulting from AAT deficiency-mediated emphysema and bronchiectasis	Baxter Healthcare Corporation 550 N. Brand Blvd. Glendale CA 91203 DD= 8/28/01 MA=
Recombinant Human Alpha-Fetoprotein TN=	Treatment of myasthenia gravis	Atlantic Biopharmaceuticals, Inc. 50 Church Street 5th floor Cambridge MA 02138 DD= 2/22/01 MA=

Orphan Products Designations and Approvals List
October 2001

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
recombinant human endostatin protein TN=	Treatment of neuroendocrine tumors.	EntreMed, Inc. 9640 Medical Center Drive Rockville MD 20850 DD= 8/13/01 MA=
Reviparin sodium TN=Clivarine	Treatment of deep vein thrombosis which may lead to pulmonary embolism in pediatric patients	Knoll AG Ludwigshafen, Germany DD= 6/18/01 MA=
Reviparin sodium TN=Clivarine	Long-term treatment of acute deep vein trombosis with or without pulmonary embolism in pregnant patients	Knoll AG Ludwigshafen, Germany DD= 6/18/01 MA=
squalamine lactate TN=	Treatment of ovarian cancer refractory or resistant to standard chemotherapy	Genaera Corporation 5110 Campus Drive Plymouth Meeting PA 19462 DD= 5/11/01 MA=
Synthetic Human Parathyroid Hormone 1-34 TN=	Treatment of hypoparathyroidism	Orphan Pharmaceuticals, U.S., Inc. 1101 Kermit Drive, Suite 608 Nashville TN 37217 DD= 1/26/01 MA=
Thyrotropin alfa TN=Thyrogen	Treatment of well-differentiated papillary, follicular or combined papillary/follicular carcinomas of the thyroid	Genzyme Corporation One Kendall Square Cambridge MA 02139-1562 DD= 8/3/01 MA=
Unconjugated Chimeric (human-murine) G250 IgG monoclonal antibody TN=	Treatment of renal cell carcinoma.	Wilex Biotechnology GmbH Grillparzerstrasse 10B 81675 Munich Germany DE DD= 3/22/01 MA=

Orphan Products Designations and Approvals List
October 2001

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Vasoactive intestinal peptide TN=	Treatment of Acute Respiratory Distress Syndrome.	Sami I. Said, M.D. State University of New York at Health Sciences Center T17, 040 Stony Brook NY 11794-8172 DD= 3/9/01 MA=
Virulizin TN=Virulizin	Treatment of pancreatic cancer.	Lorus Therapeutics Inc. 7100 Woodbine Avenue, Suite 215 Markham, ON L3R 5J2 Canada DD= 2/1/01 MA=

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO OCTOBER 2001 ADDITIONS

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021205 001	ABACAVIR SULFATE;TRIZIVIR	6180639	JAN 30, 2018	U-248		
		6294540	MAY 14, 2018	U-65		
		6294540*PED	NOV 14, 2018	U-65		
		6180639*PED	JUL 30, 2018	U-248		
020977 001	ABACAVIR SULFATE;ZIAGEN	6294540	MAY 14, 2018	U-65		
		6294540*PED	NOV 14, 2018	U-65		
020978 001	ABACAVIR SULFATE;ZIAGEN	6294978	MAY 14, 2018	U-65		
		6294978*PED	NOV 14, 2018	U-65		
		6294540*PED	NOV 14, 2018	U-65		
		6294540	MAY 14, 2018	U-65		
021082 001	ACETAMINOPHEN;TAVIST ALLERGY/SINUS				NC	MAR 01, 2004
021123 001	ACETAMINOPHEN;ULTRACET	5336691	AUG 09, 2011		NC	AUG 15, 2004
020760 001	ALATROFLOXACIN MESYLATE;TROVAN PRESERVATIVE	6194429	JUL 23, 2018			
020760 002	ALATROFLOXACIN MESYLATE;TROVAN PRESERVATIVE	6194429	JUL 23, 2018		NCE	DEC 18, 2002
020949 001	ALBUTEROL SULFATE;ACCUNEB				NP	APR 30, 2004
020949 002	ALBUTEROL SULFATE;ACCUNEB				NP	APR 30, 2004
020950 001	ALBUTEROL SULFATE;DUONEB				NP	MAR 21, 2004
020983 001	ALBUTEROL SULFATE;VENTOLIN HFA	6251368	DEC 04, 2012		I-235	SEP 23, 2001
					I-262	JUN 02, 2002
021074 001	ALCOHOL;AVAGARD	5897031	JUN 21, 2016		NC	JUN 07, 2004
020560 001	ALENDRONATE SODIUM;FOSAMAX	6194004	DEC 02, 2012			
020560 004	ALENDRONATE SODIUM;FOSAMAX	6225294	JUL 17, 2018			
020560 005	ALENDRONATE SODIUM;FOSAMAX	6225294	JUL 17, 2018			
021001 001	ALMOTRIPTAN MALATE;AXERT	5565447	MAR 27, 2014		NCE	MAY 07, 2006
021001 002	ALMOTRIPTAN MALATE;AXERT	5565447	MAR 27, 2014		NCE	MAY 07, 2006
021107 001	ALOSETRON HYDROCHLORIDE;LOTRONEX	5360800	FEB 02, 2010			
		6284770	OCT 05, 2018	U-405		
019787 001	AMLODIPINE BESYLATE;NORVASC	4879303	MAR 25, 2007			
		4572909	JUL 31, 2006			
		4879303*PED	SEP 25, 2007			
		4572909*PED	JAN 31, 2007			
019787 002	AMLODIPINE BESYLATE;NORVASC	4879303	MAR 25, 2007			
		4572909	JUL 31, 2006			
		4879303*PED	SEP 25, 2007			
		4572909*PED	JAN 31, 2007			
019787 003	AMLODIPINE BESYLATE;NORVASC	4879303	MAR 25, 2007			
		4572909	JUL 31, 2006			
		4879303*PED	SEP 25, 2007			
		4572909*PED	JAN 31, 2007			
020883 001	ARGATROBAN;ACOVA	5214052	MAR 13, 2012			
021078 001	ATOVAQUONE;MALARONE	6166046	NOV 25, 2013	U-406	NC	JUL 14, 2003
		5053432	OCT 01, 2008			
		6291488	NOV 25, 2013			
021078 002	ATOVAQUONE;MALARONE PEDIATRIC	5053432	OCT 01, 2008		NC	JUL 14, 2003
		6291488	NOV 25, 2013	U-406		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
019408 002	BETAMETHASONE DIPROPIONATE;DIPROLENE	4489070	MAY 13, 2003			
021056 001	BEXAROTENE;TARGRETIN	5780676	JUL 14, 2015		ODE	DEC 29, 2006
		5962731	OCT 05, 2016			
		5466861	NOV 14, 2012			
020498 001	BICALUTAMIDE;CASODEX	1712251	SEP 18, 2001	U-391		
		5712251	SEP 18, 2001	U-391		
021275 001	BIMATOPROST;LUMIGAN	5688819	SEP 21, 2012		NCE	MAR 16, 2006
021290 001	BOSENTAN;TRACLEER				ODE	NOV 20, 2008
					NCE	NOV 20, 2006
021290 002	BOSENTAN;TRACLEER				ODE	NOV 20, 2008
					NCE	NOV 20, 2006
020490 001	BRIMONIDINE TARTRATE;ALPHAGAN				NCE	SEP 06, 2001
					PED	MAR 06, 2002
020613 001	BRIMONIDINE TARTRATE;ALPHAGAN	6194415	JUN 28, 2015	U-394	NCE	SEP 06, 2001
		6248741	JUN 28, 2015	U-394	PED	MAR 06, 2002
		6194415*PED	DEC 28, 2015	U-394		
		6248741*PED	DEC 28, 2015	U-394		
021262 001	BRIMONIDINE TARTRATE;ALPHAGAN P	6194415*PED	DEC 28, 2015	U-395	NP	MAR 16, 2004
		5736165	APR 07, 2015	U-399	PED	SEP 16, 2004
		5736165*PED	OCT 07, 2015	U-399	NCE	SEP 06, 2001
		6248741	JUN 28, 2015	U-395	PED	MAR 06, 2002
		6194415	JUN 28, 2015	U-395		
		6248741*PED	DEC 28, 2015	U-395		
		5424078	JUN 13, 2012			
		5424078*PED	DEC 13, 2012			
020816 001	BRINZOLAMIDE;AZOPT	5378703	APR 01, 2012	U-224		
021324 001	BUDESONIDE;ENTOCORT EC	5643602	JUL 01, 2014		NP	OCT 02, 2004
020746 001	BUDESONIDE;RHINOCORT	6291445	APR 29, 2017			
020358 001	BUPROPION HYDROCHLORIDE;WELLBUTRIN SR				M-10	JUN 11, 2004
020358 002	BUPROPION HYDROCHLORIDE;WELLBUTRIN SR				M-10	JUN 11, 2004
020358 003	BUPROPION HYDROCHLORIDE;WELLBUTRIN SR				M-10	JUN 11, 2004
018731 001	BUSPIRONE HYDROCHLORIDE;BUSPAR				M-12	JUL 19, 2004
018731 002	BUSPIRONE HYDROCHLORIDE;BUSPAR				M-12	JUL 19, 2004
018731 003	BUSPIRONE HYDROCHLORIDE;BUSPAR				M-12	JUL 19, 2004
018731 004	BUSPIRONE HYDROCHLORIDE;BUSPAR				M-12	JUL 19, 2004
074253 001	BUSPIRONE HYDROCHLORIDE;BUSPIRONE HCL				PC	SEP 26, 2001
074253 002	BUSPIRONE HYDROCHLORIDE;BUSPIRONE HCL				PC	SEP 26, 2001
075272 003	BUSPIRONE HYDROCHLORIDE;BUSPIRONE HCL				PC	SEP 24, 2001
075467 002	BUSPIRONE HYDROCHLORIDE;BUSPIRONE HCL				PC	SEP 26, 2001
076008 001	BUSPIRONE HYDROCHLORIDE;BUSPIRONE HCL				PC	JAN 28, 2002
020524 001	BUTENAFINE HYDROCHLORIDE;MENTAX				I-333	JUN 06, 2004
018874 001	CALCITRIOL;CALCIJEX	4308264	JAN 28, 2001			
		6051567	AUG 02, 2019			
		4308264*PED	JUL 28, 2001			
		6051567*PED	FEB 02, 2020			
		6265392	AUG 02, 2019			
		6274169	AUG 02, 2019			
		6274169*PED	FEB 02, 2020			
		6265392*PED	FEB 02, 2020			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	018874 002	CALCITRIOL;CALCIJEX	4308264	JAN 28, 2001			
			6051567	AUG 02, 2019			
			4308264*PED	JUL 28, 2001			
			6051567*PED	FEB 02, 2020			
			6265392	AUG 02, 2019			
			6274169	AUG 02, 2019			
			6274169*PED	FEB 02, 2020			
			6265392*PED	FEB 02, 2020			
	019976 001	CALCIUM ACETATE;PHOSLO	4870105	APR 07, 2007	U-381		
	021160 001	CALCIUM ACETATE;PHOSLO	4870105	APR 07, 2007	U-381		
	021160 002	CALCIUM ACETATE;PHOSLO	4870105	APR 07, 2007	U-381		
	021160 003	CALCIUM ACETATE;PHOSLO GELCAPS	4870105	APR 07, 2007	U-381		
	020896 001	CAPECITABINE;XELODA				I-323	APR 30, 2004
						I-341	SEP 07, 2004
	020896 002	CAPECITABINE;XELODA				I-323	APR 30, 2004
						I-341	SEP 07, 2004
	020297 001	CARVEDILOL;COREG				I-343	NOV 01, 2004
	020297 002	CARVEDILOL;COREG				I-343	NOV 01, 2004
	020297 003	CARVEDILOL;COREG				I-343	NOV 01, 2004
	020297 004	CARVEDILOL;COREG				I-343	NOV 01, 2004
	021227 001	CASPOFUNGIN ACETATE;CANCIDAS	5952300	MAR 28, 2017		NCE	JAN 26, 2006
			5378804	MAR 16, 2013			
			5514650	MAR 16, 2013			
			5792746	MAR 16, 2013			
			6136783	MAR 28, 2017			
	021227 002	CASPOFUNGIN ACETATE;CANCIDAS	5952300	MAR 28, 2017		NCE	JAN 26, 2006
			5378804	MAR 16, 2013			
			5514650	MAR 16, 2013			
			5792746	MAR 16, 2013			
			6136783	MAR 28, 2017			
	020998 001	CELECOXIB;CELEBREX				I-338	OCT 17, 2004
	020998 002	CELECOXIB;CELEBREX				I-338	OCT 17, 2004
>ADD>	021197 001	CETRORELIX;CETROTIDE	6319192	APR 23, 2018	U-426		
>ADD>	021197 002	CETRORELIX;CETROTIDE	6319192	APR 23, 2018	U-426		
	019111 001	CHLORPHENIRAMINE POLISTIREX;TUSSIONEX	4762709	AUG 09, 2005			
	021149 001	CHORIOGONADOTROPIN ALFA;OVIDREL	5767251	JUN 16, 2015		NP	SEP 20, 2003
	021022 001	CICLOPIROX;PENLAC	4957730	SEP 18, 2007	U-379		
	020839 001	CLOPIDOGREL BISULFATE;PLAVIX	4847265	NOV 17, 2011			
	020705 001	DELAVIRDINE MESYLATE;RESCRIPTOR	6177101	JUN 11, 2018			
	021038 001	DEXMEDETOMIDINE;PRECEDEX	4910214	JUL 15, 2008	U-421		
	021278 001	DEXMETHYLPHENIDATE HYDROCHLORIDE;DEXMETHYLPHENIDATE H	5922736	DEC 04, 2015	U-423	NP	NOV 13, 2004
			5908850	DEC 04, 2015	U-422		
			6255325	DEC 04, 2015	U-424		
	021278 002	DEXMETHYLPHENIDATE HYDROCHLORIDE;DEXMETHYLPHENIDATE H	5922736	DEC 04, 2015	U-423	NP	NOV 13, 2004
			5908850	DEC 04, 2015	U-422		
			6255325	DEC 04, 2015	U-424		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021278 003	DEXMETHYLPHENIDATE HYDROCHLORIDE;DEXMETHYLPHENIDATE H	5908850	DEC 04, 2015	U-422	NP	NOV 13, 2004
		5922736	DEC 04, 2015	U-423		
		6255325	DEC 04, 2015	U-424		
020607 001	DICLOFENAC SODIUM;ARTHROTEC	5698225	MAY 03, 2010	U-392		
020607 002	DICLOFENAC SODIUM;ARTHROTEC	5698225	MAY 03, 2010	U-392		
021005 001	DICLOFENAC SODIUM;SOLARAZE	5639738	JUN 17, 2014	U-402	NP	OCT 16, 2003
		5792753	AUG 11, 2015			
		5852002	JUN 17, 2014	U-402		
		5914322	AUG 11, 2015			
		5929048	JUL 27, 2016	U-402		
		5985850	NOV 16, 2016			
020154 002	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248	D-58	OCT 28, 2002
		5616566	AUG 29, 2006	U-180	PED	APR 28, 2003
		5254539	AUG 29, 2006	U-248		
		5880106	JUL 22, 2011			
		4861759*PED	MAR 01, 2007	U-248		
		5254539*PED	MAR 01, 2007	U-248		
		5616566*PED	MAR 01, 2007	U-180		
		5880106*PED	JAN 22, 2012			
020154 003	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248	D-58	OCT 28, 2002
		5616566	AUG 29, 2006	U-180	PED	APR 28, 2003
		5254539	AUG 29, 2006	U-248		
		5880106	JUL 22, 2011			
		4861759*PED	MAR 01, 2007	U-248		
		5254539*PED	MAR 01, 2007	U-248		
		5616566*PED	MAR 01, 2007	U-180		
		5880106*PED	JAN 22, 2012			
020154 004	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248	D-58	OCT 28, 2002
		5616566	AUG 29, 2006	U-180	PED	APR 28, 2003
		5254539	AUG 29, 2006	U-248		
		5880106	JUL 22, 2011			
		4861759*PED	MAR 01, 2007	U-248		
		5254539*PED	MAR 01, 2007	U-248		
		5616566*PED	MAR 01, 2007	U-180		
		5880106*PED	JAN 22, 2012			
020154 005	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248	D-58	OCT 28, 2002
		5616566	AUG 29, 2006	U-180	PED	APR 28, 2003
		5254539	AUG 29, 2006	U-248		
		5880106	JUL 22, 2011			
		4861759*PED	MAR 01, 2007	U-248		
		5254539*PED	MAR 01, 2007	U-248		
		5616566*PED	MAR 01, 2007	U-180		
		5880106*PED	JAN 22, 2012			
020154 006	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248	NS	OCT 28, 2002
		5254539	AUG 29, 2006	U-248	PED	APR 28, 2003
		5880106	JUL 22, 2011			
		4861759*PED	MAR 01, 2007	U-248		
		5254539*PED	MAR 01, 2007	U-248		
		5616566*PED	MAR 01, 2007	U-180		
		5880106*PED	JAN 22, 2012			
		5616566	AUG 29, 2006	U-180		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020155 003	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248		
		5616566	AUG 29, 2006	U-180		
		5254539	AUG 29, 2006	U-248		
		4861759*PED	MAR 01, 2007	U-248		
		5254539*PED	MAR 01, 2007	U-248		
		5616566*PED	MAR 01, 2007	U-180		
020155 004	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248		
		5616566	AUG 29, 2006	U-180		
		5254539	AUG 29, 2006	U-248		
		4861759*PED	MAR 01, 2007	U-248		
		5254539*PED	MAR 01, 2007	U-248		
		5616566*PED	MAR 01, 2007	U-180		
020155 005	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248		
		5616566	AUG 29, 2006	U-180		
		5254539	AUG 29, 2006	U-248		
		4861759*PED	MAR 01, 2007	U-248		
		5254539*PED	MAR 01, 2007	U-248		
		5616566*PED	MAR 01, 2007	U-180		
020155 006	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-52		
		4861759*PED	MAR 01, 2007	U-248		
		5254539*PED	MAR 01, 2007	U-248		
		5616566*PED	MAR 01, 2007	U-180		
		5616566	AUG 29, 2006	U-180		
		5254539	AUG 29, 2006	U-248		
020156 001	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248		
		5616566	AUG 29, 2006	U-180		
		5254539	AUG 29, 2006	U-248		
		4861759*PED	MAR 01, 2007	U-248		
		5254539*PED	MAR 01, 2007	U-248		
		5616566*PED	MAR 01, 2007	U-180		
021183 001	DIDANOSINE;VIDEX EC	4861759	AUG 29, 2006	U-248	NDF	OCT 31, 2003
		5254539	AUG 29, 2006	U-248	PED	MAY 01, 2004
		4861759*PED	MAR 01, 2007	U-248		
		5254539*PED	MAR 01, 2007	U-248		
021183 002	DIDANOSINE;VIDEX EC	4861759	AUG 29, 2006	U-248	NDF	OCT 31, 2003
		5254539	AUG 29, 2006	U-248	PED	MAY 01, 2004
		4861759*PED	MAR 01, 2007	U-248		
		5254539*PED	MAR 01, 2007	U-248		
021183 003	DIDANOSINE;VIDEX EC	4861759	AUG 29, 2006	U-248	NDF	OCT 31, 2003
		5254539	AUG 29, 2006	U-248	PED	MAY 01, 2004
		4861759*PED	MAR 01, 2007	U-248		
		5254539*PED	MAR 01, 2007	U-248		
021183 004	DIDANOSINE;VIDEX EC	4861759	AUG 29, 2006	U-248	NDF	OCT 31, 2003
		5254539	AUG 29, 2006	U-248	PED	MAY 01, 2004
		4861759*PED	MAR 01, 2007	U-248		
		5254539*PED	MAR 01, 2007	U-248		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020623 001	DOLASETRON MESYLATE MONOHYDRATE;ANZEMET	4906755	JUL 02, 2011			
020623 002	DOLASETRON MESYLATE MONOHYDRATE;ANZEMET	4906755	JUL 02, 2011			
020624 001	DOLASETRON MESYLATE MONOHYDRATE;ANZEMET	4906755	JUL 02, 2011			
020690 001	DONEPEZIL HYDROCHLORIDE;ARICEPT	6140321	DEC 30, 2016			
		6245911	DEC 01, 2018			
		5985864	DEC 30, 2016			
020690 002	DONEPEZIL HYDROCHLORIDE;ARICEPT	6140321	DEC 30, 2016			
		6245911	DEC 01, 2018			
		5985864	DEC 30, 2016			
020869 001	DORZOLAMIDE HYDROCHLORIDE;COSOPT	6248735	APR 17, 2011			
021098 001	DROSPIRENONE;YASMIN				NC	MAY 11, 2004
021319 001	DUTASTERIDE;DUTASTERIDE				NCE	NOV 20, 2006
020706 001	EMEDASTINE DIFUMARATE;EMADINE	4430343	AUG 14, 2005	U-403		
		5441958	DEC 08, 2013	U-404		
020668 001	ENALAPRIL MALEATE;LEXXEL	4264611	JUN 19, 2001	U-3		
		4803081	APR 03, 2007			
		4264611*PED	DEC 19, 2001	U-3		
		4803081*PED	OCT 03, 2007			
020668 002	ENALAPRIL MALEATE;LEXXEL	4374829	DEC 30, 2001	U-3		
		4472380	SEP 18, 2001			
		4703038	OCT 07, 2005	U-3		
		4803081	APR 03, 2007			
		4264611	JUN 19, 2001	U-3		
		4264611*PED	DEC 19, 2001	U-3		
		4803081*PED	OCT 03, 2007			
018998 001	ENALAPRIL MALEATE;VASOTEC				M-7	FEB 13, 2004
					PED	AUG 13, 2004
018998 002	ENALAPRIL MALEATE;VASOTEC				M-7	FEB 13, 2004
					PED	AUG 13, 2004
018998 003	ENALAPRIL MALEATE;VASOTEC				M-7	FEB 13, 2004
					PED	AUG 13, 2004
018998 005	ENALAPRIL MALEATE;VASOTEC				M-7	FEB 13, 2004
					PED	AUG 13, 2004
020164 002	ENOXAPARIN SODIUM;LOVENOX	4486420	DEC 04, 2001	U-122		
		4692435	DEC 24, 2004	U-123		
		5389618	FEB 14, 2012			
020164 003	ENOXAPARIN SODIUM;LOVENOX	4486420	DEC 04, 2001	U-122		
		4692435	DEC 24, 2004	U-123		
		5389618	FEB 14, 2012			
020164 004	ENOXAPARIN SODIUM;LOVENOX	4486420	DEC 04, 2001	U-122		
		4692435	DEC 24, 2004	U-123		
		5389618	FEB 14, 2012			
020164 005	ENOXAPARIN SODIUM;LOVENOX	4486420	DEC 04, 2001	U-122		
		4692435	DEC 24, 2004	U-123		
		5389618	FEB 14, 2012			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020164 006	ENOXAPARIN SODIUM;LOVENOX	4486420	DEC 04, 2001			
		4692435	DEC 24, 2004	U-123		
		5389618	FEB 14, 2012			
020164 007	ENOXAPARIN SODIUM;LOVENOX	4486420	DEC 04, 2001	U-122		
		4692435	DEC 24, 2004	U-123		
		5389618	FEB 14, 2012			
020164 008	ENOXAPARIN SODIUM;LOVENOX	4486420	DEC 04, 2001	U-122		
		4692435	DEC 24, 2004	U-123		
		5389618	FEB 14, 2012			
021268 001	EPROSARTAN MESYLATE;TEVETEN HCT	5185351	FEB 09, 2010	U-3	NC	NOV 01, 2004
					NCE	DEC 22, 2002
021268 002	EPROSARTAN MESYLATE;TEVETEN HCT	5185351	FEB 09, 2010	U-3	NC	NOV 01, 2004
					NCE	DEC 22, 2002
020718 001	EPTIFIBATIDE;INTEGRILIN				D-66	JUN 08, 2004
020718 002	EPTIFIBATIDE;INTEGRILIN				D-66	JUN 08, 2004
019386 001	ESMOLOL HYDROCHLORIDE;BREVIBLOC	5017609	MAY 21, 2008			
		6310094	JAN 12, 2021			
019386 002	ESMOLOL HYDROCHLORIDE;BREVIBLOC	5017609	MAY 21, 2008			
019386 003	ESMOLOL HYDROCHLORIDE;BREVIBLOC	5017609	MAY 21, 2008			
		4593119	JUN 03, 2003			
021153 001	ESOMEPRAZOLE MAGNESIUM;NEXIUM	4255431	APR 05, 2001	U-373	NP	FEB 20, 2004
		4738974	APR 19, 2005	U-373		
		4636499	MAY 30, 2005	U-373		
		5900424	MAY 04, 2016	U-373		
		4786505	APR 20, 2007	U-373		
		4853230	APR 20, 2007	U-373		
		5714504	FEB 03, 2015	U-373		
		5877192	MAY 27, 2014	U-373		
		5093342	FEB 02, 2010	U-373		
		5599794	FEB 04, 2014	U-373		
		5629305	FEB 04, 2014	U-373		
		5690960	NOV 25, 2014	U-373		
		6147103	OCT 09, 2018			
		6166213	OCT 09, 2018			
		6191148	OCT 09, 2018			
		4508905	FEB 20, 2001			
021153 002	ESOMEPRAZOLE MAGNESIUM;NEXIUM	4255431	APR 05, 2001	U-373	NP	FEB 20, 2004
		4738974	APR 19, 2005	U-373		
		4636499	MAY 30, 2005	U-373		
		5900424	MAY 04, 2016	U-373		
		4786505	APR 20, 2007	U-373		
		4853230	APR 20, 2007	U-373		
		5714504	FEB 03, 2015	U-373		
		5877192	MAY 27, 2014	U-373		
		5093342	FEB 02, 2010	U-373		
		5599794	FEB 04, 2014	U-373		
		5629305	FEB 04, 2014	U-373		
		5690960	NOV 25, 2014	U-373		
		6147103	OCT 09, 2018			
		6166213	OCT 09, 2018			
		6191148	OCT 09, 2018			
		4508905	FEB 20, 2001			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020870 001	ESTRADIOL;COMBIPATCH	5474783	DEC 12, 2012			
		5656286	AUG 12, 2014			
		5958446	DEC 12, 2012			
		6024976	JAN 07, 2014			
020870 002	ESTRADIOL;COMBIPATCH	5474783	DEC 12, 2012			
		5656286	AUG 12, 2014			
		5958446	DEC 12, 2012			
		6024976	JAN 07, 2014			
020538 005	ESTRADIOL;VIVELLE-DOT	6024976	JAN 07, 2014			
		5474783	DEC 12, 2012			
		5656286	AUG 12, 2014			
		5958446	DEC 12, 2012			
020538 006	ESTRADIOL;VIVELLE-DOT	6024976	JAN 07, 2014			
		5474783	DEC 12, 2012			
		5656286	AUG 12, 2014			
		5958446	DEC 12, 2012			
020538 007	ESTRADIOL;VIVELLE-DOT	6024976	JAN 07, 2014			
		5474783	DEC 12, 2012			
		5656286	AUG 12, 2014			
		5958446	DEC 12, 2012			
020538 008	ESTRADIOL;VIVELLE-DOT	6024976	JAN 07, 2014			
		5474783	DEC 12, 2012			
		5656286	AUG 12, 2014			
		5958446	DEC 12, 2012			
020130 002	ETHINYL ESTRADIOL;ESTROSTEP FE	5010070	APR 23, 2008		I-331	JUL 01, 2004
020130 001	ETHINYL ESTRADIOL;ESTROSTEP 21	5010070	APR 23, 2008		I-331	JUL 01, 2004
021187 001	ETHINYL ESTRADIOL;NUVARING				NP	OCT 03, 2004
021180 001	ETHINYL ESTRADIOL;ORTHO EVRA				NP	NOV 20, 2004
020946 001	ETHINYL ESTRADIOL;PREVEN EMERGENCY CON	6156742	DEC 05, 2020	U-374		
020584 001	ETODOLAC;LODINE XL				I-321	AUG 11, 2003
					PED	FEB 11, 2004
020584 002	ETODOLAC;LODINE XL				I-321	AUG 11, 2003
					PED	FEB 11, 2004
020584 003	ETODOLAC;LODINE XL				I-321	AUG 11, 2003
					PED	FEB 11, 2004
020457 001	ETOPOSIDE PHOSPHATE;ETOPOPHOS PRESERVATI	RE35524	MAY 17, 2010			
020906 001	ETOPOSIDE PHOSPHATE;ETOPOPHOS PRESERVATI	5041424	AUG 20, 2008	U-135		
		RE35524	MAY 17, 2010			
020906 002	ETOPOSIDE PHOSPHATE;ETOPOPHOS PRESERVATI	5041424	AUG 20, 2008	U-135		
		RE35524	MAY 17, 2010			
075312 001	FAMOTIDINE;FAMOTIDINE				PC	NOV 28, 2001
020902 001	FAMOTIDINE;PEPCID AC				D-47	NOV 09, 2001
					PED	MAY 09, 2002
019834 001	FELODIPINE;PLENDIL	4264611	JUN 19, 2001	U-3		
		4803081	APR 03, 2007			
		4803081*PED	OCT 03, 2007			
		4264611*PED	DEC 19, 2001	U-3		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	019834 002	FELODIPINE;PLENDIL	4264611	JUN 19, 2001	U-3		
			4803081	APR 03, 2007			
			4264611*PED	DEC 19, 2001	U-3		
			4803081*PED	OCT 03, 2007			
	019834 004	FELODIPINE;PLENDIL	4264611	JUN 19, 2001	U-3		
			4803081	APR 03, 2007			
			4264611*PED	DEC 19, 2001	U-3		
			4803081*PED	OCT 03, 2007			
>ADD> >ADD>	021203 001	FENOFIBRATE;TRICOR	6277405	JAN 09, 2018			
			6074670	JAN 09, 2018			
			4895726	JAN 19, 2009			
>ADD> >ADD>	021203 003	FENOFIBRATE;TRICOR	6277405	JAN 09, 2018			
			6074670	JAN 09, 2018			
			4895726	JAN 19, 2009			
	020625 001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	6187791	MAY 11, 2012	U-138		
	020872 001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	6187791	MAY 11, 2012	U-138		
	020872 002	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	6187791	MAY 11, 2012	U-138		
	020872 004	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	6187791	MAY 11, 2012	U-138		
	020786 001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA-D	6187791	MAY 11, 2012	U-138		
	019452 001	FLUOCINOLONE ACETONIDE;DERMA-SMOOTHE/FS				I-340	OCT 10, 2004
	020985 001	FLUOROURACIL;CARAC	4690825	OCT 04, 2005			
	074803 001	FLUOXETINE HYDROCHLORIDE;FLUOXETINE				PC	JAN 23, 2002
	075049 001	FLUOXETINE HYDROCHLORIDE;FLUOXETINE				PC	JAN 23, 2002
	075465 003	FLUOXETINE HYDROCHLORIDE;FLUOXETINE				PC	JAN 23, 2002
	075506 001	FLUOXETINE HYDROCHLORIDE;FLUOXETINE				PC	JAN 23, 2002
	075755 001	FLUOXETINE HYDROCHLORIDE;FLUOXETINE HCL				PC	JAN 23, 2002
	075755 002	FLUOXETINE HYDROCHLORIDE;FLUOXETINE HCL				PC	JAN 23, 2002
	021235 001	FLUOXETINE HYDROCHLORIDE;PROZAC WEEKLY	5910319	MAY 29, 2017	U-396	NDF	FEB 26, 2004
			5985322	MAY 29, 2017	U-397		
			5910319*PED	NOV 29, 2017	U-396		
			5985322*PED	NOV 29, 2017	U-397		
	018936 007	FLUOXETINE HYDROCHLORIDE;SARAFEM				PED	JAN 06, 2004
	021077 001	FLUTICASONE PROPIONATE;ADVAIR DISKUS 100/50	5270305	SEP 07, 2010	U-387		
			5290815	MAR 01, 2011	U-386		
	021077 002	FLUTICASONE PROPIONATE;ADVAIR DISKUS 250/50	5270305	SEP 07, 2010	U-387		
			5290815	MAR 01, 2011	U-386		
	021077 003	FLUTICASONE PROPIONATE;ADVAIR DISKUS 500/50	5270305	SEP 07, 2010	U-387		
			5290815	MAR 01, 2011	U-386		
	020549 001	FLUTICASONE PROPIONATE;FLOVENT	4335121	NOV 14, 2003	U-409		
	020549 002	FLUTICASONE PROPIONATE;FLOVENT	4335121	NOV 14, 3003	U-409		
	020549 003	FLUTICASONE PROPIONATE;FLOVENT	4335121	NOV 14, 2003	U-409		
	020833 001	FLUTICASONE PROPIONATE;FLOVENT DISKUS 50	4335121	NOV 14, 2003	U-409		
	020833 002	FLUTICASONE PROPIONATE;FLOVENT DISKUS 100	4335121	NOV 14, 2003	U-409		
	020833 003	FLUTICASONE PROPIONATE;FLOVENT DISKUS 250	4335121	NOV 14, 2003	U-409		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020261 001	FLUVASTATIN SODIUM;LESCOL	5356896	DEC 12, 2011			
020261 002	FLUVASTATIN SODIUM;LESCOL	5356896	DEC 12, 2011			
021192 001	FLUVASTATIN SODIUM;LESCOL XL	5354772	OCT 11, 2011	U-413		
		5356896	DEC 12, 2011			
020831 001	FORMOTEROL FUMARATE;FORADIL				NCE	FEB 16, 2006
021279 001	FORMOTEROL FUMARATE;FORADIL				I-342	SEP 25, 2004
					NCE	FEB 16, 2006
021006 001	FROVATRIPTAN SUCCINATE;FROVA	5464864	NOV 07, 2012	U-72	NCE	NOV 08, 2006
		5616603	APR 01, 2014	U-72		
		5637611	JUN 10, 2014	U-72		
		5827871	OCT 27, 2015	U-72		
		5962501	DEC 16, 2013	U-72		
021129 001	GABAPENTIN;NEURONTIN	4894476	MAY 02, 2008			
		5084479	JAN 02, 2010	U-258		
021169 001	GALANTAMINE HYDROBROMIDE;REMINYL	4663318	JAN 15, 2006		NCE	FEB 28, 2006
		6099863	JUN 06, 2017			
021169 002	GALANTAMINE HYDROBROMIDE;REMINYL	4663318	JAN 15, 2006		NCE	FEB 28, 2006
		6099863	JUN 06, 2017			
021169 003	GALANTAMINE HYDROBROMIDE;REMINYL	4663318	JAN 15, 2006		NCE	FEB 28, 2006
		6099863	JUN 06, 2017			
021224 001	GALANTAMINE HYDROBROMIDE;REMINYL	4663318	JAN 15, 2006		NCE	FEB 28, 2006
021061 001	GATIFLOXACIN;TEQUIN				D-69	OCT 12, 2004
021061 002	GATIFLOXACIN;TEQUIN				D-69	OCT 12, 2004
021062 001	GATIFLOXACIN;TEQUIN				D-69	OCT 12, 2004
021062 002	GATIFLOXACIN;TEQUIN				D-69	OCT 12, 2004
021178 001	GLYBURIDE;GLUCOVANCE	6303146	JUL 14, 2019	U-412		
021178 002	GLYBURIDE;GLUCOVANCE	6303146	JUL 14, 2019	U-412		
021178 003	GLYBURIDE;GLUCOVANCE	6303146	JUL 14, 2019	U-412		
020239 001	GRANISETRON HYDROCHLORIDE;KYTRIL	6294548	MAY 04, 2019			
020239 002	GRANISETRON HYDROCHLORIDE;KYTRIL	4886808	DEC 29, 2007	U-89		
		6294548	MAY 04, 2019			
021238 001	GRANISETRON HYDROCHLORIDE;KYTRIL	4886808	DEC 29, 2007	U-105	I-264	JUL 27, 2002
020387 001	HYDROCHLOROTHIAZIDE;HYZAAR	5608075	MAR 04, 2014			
020387 002	HYDROCHLOROTHIAZIDE;HYZAAR	5608075	MAR 04, 2014			
019778 001	HYDROCHLOROTHIAZIDE;PRINZIDE	4374829	DEC 29, 2001	U-3		
		4374829*PED	JUN 29, 2002			
019778 002	HYDROCHLOROTHIAZIDE;PRINZIDE	4374829	DEC 29, 2001	U-3		
		4374829*PED	JUN 29, 2002	U-3		
019778 003	HYDROCHLOROTHIAZIDE;PRINZIDE	4374829	DEC 29, 2001	U-3		
		4374829*PED	JUN 29, 2002	U-3		
019888 001	HYDROCHLOROTHIAZIDE;ZESTORETIC	4374829	DEC 29, 2001	U-3		
		4374829*PED	JUN 29, 2002	U-3		
019888 002	HYDROCHLOROTHIAZIDE;ZESTORETIC	4374829	DEC 29, 2001	U-3		
		4374829*PED	JUN 29, 2002	U-3		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
019888 003	HYDROCHLOROTHIAZIDE;ZESTORETIC	4374829	DEC 29, 2001	U-3		
		4374829*PED	JUN 29, 2002	U-3		
020402 002	IBUPROFEN POTASSIUM;ADVIL MIGRAINE LIQUI				NP	MAR 16, 2003
021128 001	IBUPROFEN;CHILDREN'S MOTRIN CO	6211246	JUN 10, 2019			
021335 001	IMATINIB MESYLATE;GLEEVEC	5521184	MAY 28, 2013		NCE	MAY 10, 2006
					ODE	MAY 10, 2008
021335 002	IMATINIB MESYLATE;GLEEVEC	5521184	MAY 28, 2013		NCE	MAY 10, 2006
					ODE	MAY 10, 2008
021172 001	INSULIN ASPART RECOMBINANT;NOVOLOG MIX 70/30				NC	NOV 01, 2004
021081 001	INSULIN GLARGINE;LANTUS	5656722	SEP 12, 2014			
		5656722*PED	MAR 12, 2015			
020394 001	IPRATROPIUM BROMIDE;ATROVENT				I-327	OCT 27, 2003
018662 002	ISOTRETINOIN;ACCUTANE	4464394	AUG 07, 2001			
		4464394*PED	FEB 07, 2002			
018662 003	ISOTRETINOIN;ACCUTANE	4464394	AUG 07, 2001			
		4464394*PED	FEB 07, 2002			
018662 004	ISOTRETINOIN;ACCUTANE	4464394	AUG 07, 2001			
		4464394*PED	FEB 07, 2002			
020657 001	ITRACONAZOLE;SPORANOX				I-332	MAY 09, 2004
020966 001	ITRACONAZOLE;SPORANOX	4791111	DEC 23, 2005		I-332	MAY 09, 2004
019700 001	KETOROLAC TROMETHAMINE;ACULAR	4454151	MAR 22, 2002	U-75		
		5110493	MAY 05, 2009			
		4454151*PED	SEP 22, 2002	U-75		
		5110493*PED	NOV 05, 2009	U-75		
				U-75		
020811 001	KETOROLAC TROMETHAMINE;ACULAR PRESERVATIVE	4454151	MAR 22, 2002			
		4454151*PED	SEP 22, 2002			
020857 001	LAMIVUDINE;COMBIVIR	6180639	JAN 30, 2018	U-248		
		6180639*PED	JUL 30, 2018	U-248		
020564 001	LAMIVUDINE;EPIVIR	6180639	JAN 30, 2018	U-248		
		6180639*PED	JUL 30, 2018	U-248		
020596 001	LAMIVUDINE;EPIVIR	6180639	JAN 30, 2018	U-248		
		6180639*PED	JUL 30, 2018	U-248		
021003 001	LAMIVUDINE;EPIVIR-HBV				I-339	AUG 16, 2004
					PED	FEB 16, 2005
021004 001	LAMIVUDINE;EPIVIR-HBV				PED	FEB 16, 2005
					I-339	AUG 16, 2004
021281 001	LANSOPRAZOLE;PREVACID				I-316	NOV 30, 2003
					M-1	JUL 06, 2002
					D-42	JUL 20, 2001
021281 002	LANSOPRAZOLE;PREVACID				I-316	NOV 30, 2003
					M-1	JUL 06, 2002
					D-42	JUL 20, 2001
020905 001	LEFLUNOMIDE;ARAVA	4284786	DEC 13, 2001			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020905 002	LEFLUNOMIDE;ARAVA	4284786	DEC 13, 2001			
020905 003	LEFLUNOMIDE;ARAVA	4284786	DEC 13, 2001			
020726 001	LETROZOLE;FEMARA	4978672	JUN 03, 2011	U-203		
019732 001	LEUPROLIDE ACETATE;LUPRON DEPOT	5631021	NOV 01, 2004			
		5476663	NOV 01, 2004			
		5575987	SEP 02, 2013			
		6036976	DEC 13, 2013			
020011 001	LEUPROLIDE ACETATE;LUPRON DEPOT	5631020	NOV 01, 2004			
		5476663	NOV 01, 2004			
		5575987	SEP 02, 2013			
020517 001	LEUPROLIDE ACETATE;LUPRON DEPOT	5643607	JAN 02, 2013			
		5631021	NOV 01, 2004			
		5476663	NOV 01, 2004			
		5814342	FEB 01, 2011			
		6036976	DEC 13, 2016			
020263 002	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5631021	NOV 01, 2004			
		5476663	NOV 01, 2004			
		5575987	SEP 02, 2013			
		6036976	DEC 13, 2013			
020263 003	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5631021	NOV 01, 2004			
		5575987	SEP 02, 2013			
		5476663	NOV 01, 2004			
		6036976	DEC 13, 2013			
020263 004	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5631021	NOV 01, 2004			
		5476663	NOV 01, 2004			
		5575987	SEP 02, 2013			
		6036976	DEC 13, 2013			
020263 005	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5631021	NOV 01, 2004			
		5476663	NOV 01, 2004			
		5575987	SEP 02, 2013			
		6036976	DEC 13, 2013			
020263 006	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5631021	NOV 01, 2004			
		5476663	NOV 01, 2004			
		5575987	SEP 02, 2013			
		6036976	DEC 13, 2013			
020708 001	LEUPROLIDE ACETATE;LUPRON DEPOT-3	5631021	NOV 01, 2004			
		5476663	NOV 01, 2004			
		5643607	JAN 02, 2013			
		5814342	FEB 01, 2011			
		6036976	DEC 13, 2016			
020517 002	LEUPROLIDE ACETATE;LUPRON DEPOT-4	5631021	NOV 01, 2004			
		5476663	NOV 01, 2004			
		5643607	JAN 02, 2013			
		5814342	FEB 01, 2011			
		6036976	DEC 13, 2016			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021088 001	LEUPROLIDE ACETATE;VIADUR	6235712	JUN 13, 2017			
019558 001	LISINOPRIL;PRINIVIL	4374829	DEC 29, 2001			
		4374829*PED	JUN 29, 2002			
019558 002	LISINOPRIL;PRINIVIL	4374829	DEC 29, 2001			
		4374829*PED	JUN 29, 2002			
019558 003	LISINOPRIL;PRINIVIL	4374829	DEC 29, 2001			
		4374829*PED	JUN 29, 2002			
019558 004	LISINOPRIL;PRINIVIL	4374829	DEC 29, 2001			
		4374829*PED	JUN 29, 2002			
019558 006	LISINOPRIL;PRINIVIL	4374829	DEC 29, 2001			
		4374829*PED	JUN 29, 2002			
019777 001	LISINOPRIL;ZESTRIL	4374829	DEC 29, 2001		I-288	FEB 07, 2003
		4374829*PED	JUN 29, 2002		PED	AUG 07, 2003
019777 002	LISINOPRIL;ZESTRIL	4374829	DEC 29, 2001		I-288	FEB 07, 2003
		4374829*PED	JUN 29, 2002		PED	AUG 07, 2003
019777 003	LISINOPRIL;ZESTRIL	4374829	DEC 29, 2001		I-288	FEB 07, 2003
		4374829*PED	JUN 29, 2002		PED	AUG 07, 2003
019777 004	LISINOPRIL;ZESTRIL	4374829	DEC 29, 2001		I-288	FEB 07, 2003
		4374829*PED	JUN 29, 2002		PED	AUG 07, 2003
019777 005	LISINOPRIL;ZESTRIL	4374829	DEC 29, 2001		I-288	FEB 07, 2003
		4374829*PED	JUN 29, 2002		PED	AUG 07, 2003
019777 006	LISINOPRIL;ZESTRIL	4374829	DEC 29, 2001		I-288	FEB 07, 2003
		4374829*PED	JUN 29, 2002		PED	AUG 07, 2003
021226 001	LOPINAVIR;KALETRA	6232333	NOV 07, 2017			
		6284767	FEB 14, 2016	U-401		
021251 001	LOPINAVIR;KALETRA	6284767	FEB 14, 2016	U-401		
020386 001	LOSARTAN POTASSIUM;COZAAR	5608075	MAR 04, 2014			
020386 002	LOSARTAN POTASSIUM;COZAAR	5608075	MAR 04, 2014			
020386 003	LOSARTAN POTASSIUM;COZAAR	5138069	AUG 11, 2009			
		5153197	OCT 06, 2009	U-3		
		5608075	MAR 04, 2014			
019643 002	LOVASTATIN;MEVACOR	4231938	JUN 15, 2001		I-250	MAR 11, 2002
		4231938*PED	DEC 15, 2001		PED	SEP 11, 2002
019643 003	LOVASTATIN;MEVACOR	4231938	JUN 15, 2001		I-250	MAR 11, 2002
		4231938*PED	DEC 15, 2001		PED	SEP 11, 2002
019643 004	LOVASTATIN;MEVACOR	4231938	JUN 15, 2001		I-250	MAR 11, 2002
		4231938*PED	DEC 15, 2001		PED	SEP 11, 2002
075671 001	MEGESTROL ACETATE;MEGESTROL ACETATE				PC	JAN 12, 2002
020357 001	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				M-6	APR 19, 2004
020357 002	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				M-6	APR 19, 2004
020357 003	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				M-6	APR 19, 2004
020357 004	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				M-6	APR 19, 2004
020357 005	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				M-6	APR 19, 2004
021121 001	METHYLPHENIDATE HYDROCHLORIDE;CONCERTA	4783337	SEP 16, 2003	U-372		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021121 002	METHYLPHENIDATE HYDROCHLORIDE;CONCERTA	4783337	SEP 16, 2003	U-372		
021121 003	METHYLPHENIDATE HYDROCHLORIDE;CONCERTA	4783337	SEP 16, 2003	U-372	NP	AUG 01, 2003
021259 001	METHYLPHENIDATE HYDROCHLORIDE;METADATE CD				NDF	APR 03, 2004
019962 001	METOPROLOL SUCCINATE;TOPROL-XL	4927640	MAY 22, 2007		I-194	FEB 05, 2004
		5246714	SEP 21, 2010			
019962 002	METOPROLOL SUCCINATE;TOPROL-XL	4927640	MAY 22, 2007		I-194	FEB 05, 2004
		5246714	SEP 21, 2010			
019962 003	METOPROLOL SUCCINATE;TOPROL-XL	4927640	MAY 27, 2007		I-194	FEB 05, 2004
		5246714	SEP 21, 2010			
019962 004	METOPROLOL SUCCINATE;TOPROL-XL	4957745	SEP 18, 2007	U-107	NS	FEB 05, 2004
		5001161	MAR 19, 2008	U-107	I-194	FEB 05, 2004
		5081154	JAN 14, 2009	U-107		
		4927640	MAY 22, 2007			
		5246714	SEP 21, 2010			
021308 001	MICONAZOLE NITRATE;MONISTAT 1 COMBINATI	6153635	NOV 28, 2020			
		5514698	MAR 21, 2014			
019436 001	MILRINONE LACTATE;PRIMACOR	4313951	NOV 26, 2001			
		4313951*PED	MAY 26, 2002			
020343 001	MILRINONE LACTATE;PRIMACOR IN DEXTROSE	4313951	NOV 26, 2001			
		4313951*PED	MAY 26, 2002			
020343 002	MILRINONE LACTATE;PRIMACOR IN DEXTROSE	4313951	NOV 26, 2001			
		4313951*PED	MAY 26, 2002			
020343 003	MILRINONE LACTATE;PRIMACOR IN DEXTROSE	4313951	NOV 26, 2001			
		4313951*PED	MAY 26, 2002			
021208 001	MIRTAZAPINE;REMERON SOLTAB	5178878	JAN 12, 2010		NCE	JUN 14, 2001
021208 002	MIRTAZAPINE;REMERON SOLTAB	5178878	JAN 12, 2010		NCE	JUN 14, 2001
021208 003	MIRTAZAPINE;REMERON SOLTAB	5178878	JAN 12, 2010		NCE	JUN 14, 2001
019297 001	MITOXANTRONE HYDROCHLORIDE;NOVANTRONE	4617319	JUN 13, 2005	U-390	I-324	OCT 13, 2003
020762 001	MOMETASONE FUROATE MONOHYDRATE;NASONEX	4472393	SEP 18, 2001		I-285	DEC 02, 2002
		5837699	JAN 27, 2014	U-249	PED	JUN 02, 2003
		6127353	OCT 03, 2017			
		4472393*PED	MAR 18, 2002			
		5837699*PED	JUL 27, 2014	U-249		
		6127353*PED	APR 03, 2018			
019543 001	MOMETASONE FUROATE;ELOCON	4472393	SEP 18, 2001			
		4472393*PED	MAR 18, 2002			
019625 001	MOMETASONE FUROATE;ELOCON	4808610	OCT 02, 2006			
		4472393	SEP 18, 2001			
		4472393*PED	MAR 18, 2002			
		4808610*PED	APR 02, 2007			
019796 001	MOMETASONE FUROATE;ELOCON	4775529	MAY 21, 2007			
		4472393	SEP 18, 2001			
		4472393*PED	MAR 18, 2002			
		4775529*PED	NOV 21, 2007			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020829 002	MONTELUKAST SODIUM;SINGULAIR	5565473	FEB 03, 2012	U-228	NCE	FEB 20, 2003
		5565473*PED	AUG 03, 2012	U-228	PED	AUG 20, 2003
020830 001	MONTELUKAST SODIUM;SINGULAIR	5565473	FEB 03, 2012	U-228	NCE	FEB 20, 2003
		5565473*PED	AUG 03, 2012	U-228	PED	AUG 20, 2003
020830 002	MONTELUKAST SODIUM;SINGULAIR	5565473	FEB 03, 2012	U-228	I-300	MAR 03, 2003
		5565473*PED	AUG 03, 2012	U-228	NS	MAR 03, 2003
					NCE	FEB 20, 2003
					PED	SEP 03, 2003
					PED	AUG 20, 2003
					PED	SEP 03, 2003
021085 001	MOXIFLOXACIN HYDROCHLORIDE;AVELOX				I-329	APR 27, 2004
021277 001	MOXIFLOXACIN HYDROCHLORIDE;AVELOX IV				NCE	DEC 10, 2004
					NDF	NOV 30, 2004
					I-329	APR 27, 2004
075179 001	NABUMETONE;NABUMETONE				PC	FEB 23, 2002
075189 001	NABUMETONE;NABUMETONE				PC	FEB 16, 2002
075189 002	NABUMETONE;NABUMETONE				PC	FEB 23, 2002
019583 001	NABUMETONE;RELAFEN	4420639	DEC 13, 2002			
		4420639*PED	JUN 13, 2003			
019583 002	NABUMETONE;RELAFEN	4420639	DEC 13, 2002			
		4420639*PED	JUN 13, 2003			
021204 001	NATEGLINIDE;STARLIX	RE34878	MAR 28, 2006			
		5463116	OCT 21, 2012			
		5488150	JAN 30, 2013			
021204 002	NATEGLINIDE;STARLIX	RE34878	MAR 28, 2006			
		5463116	OCT 21, 2012			
		5488150	JAN 30, 2013			
020920 001	NESIRITIDE;NATRECOR	5114923	MAY 19, 2009		NCE	AUG 10, 2006
		5674710	OCT 07, 2014			
020165 004	NICOTINE;NICODERM CQ	6165497	JUN 14, 2008	U-388		
		5633008	JUN 14, 2008	U-389		
020165 005	NICOTINE;NICODERM CQ	5633008	JUN 14, 2008	U-389		
		6165497	JUN 14, 2008	U-388		
020165 006	NICOTINE;NICODERM CQ	5633008	JUN 14, 2008	U-389		
		6165497	JUN 14, 2008	U-388		
075269 002	NIFEDIPINE;NIFEDIPINE				PC	JUN 05, 2001
019667 001	OCTREOTIDE ACETATE;SANDOSTATIN	5753618	JUL 08, 2008			
019667 002	OCTREOTIDE ACETATE;SANDOSTATIN	5753618	JUL 08, 2008			
019667 003	OCTREOTIDE ACETATE;SANDOSTATIN	5753618	JUL 08, 2008			
019667 004	OCTREOTIDE ACETATE;SANDOSTATIN	5753618	JUL 08, 2008			
019667 005	OCTREOTIDE ACETATE;SANDOSTATIN	5753618	JUL 08, 2008			
021008 001	OCTREOTIDE ACETATE;SANDOSTATIN LAR	5753618	JUL 08, 2008			
021008 002	OCTREOTIDE ACETATE;SANDOSTATIN LAR	5753618	JUL 08, 2008			
021008 003	OCTREOTIDE ACETATE;SANDOSTATIN LAR	5753618	JUL 08, 2008			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020799 001	OFLOXACIN;FLOXIN	5401741	MAR 27, 2012	U-407		
020592 001	OLANZAPINE;ZYPREXA	6251895	SEP 23, 2017			
020592 002	OLANZAPINE;ZYPREXA	6251895	SEP 23, 2017			
020592 003	OLANZAPINE;ZYPREXA	6251895	SEP 23, 2017			
020592 004	OLANZAPINE;ZYPREXA	6251895	SEP 23, 2017			
020592 005	OLANZAPINE;ZYPREXA	5229382	APR 23, 2011	U-149	NCE	SEP 30, 2001
		5605897	FEB 25, 2014	U-176		
		6251895	SEP 23, 2017			
020592 006	OLANZAPINE;ZYPREXA	6251895	SEP 23, 2017			
		5229382	APR 23, 2011	U-149		
		5605897	FEB 25, 2014	U-176		
021086 001	OLANZAPINE;ZYPREXA ZYDIS	6020487	SEP 23, 2017			
		6251895	SEP 23, 2017			
021086 002	OLANZAPINE;ZYPREXA ZYDIS	6020487	SEP 23, 2017			
		6251895	SEP 23, 2017			
021086 003	OLANZAPINE;ZYPREXA ZYDIS	6020487	SEP 23, 2017			
		6251895	SEP 23, 2017			
021086 004	OLANZAPINE;ZYPREXA ZYDIS	6020487	SEP 23, 2017			
		6251895	SEP 23, 2017			
020688 001	OLOPATADINE HYDROCHLORIDE;PATANOL	5641805	JUN 06, 2015	U-184		
019810 001	OMEPRAZOLE;PRILOSEC	6150380	NOV 10, 2018		PED	DEC 29, 2001
		6147103	OCT 09, 2018			
		6166213	OCT 09, 2018			
		6191148	OCT 09, 2018			
		4255431*PED	OCT 05, 2001	U-108		
		4636499*PED	JAN 30, 2006			
		4786505*PED	OCT 20, 2007	U-108		
		4853230*PED	OCT 20, 2007	U-108		
		5093342*PED	AUG 02, 2010	U-166		
		5599794*PED	AUG 04, 2014	U-166		
		5629305*PED	AUG 04, 2014	U-188		
		6147103*PED	APR 09, 2019			
		6150380*PED	MAY 10, 2019			
		6166213*PED	APR 09, 2018			
		6191148*PED	APR 09, 2019			
		4508905	APR 02, 2002			
		4508905*PED	OCT 02, 2002			
019810 002	OMEPRAZOLE;PRILOSEC	6150380	NOV 10, 2018		PED	DEC 29, 2001
		6147103	OCT 09, 2018			
		6166213	OCT 09, 2018			
		6191148	OCT 09, 2018			
		4255431*PED	OCT 05, 2001	U-108		
		4636499*PED	JAN 30, 2006			
		4786505*PED	OCT 20, 2007	U-108		
		4853230*PED	OCT 20, 2007	U-108		
		5093342*PED	AUG 02, 2010	U-166		
		5599794*PED	AUG 04, 2014			
		5629305*PED	AUG 04, 2014	U-166		
		6147103*PED	APR 09, 2019	U-188		
		6150380*PED	MAY 10, 2019			
		6166213*PED	APR 09, 2018			
		6191148*PED	APR 09, 2019			
		4508905	APR 02, 2002			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
		4508905*PED	OCT 02, 2002			
019810 003	OMEPRAZOLE;PRILOSEC	6150380	NOV 10, 2018		I-229	JUN 29, 2001
		6147103	OCT 09, 2018		PED	DEC 29, 2001
		6166213	NOV 10, 2018			
		6191148	OCT 09, 2018			
		4255431*PED	OCT 05, 2001	U-108		
		4636499*PED	JAN 30, 2006			
		4786505*PED	OCT 20, 2007	U-108		
		4853230*PED	OCT 20, 2007	U-108		
		5093342*PED	AUG 02, 2010	U-166		
		5599794*PED	AUG 04, 2014	U-166		
		5629305*PED	AUG 04, 2014	U-188		
		6147103*PED	APR 09, 2019			
		6150380*PED	MAY 10, 2019			
		6166213*PED	APR 09, 2018			
		6191148*PED	APR 09, 2019			
		4508905	APR 02, 2002			
		4508905*PED	OCT 02, 2002			
020781 001	ONDANSETRON;ZOFRAN ODT	4753789	JUN 24, 2006	U-330		
021246 001	OSELTAMIVIR PHOSPHATE;TAMIFLU	5763483	DEC 27, 2016	U-376	I-317	NOV 17, 2003
		5866601	FEB 02, 2016		NDF	DEC 14, 2003
		5952375	FEB 02, 2016		NCE	OCT 27, 2004
020897 001	OXYBUTYNIN CHLORIDE;DITROPAN XL	6124355	MAY 22, 2015	U-378		
		6262115	MAY 22, 2015	U-393		
020897 002	OXYBUTYNIN CHLORIDE;DITROPAN XL	6124355	MAY 22, 2015	U-378		
		6262115	MAY 22, 2015	U-393		
020897 003	OXYBUTYNIN CHLORIDE;DITROPAN XL	6124355	MAY 22, 2015	U-378		
		6262115	MAY 22, 2015	U-393		
020553 004	OXYCODONE HYDROCHLORIDE;OXYCONTIN	4861598	AUG 29, 2006			
		4970075	NOV 13, 2007			
		5266331	FEB 05, 2008			
		5549912	FEB 05, 2008			
020553 005	OXYCODONE HYDROCHLORIDE;OXYCONTIN	4861598	AUG 29, 2006			
		4970075	NOV 13, 2007			
		5266331	FEB 05, 2008			
		5549912	FEB 05, 2008			
		5508042	APR 16, 2013			
		5656295	FEB 05, 2008			
020262 001	PACLITAXEL;TAXOL	6096331	FEB 22, 2013			
		6150398	MAY 08, 2011	U-380		
020036 001	PAMIDRONATE DISODIUM;AREDIA				D-68	AUG 20, 2004
020036 003	PAMIDRONATE DISODIUM;AREDIA				D-68	AUG 20, 2004
020036 004	PAMIDRONATE DISODIUM;AREDIA				D-68	AUG 20, 2004
075290 001	PAMIDRONATE DISODIUM;PAMIDRONATE DISODIUM				PC	MAY 05, 2002

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
075290 003	PAMIDRONATE DISODIUM;PAMIDRONATE DISODIUM				PC	MAY 05, 2002
020987 001	PANTOPRAZOLE SODIUM;PROTONIX				I-330	JUN 12, 2004
020988 001	PANTOPRAZOLE SODIUM;PROTONIX IV	4758579	JUL 19, 2005		NDF	MAR 22, 2004
					NCE	FEB 02, 2005
					I-337	OCT 19, 2004
020819 001	PARICALCITOL;ZEMPLAR	5246925	APR 17, 2012	U-314		
020031 001	PAROXETINE HYDROCHLORIDE;PAXIL				I-326	APR 13, 2004
020031 002	PAROXETINE HYDROCHLORIDE;PAXIL				I-326	APR 13, 2004
020031 003	PAROXETINE HYDROCHLORIDE;PAXIL				I-326	APR 13, 2004
020031 004	PAROXETINE HYDROCHLORIDE;PAXIL				I-326	APR 13, 2004
020031 005	PAROXETINE HYDROCHLORIDE;PAXIL				I-326	APR 13, 2004
020936 003	PAROXETINE HYDROCHLORIDE;PAXIL CR	4721723	DEC 29, 2006			
		4839177	JUN 13, 2006			
		5422123	JUN 06, 2012			
		5789449	JAN 06, 2009	U-286		
		5872132	MAY 19, 2015			
		5900423	MAY 19, 2015			
		6063927	APR 23, 2019			
		6080759	MAY 19, 2015			
		6121291	MAR 17, 2017	U-286		
		6133289	MAY 19, 2015	U-286		
		6172233	JAN 15, 2018			
021064 001	PERFLUTREN;DEFINITY	5527521	APR 05, 2011		NCE	JUL 31, 2006
		5547656	APR 05, 2011			
		5769080	JUL 20, 2010			
021073 001	PIOGLITAZONE HYDROCHLORIDE;ACTOS	6211205	JUN 19, 2016	U-410		
		6271243	JUN 19, 2016	U-411		
		6303640	JUN 19, 2016	U-425		
		6166042	JUN 19, 2016	U-414		
		6166043	JUN 19, 2016	U-415		
		6172090	JUN 19, 2016	U-416		
		5965584	JUN 19, 2016	U-417		
		6150383	JUN 19, 2016	U-418		
		6150384	JUN 19, 2016	U-419		
021073 002	PIOGLITAZONE HYDROCHLORIDE;ACTOS	6211205	JUN 19, 2016	U-410		
		6271243	JUN 19, 2016	U-411		
		6303640	JUN 19, 2016	U-425		
		6166042	JUN 19, 2016	U-414		
		6166043	JUN 19, 2016	U-415		
		6172090	JUN 19, 2016	U-416		
		5965584	JUN 19, 2016	U-417		
		6150383	JUN 19, 2016	U-418		
		6150384	JUN 19, 2016	U-419		
021073 003	PIOGLITAZONE HYDROCHLORIDE;ACTOS	6211205	JUN 19, 2016	U-410		
		6271243	JUN 19, 2016	U-411		
		6303640	JUN 19, 2016	U-425		
		6166042	JUN 19, 2016	U-414		
		6166043	JUN 19, 2016	U-415		
		6172090	JUN 19, 2016	U-416		
		5965584	JUN 19, 2016	U-417		
		6150383	JUN 19, 2016	U-418		
		6150384	JUN 19, 2016			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
						PC	FEB 28, 2002
>ADD>	074726 001	POTASSIUM CHLORIDE;KLOR-CON M20					
	020667 005	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4886812	MAR 25, 2011			
	019627 002	PROPOFOL;DIPRIVAN				I-322	FEB 20, 2004
						PED	AUG 20, 2004
>ADD>	020639 001	QUETIAPINE FUMARATE;SEROQUEL	4879288	SEP 26, 2011			
>ADD>	020639 002	QUETIAPINE FUMARATE;SEROQUEL	4879288	SEP 26, 2011			
>ADD>	020639 003	QUETIAPINE FUMARATE;SEROQUEL	4879288	SEP 26, 2011			
>ADD>	020639 004	QUETIAPINE FUMARATE;SEROQUEL	4879288	SEP 26, 2011			
>ADD>	020639 005	QUETIAPINE FUMARATE;SEROQUEL	4879288	SEP 26, 2011			
	020973 002	RABEPRAZOLE SODIUM;ACIPHEX	5045552	SEP 03, 2008	U-385		
			5035899	APR 04, 2009	U-385		
	020815 001	RALOXIFENE HYDROCHLORIDE;EVISTA	4418068	APR 03, 2002			
	019901 001	RAMIPRIL;ALTACE	5061722	OCT 19, 2008			
	019901 002	RAMIPRIL;ALTACE	5061722	OCT 19, 2008			
	019901 003	RAMIPRIL;ALTACE	5061722	OCT 19, 2008			
	019901 004	RAMIPRIL;ALTACE	5061722	OCT 19, 2008			
	020741 001	REPAGLINIDE;PRANDIN	6143769	MAR 24, 2009			
	020741 002	REPAGLINIDE;PRANDIN	6143769	MAR 14, 2009			
	020741 003	REPAGLINIDE;PRANDIN	6143769	MAR 14, 2009			
	020903 001	RIBAVIRIN;REBETOL	5767097	JAN 23, 2016	U-235	PED	JUN 09, 2002
			5914128	DEC 22, 2017		PED	DEC 03, 2001
			6051252	DEC 22, 2017			
			6063772	JAN 23, 2016	U-375		
			6172046	SEP 21, 2017	U-377		
			5767097*PED	JUL 23, 2016	U-235		
			5914128*PED	JUN 22, 2018			
			6051252*PED	JUN 22, 2018			
			6063772*PED	JUL 23, 2016	U-375		
			6172046*PED	MAR 21, 2018	U-377		
	018859 001	RIBAVIRIN;VIRAZOLE	6150337	NOV 21, 2017	U-400		
	020945 001	RITONAVIR;NORVIR	6232333	NOV 07, 2017			
	021042 001	ROFECOXIB;VIOXX	5474995	JUN 24, 2013	U-266		
			5691374	NOV 25, 2017			
			6239173	JUN 24, 2013			
	021042 002	ROFECOXIB;VIOXX	5474995	JUN 24, 2013	U-266		
			5691374	NOV 25, 2017			
			6239173	JUN 24, 2013			
	021042 003	ROFECOXIB;VIOXX	6239173	JUN 24, 2013			
			5474995	JUN 24, 2013	U-266		
			5691374	NOV 25, 2017			
			6239173	JUN 24, 2013			
	021052 001	ROFECOXIB;VIOXX	6239173	JUN 24, 2013			
	021052 002	ROFECOXIB;VIOXX	6239173	JUN 24, 2013			
	021071 002	ROSIGLITAZONE MALEATE;AVANDIA	6288095	FEB 11, 2017	U-420		
	021071 003	ROSIGLITAZONE MALEATE;AVANDIA	6288095	FEB 11, 2017	U-420		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021071 004	ROSIGLITAZONE MALEATE;AVANDIA	6288095	FEB 11, 2017	U-420		
020692 001	SALMETEROL XINAFOATE;SEREVENT	5290815	MAR 01, 2011	U-386		
020828 001	SAQUINAVIR;FORTOVASE	5196438	NOV 19, 2010			
019839 001	SERTRALINE HYDROCHLORIDE;ZOLOFT				M-11	AUG 06, 2004
019839 002	SERTRALINE HYDROCHLORIDE;ZOLOFT				M-11	AUG 06, 2004
019839 005	SERTRALINE HYDROCHLORIDE;ZOLOFT				M-11	AUG 06, 2004
020990 001	SERTRALINE HYDROCHLORIDE;ZOLOFT				M-11	AUG 06, 2004
020478 001	SEVOFLURANE;ULTANE	6288127	JAN 27, 2017			
		6288127*PED	JUL 27, 2018			
020632 001	SIBUTRAMINE HYDROCHLORIDE;MERIDIA				D-65	FEB 16, 2004
					M-9	FEB 16, 2004
020632 002	SIBUTRAMINE HYDROCHLORIDE;MERIDIA				D-65	FEB 16, 2004
					M-9	FEB 16, 2004
020632 003	SIBUTRAMINE HYDROCHLORIDE;MERIDIA				D-65	FEB 16, 2004
					M-9	FEB 16, 2004
021097 001	SODIUM PHOSPHATE, DIBASIC, ANHYDROUS;VISICOL	5616346	MAY 18, 2013	U-359		
020280 006	SOMATROPIN RECOMBINANT;GENOTROPIN	5633352	MAY 27, 2014		I-334	JUL 25, 2004
					ODE	JUL 25, 2008
020280 007	SOMATROPIN RECOMBINANT;GENOTROPIN	5633352	MAY 27, 2014		I-334	JUL 25, 2004
					ODE	JUL 25, 2008
020280 001	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	6152897	JUN 11, 2018		I-334	JUL 25, 2004
		5633352	MAY 27, 2014		ODE	JUL 25, 2008
020280 002	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	6152897	JUN 11, 2018		I-334	JUL 25, 2004
		5633352	MAY 27, 2014		ODE	JUL 25, 2008
020280 003	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	6152897	JUN 11, 2018		I-334	JUL 25, 2004
		5633352	MAY 27, 2014		ODE	JUL 25, 2008
020280 004	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	5633352	MAY 27, 2014		I-334	JUL 25, 2004
					ODE	JUL 25, 2008
020280 005	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	6152897	JUN 11, 2018		I-334	JUL 25, 2004
		5633352	MAY 27, 2014		ODE	JUL 25, 2008
020280 008	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	6152897	JUN 11, 2018		I-334	JUL 25, 2004
		5633352	MAY 27, 2014		ODE	JUL 25, 2008
020280 009	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	6152897	JUN 11, 2018		I-334	JUL 25, 2004
		5633352	MAY 27, 2014		ODE	JUL 25, 2008
020280 010	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	5633352	MAY 27, 2014		I-334	JUL 25, 2004
					ODE	JUL 25, 2008
020280 011	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	5633352	MAY 27, 2014		I-334	JUL 25, 2004
					ODE	JUL 25, 2008
020280 012	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	5633352	MAY 27, 2014		I-334	JUL 25, 2004
					ODE	JUL 25, 2008
020280 013	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	5633352	MAY 27, 2014		I-334	JUL 25, 2004
					ODE	JUL 25, 2008
021151 001	SOTALOL HYDROCHLORIDE;BETAPACE AF				NP	FEB 22, 2003
					PED	AUG 22, 2003

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021151 002	SOTALOL HYDROCHLORIDE;BETAPACE AF				NP	FEB 22, 2003
					PED	AUG 22, 2003
021151 003	SOTALOL HYDROCHLORIDE;BETAPACE AF				NP	FEB 22, 2003
					PED	AUG 22, 2003
020412 001	STAVUDINE;ZERIT	4978655	JUN 24, 2008	U-94		
		4978655*PED	DEC 24, 2008	U-94		
020412 002	STAVUDINE;ZERIT	4978655	JUN 24, 2008	U-94		
		4978655*PED	DEC 24, 2008	U-94		
020412 003	STAVUDINE;ZERIT	4978655	JUN 24, 2008	U-94		
		4978655*PED	DEC 24, 2008			
020412 004	STAVUDINE;ZERIT	4978655	JUN 24, 2008	U-94		
		4978655*PED	DEC 24, 2008	U-94		
020412 005	STAVUDINE;ZERIT	4978655	JUN 24, 2008	U-94		
		4978655*PED	DEC 24, 2008	U-94		
021184 002	TAZAROTENE;TAZORAC				I-344	OCT 11, 2004
021356 001	TENOFOVIR DISOPROXIL FUMARATE;VIREAD	5977089	JUL 25, 2017	U-248	NCE	OCT 26, 2006
		6043230	JUL 25, 2017	U-248		
		5935946	JUL 25, 2017	U-248		
		4808716	APR 25, 2006	U-248		
		6057305	MAY 02, 2017	U-248		
		5922695	JUL 25, 2017	U-248		
019964 001	TERCONAZOLE;TERAZOL 3	4358449	NOV 09, 2001			
020898 001	THYROTROPIN ALFA;THYROGEN	5674711	AUG 31, 2010			
		5602006	FEB 11, 2014			
		5658760	AUG 19, 2014			
		5240832	AUG 31, 2010			
		6114144	NOV 24, 2015			
		5840566	NOV 24, 2015			
020330 001	TIMOLOL MALEATE;TIMOPTIC-XE	4861760	SEP 25, 2006			
020330 002	TIMOLOL MALEATE;TIMOPTIC-XE	4861760	SEP 25, 2006			
020397 002	TIZANIDINE HYDROCHLORIDE;ZANAFLEX				NCE	NOV 27, 2001
020771 001	TOLTERODINE TARTRATE;DETROL	5559269	NOV 05, 2013	U-318		
020771 002	TOLTERODINE TARTRATE;DETROL	5559269	NOV 05, 2013	U-318		
020505 001	TOPIRAMATE;TOPAMAX				ODE	AUG 28, 2008
					I-335	AUG 28, 2004
020505 002	TOPIRAMATE;TOPAMAX				ODE	AUG 28, 2008
					I-335	AUG 28, 2004
020505 003	TOPIRAMATE;TOPAMAX				ODE	AUG 28, 2008
					I-335	AUG 28, 2004
020505 004	TOPIRAMATE;TOPAMAX				ODE	AUG 28, 2008
					I-335	AUG 28, 2004
020505 005	TOPIRAMATE;TOPAMAX				ODE	AUG 28, 2008
					I-335	AUG 28, 2004

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020505 006	TOPIRAMATE;TOPAMAX				ODE	AUG 28, 2008
					I-335	AUG 28, 2004
020844 001	TOPIRAMATE;TOPAMAX SPRINKLE				ODE	AUG 28, 2008
					I-335	AUG 28, 2004
020844 002	TOPIRAMATE;TOPAMAX SPRINKLE				ODE	AUG 28, 2008
					I-335	AUG 28, 2004
020844 003	TOPIRAMATE;TOPAMAX SPRINKLE				ODE	AUG 28, 2008
					I-335	AUG 28, 2004
020528 001	TRANDOLAPRIL;MAVIK	4933361	JUN 12, 2007			
020528 002	TRANDOLAPRIL;MAVIK	4933361	JUN 12, 2007			
020528 003	TRANDOLAPRIL;MAVIK	4933361	JUN 12, 2007			
020591 001	TRANDOLAPRIL;TARKA	5721244	FEB 24, 2015			
020591 002	TRANDOLAPRIL;TARKA	5721244	FEB 24, 2015			
020591 003	TRANDOLAPRIL;TARKA	5721244	FEB 24, 2015			
020591 004	TRANDOLAPRIL;TARKA	5721244	FEB 24, 2015			
021257 001	TRAVOPROST;TRAVATAN	6011062	DEC 22, 2014	U-382	NCE	MAR 16, 2006
		5631287	DEC 22, 2014	U-382		
		5849792	DEC 22, 2014	U-383		
		5889052	AUG 03, 2013	U-383		
		6235781	JUN 15, 2019	U-382		
019963 001	TRETINOIN;RENOVA	RE36068	JUL 29, 2003	U-131		
021108 001	TRETINOIN;RENOVA	RE36068	JUL 29, 2003	U-131		
		4603146	JUL 29, 2003	U-131		
020475 001	TRETINOIN;RETIN-A MICRO	5955109	SEP 21, 2016	U-134		
020468 001	TRIAMCINOLONE ACETONIDE;NASACORT AQ	6143329	JUL 03, 2016			
021288 001	TRIPTORELIN PAMOATE;TRELSTAR	5225205	JUL 20, 2010		NP	JUN 29, 2004
		5192741	MAR 09, 2010		NCE	JUN 15, 2005
020715 001	TRIPTORELIN PAMOATE;TRELSTAR DEPOT	5776885	JUL 07, 2015			
020759 001	TROVAFLOXACIN MESYLATE;TROVAN	6187341	JAN 20, 2019			
020759 002	TROVAFLOXACIN MESYLATE;TROVAN	6187341	JAN 20, 2019			
020586 002	UREA, C-13;BREATHTEK UBT FOR H-	4830010	OCT 27, 2009	U-147		
		5140993	AUG 24, 2009			
				U-148		
019415 004	UROFOLLITROPIN;FERTINEX	5767067	JUN 16, 2015			
		4845077	JUL 04, 2006	U-408		
		4725579	FEB 21, 2005	U-408		
019415 005	UROFOLLITROPIN;FERTINEX	5767067	JUN 16, 2015			
		4845077	JUL 04, 2006	U-408		
		4725579	FEB 21, 2005	U-408		
020550 001	VALACYCLOVIR HYDROCHLORIDE;VALTREX				D-67	JUN 25, 2004
020550 002	VALACYCLOVIR HYDROCHLORIDE;VALTREX				D-67	JUN 25, 2004
021304 001	VALGANCICLOVIR HYDROCHLORIDE;VALCYTE	6083953	JUL 28, 2014	U-384	NE	MAR 29, 2004
021283 001	VALSARTAN;DIOVAN	5399578	MAR 21, 2012		NCE	DEC 23, 2001

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021283 002	VALSARTAN;DIOVAN	5399578	MAR 21, 2012		NCE	DEC 23, 2001
021283 003	VALSARTAN;DIOVAN	5399578	MAR 21, 2012		NCE	DEC 23, 2001
020151 001	VENLAFAXINE HYDROCHLORIDE;EFFEXOR				I-325	MAY 02, 2004
020151 002	VENLAFAXINE HYDROCHLORIDE;EFFEXOR				I-325	MAY 02, 2004
020151 003	VENLAFAXINE HYDROCHLORIDE;EFFEXOR				I-325	MAY 02, 2004
020151 004	VENLAFAXINE HYDROCHLORIDE;EFFEXOR				I-325	MAY 02, 2004
020151 005	VENLAFAXINE HYDROCHLORIDE;EFFEXOR				I-325	MAY 02, 2004
020151 006	VENLAFAXINE HYDROCHLORIDE;EFFEXOR				I-325	MAY 02, 2004
020699 001	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	6274171	MAR 20, 2017		I-325	MAY 02, 2004
		5916923	JUN 28, 2013	U-398		
020699 002	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	6274171	MAR 20, 2017		I-325	MAY 02, 2004
		5916923	JUN 28, 2013	U-398		
020699 003	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	6274171	MAR 20, 2017			
		5916923	JUN 28, 2013	U-398		
020699 004	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	6274171	MAR 20, 2017		I-325	MAY 02, 2004
		5916923	JUN 28, 2013	U-398		
021119 001	VERTEPORFIN;VISUDYNE	4833790	JAN 20, 2007	U-357	I-336	AUG 22, 2004
		5283255	JAN 20, 2007	U-357		
020547 001	ZAFIRLUKAST;ACCOLATE				I-328	SEP 17, 2002
020547 003	ZAFIRLUKAST;ACCOLATE				I-328	SEP 17, 2002
020859 001	ZALEPLON;SONATA				M-8	FEB 22, 2004
020859 002	ZALEPLON;SONATA				M-8	FEB 22, 2004
020825 001	ZIPRASIDONE HYDROCHLORIDE;GEODON	4831031	MAR 02, 2007		NCE	FEB 05, 2006
		5312925	SEP 01, 2012			
020825 002	ZIPRASIDONE HYDROCHLORIDE;GEODON	4831031	MAR 02, 2007		NCE	FEB 05, 2006
		5312925	SEP 01, 2012			
020825 003	ZIPRASIDONE HYDROCHLORIDE;GEODON	4831031	MAR 02, 2007		NCE	FEB 05, 2006
		5312925	SEP 01, 2012			
020825 004	ZIPRASIDONE HYDROCHLORIDE;GEODON	4831031	MAR 02, 2007		NCE	FEB 05, 2006
		5312925	SEP 01, 2012			
021223 001	ZOLEDRONIC ACID;ZOMETA	4939130	NOV 13, 2007	U-53	NCE	AUG 20, 2006
		4777163	JUL 24, 2007		ODE	AUG 20, 2008
021231 001	ZOLMITRIPTAN;ZOMIG-ZMT				NDF	FEB 13, 2004

PATENT AND EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE PATENT AND EXCLUSIVITY COLUMNS, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. PLEASE REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 21ST EDITION FOR A FULL LISTING OF PATENT AND EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). THE CUMULATIVE SUPPLEMENT WILL LIST NEW CODES ADDED SINCE THE LAST ANNUAL EDITION.

ABBREVIATIONS

REFERENCES

NEW DOSING SCHEDULE

D-47	PREVENTION OF HEARTBURN SYMPTOMS WHEN ADMINISTERED FROM 15 MINUTES UP TO, BUT NOT INCLUDING, 1 HOUR PRIOR TO A PROVOCATIVE MEAL
D-65	CHANGE DOSING AND ADMINISTRATION TO INDICATE MAINTENANCE OF WEIGHT LOSS OVER AN 18 MONTH PERIOD THUS EXTENDING THE USE OF THIS DRUG FROM ONE TO TWO YEARS
D-66	DOSING RECOMMENDATIONS FOR PATIENTS UNDERGOING PCI
D-67	SHORTER TREATMENT COURSE OF THREE DAYS IN THE TREATMENT OF RECURRENT EPISODES OF GENITAL HERPES
D-68	CHANGE OF ADMIN RATE FOR INFUSION OF AREDIA FOR TREATMENT OF MODERATE AND SEVERE HYPERCALCEMIA OF MALIGNANCY FROM 24 HOURS TO 2 HOURS UP TO BUT NOT INCLUDING 24 HOURS
D-69	SHORTENED DOSING REGIMEN TO 5 DAYS FOR THE TREATMENT OF ACUTE EXACERBATION OF CHRONIC BRONCHITIS

NEW INDICATION

I-321	JUVENILE RHEUMATOID ARTHRITIS
I-322	USE OF DIPRIVAN IN PATIENTS 3 MONTHS TO 16 YEARS
I-323	COLORECTAL CANCER
I-324	REDUCING NEUROLOGIC DISABILITY AND/OR FREQUENCY OF CLINICAL RELAPSES IN PATIENTS WITH SECONDARY (CHRONIC) PROGRESSIVE, PROGRESSIVE RELAPSING, OR WORSENING RELAPSING-REMITTING MULTIPLE SCLEROSIS
I-325	PREVENTION OF RELAPSE AND RECURRENCE OF DEPRESSION
I-326	GENERALIZED ANXIETY DISORDER
I-327	SYMPTOMATIC RELIEF OF RHINOORRHEA ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN PATIENTS 5 YEARS AND OLDER
I-328	PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA IN PATIENTS 5-6 YEARS OF AGE
I-329	UNCOMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS
I-330	MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS AND CONTROL OF DAYTIME AND NIGHTTIME HEARTBURN SYSTOMS IN PATIENTS WITH GERD
I-331	TREATMENT OF MODERATE ACNE VULGARIS
I-332	EMPIRIC THERAPY IN FEBRILE NEUTROPENIC PATIENTS WITH SUSPECTED FUNGAL INFECTIONS (ETFN)
I-333	TOPICAL TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR DUE TO MALASSEZIA FURFUR (FORMERLY PITYROSPORUM ORBICULARE)
I-334	LONG-TERM TREATMENT OF GROWTH FAILURE IN CHILDREN BORN SMALL FOR GESTATIONAL AGE WHO FAIL TO MANIFEST CATCH-UP GROWTH BY TWO YEARS OF AGE
I-335	ADJUNCTIVE THERAPY IN PATIENTS TWO YEARS AND OLDER WITH SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME

PATENT AND EXCLUSIVITY TERMS

REFERENCES

NEW INDICATION

I-336	EXPANSION OF INDICATION TO INCLUDE THE TREATMENT OF PATIENTS WITH PREDOMINATELY CLASSIC SUBFOVEAL CHOROIDAL NEOVASCULARIZATION DUE TO PATHOLOGIC MYOPIA OR PRESUMED OCULAR HISTOPLASMOSIS
I-337	PATHOLOGICAL HYPERSECRETION ASSOCIATED WITH ZOLLINGER-ELLISON SNYDROME
I-338	MANAGEMENT OF ACUTE PAIN IN ADULTS AND TREATMENT OF PRIMARY DYSMENORRHEA
I-339	TREATMENT OF HEPATITIS B IN PEDIATRIC PATIENTS AGES 2-17 YEARS
I-340	ATOPIC DERMATITIS IN PEDIATRIC PATIENTS AGES 2-5
I-341	BREAST CANCER COMBINATION THERAPY
I-342	USE OF FORADIL FOR LONG-TERM, TWICE DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHO-CONSTRICTION IN PATIENTS WITH COPD INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
I-343	USE OF COREG FOR SEVERE HEART FAILURE
I-344	ACNE VULGARIS

MISCELLANEOUS EXCLUSIVITY CODES

M-6	ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES DONE WITH GLUOPHAGE/GLYBURIDE COMBINATION ADDED TO CLIN PHARM AND DOSING AND ADMIN
M-7	CLINICAL PHARMACOLOGY IN PEDIATRIC PATIENTS; DOSAGE AND ADMINISTRATION INFORMATION
M-8	ADDITIONAL INFORMATION FOR THE USE OF SONATA CAPSULES FOR UP TO 5 WEEKS (35 NIGHTS) OF TREATMENT IN A CONTROLLED TRIAL SETTING
M-9	ADDITION TO THE CLINICAL STUDIES SECTION OF THE LABELING OF TEXT AND TWO TABLES CONTAINING INFORMATION FOR THE PRESCRIBING PHYSICIAN ON BLOOD PRESSURE, HEART RATE, AND HEART RATE VARIABILITY
M-10	INFORMATION REGARDING MAINTENANCE OF AN ANTIDEPRESSANT EFFECT UP TO 1 YEAR OF DOSING
M-11	USE FOR LONG-TERM TREATMENT OF POSTTRAUMATIC STRESS DISORDER
M-12	NEW LANGUAGE FOR PEDIATRIC USE

PATENT USE CODES

U-267	PREVENTING HEARTBURN EPISODES FOLLOWING INGESTION OF HEARTBURN-INDUCING FOOD/BEVERAGE, COMPRISING ADMIN TO PT, 30 MIN PRIOR TO CONSUMPTION BY THE PT THE FOOD/BEVERAGE, A COMPOSITION COMPRISING 10MG FAMOTIDINE
U-372	METHOD FOR ADMINISTERING A BENEFICIAL DRUG TO THE GI TRACT OF AN ANIMAL, WHICH METHOD COMPRISES ADMITTING AN OSMOTIC DEVICE ORALLY INTO THE ANIMAL...
U-373	GENERAL USE CLAIM SUBMITTED FOR 12 NEXIUM PATIENTS STATING "PERTINENT TO THE CAPSULE FORMULATION FOR NEXIUM AND ITS INDICATIONS FOR THE TREATMENT OFGERD AND ERADICATION OF H.PYLORI TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE
U-374	KIT ADAPTED AND DESIGNED TO PROVIDE BOTH DATA ON THE CURRENT REPRODUCTIVE STATUS OF A PATIENT AND CONTRACEPTION FOR THOSE WHO ARE NOT PREGNANT, BUT RECENTLY ENGAGED IN UNPROTECTED SEX
U-375	METHOD OF USING RIBAVIRIN FOR TREATING A DISEASE RESPONSIVE TO RIBAVIRIN, E.G. HEPATITIS C
U-376	TREATMENT OF INFLUENZA
U-377	METHOD OF TREATING PT WITH CHRONIC HEPATITIS C HAVING HCV GENOTYPE 1 AND VIRAL LOAD GREATER THAN 2 MILLION COPIES/ML TO ERADICATE DETECTABLE HCV-RNA BY ADMIN COMBINATION OF RIBAVIRIN AND INTERFERON ALFA-2B FOR A LEAST 24 WEEKS
U-378	METHOD FOR TREATING INCONTINENCE
U-379	METHOD OF TREATING ONYCHROMYCOSIS
U-380	COMBINATIONS OF TAXOL (PACLITAXEL) AND CISPLATIN WHICH ARE SUITABLE FOR THE TREATMENT OF OVARIAN AND NON-SMALL CELL LUNG CARCINOMAS
U-381	TREATMENT OF HYPERPHOSPHATEMIA
U-382	METHOD OF STABLIZING PROSTAGLANDIN
U-383	METHOD FOR TREATING GLAUCOMA AND OCULAR HYPERTENSION

PATENT AND EXCLUSIVITY TERMS

REFERENCES
PATENT USE CODES

U-384	TREATMENT OF CMV RETINITIS
U-385	TREATMENT OF PEPTIC ULCERS
U-386	TREATMENT OF PATIENTS SUFFERING FROM A LATE ASTHMATIC REACTION OR LATE PHASE ASTHMA
U-387	TREATMENT OF PATIENTS WITH RESPIRATORY DISORDERS
U-388	SMOKING CESSATION AID APPLIED TO THE SKIN
U-389	SMOKING CESSATION AID APPLIED TO THE SKIN ON WAKING AND REMOVED PRIOR TO SLEEP AFTER ABOUT 16 HOURS
U-390	METHOD OF USING THE DRUG TO TREAT NEUROIMMUNOLOGIC DISEASES (INCLUDING MULTIPLE SCLEROSIS)
U-391	USE OF CASODEX IN COMBINATION WITH LHRH AGONISTS FOR THE TREATMENT OF PROSTATE CANCER
U-392	TREATMENT OF PATIENTS FOR INFLAMMATION
U-393	MANAGEMENT OF INCONTINENCE, MGT OF HORMONE REPLACEMENT THERAPY, TREATMENT OF INVOLUNTARY !NCONTINENCE, MGT OVERACTIVE BLADDER AND INCREASING COMPLIANCE IN SUCH PT
U-394	METHOD OF USE OF ALPHAGAN
U-395	METHOD OF USE OF ALPHAGAN P
U-396	METHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION
U-397	METHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION WITHOUT AN INCREASE IN NAUSEA
U-398	TREATMENT OF GENERALIZED ANXIETY DISORDER
U-399	IN-THE-EYE USE OF CHLORINE DIOXIDE CONTAINING COMPOSITIONS
U-400	USE OF RIBAVIRIN TO INCREASE TYPE 1 CYTOKINE RESPONSE AND SUPPRESS TYPE 2 CYTOKINE RESP0NSE TO LYMPHOCYTES, INCLUDING METHODS THAT TAKE ADVANTAGE OF SUCH MODULATION TO TREAT INFECTIONS AND INFESTATIONS
U-401	USE OF LOPINAVIR IN COMBINATION WITH REVERSE TRANSCRIPTASE INHIBITORS FOR TREATING HIV INFECTION AND IN COMBO WITH OTHER HIV PROTEASE INHIBITORS
U-402	TREATMENT OF ACTINIC KERATOSES
U-403	ANTI-ALLERGIC FOR VARIOUS ALLERGIC DISEASES
U-404	TREATMENT OF ALLERGIC CONJUNCTIVITIS
U-405	METHOD OF USE OF LOTRONEX
U-406	METHOD OF USE OF ATOVAQUONE AND PROGUANIL
U-407	METHOD OF TREATING OTOPATHY
U-408	FOR INDUCING OVULATION IN CONJUNCTION WITH A GONADOTROPIN RELEASING FACTOR ANTAGONIST AND RECRUITING OOCYTES FOR IN-VITRO FERTILIZATION
U-409	METHOD OF TREATING INFLAMMATION USING DRUG SUBSTANCE
U-410	METHOD OF REDUCING AMOUNT OF RESPECTIVE ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (INCLUDING PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
U-411	METHOD OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (WHICH INCLUDES PIOGLITAZONE) IN COMBINATION WITH AN INSULIN PREPARATION
U-412	TREATMENT OF TYPE 2 DIABETES
U-413	USE OF THE ACTIVE INGREDIENT FOR INHIBITING THE BIOSYNTHESIS OF CHOLESTEROL AND TREATMENT OF ATHEROSCLEROSIS
U-414	A METHOD OF TREATING GLYCOMETABOLISM DISORDERS BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE
U-415	A METHOD FOR REDUCING THE AMOUNT OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE AS SAID ACTIVE COMPONENTS
U-416	A METHOD FOR REDUCING SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE AS SAID ACTIVE COMPONENTS
U-417	COMBINATION USE OF AD-4833 WITH A BIGUANIDE
U-418	A METHOD OF TREATING LIPID METABOLISM DISORDERS BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (WHICH INCLUDES PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
U-419	A METHOD OF TREATING LIPID METABOLISM DISORDERS BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE
U-420	METHOD OF TREATMENT OF TYPE II DIABETES

PATENT AND EXCLUSIVITY TERMS

REFERENCES
PATENT USE CODES

U-421	USE FOR SEDATION
U-422	METHOD OF TREATING AT LEAST ONE OF ATTENTION DEFICIT DISORDER AND ATTENTION DEFICIT HYPERACTIVITY DISORDER
U-423	METHOD OF TREATING AT LEAST ONE OF ATTENTION DEFICIT DISORDER, ATTENTION DEFICIT HYPERACTIVITY DISORDER, OR AIDS RELATED DEMENTIA
U-424	FOR ONCE DAILY, BOLUS ADMINISTRATION TO A PATIENT IN ORDER TO ENGENDER TREATMENT FOR A NERVOUS DISORDER FOR SUBSTANTIALLY AN ENTIRE DAY ON A CHRONIC BASIS
U-425	METHOD OF REDUCING SIDE EFFECTS OF ACTIVE COMPONENTS ADMIN TO A DIABETIC BY ADMIN A CHEMICAL COMPOUND HAVING FORMULA (INCL PIOGLITAZONE) IN COMBINATION WITH AN INSULIN ECRETION ENHANCER
U-426	PREVENTION OF PREMATURE LH SURGES IN WOMEN UNDERGOING CONTROLLED OVARIAN STIMULATION

*U.S. Government Printing Office: 2002 — 491-214/40005

New 22nd Edition



APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

22nd EDITION

Superintendent of Documents Subscription Order Form

Order Processing Code
* 8392

Charge your order. It's easy! MasterCard VISA

☐ **Yes,** enter my subscription as follows:

_ subscriptions of **APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS**, ADP, and the monthly Cumulative Supplements, for $105.00 per year.

The total cost of my order is $____. Price includes regular shipping and handling and is subject to change. International customers please add 25%.

For privacy protection, check the box below:

☐ Do not make my name available to other mailers.

Please choose method of payment:

☐ Check payable to Superintendent of Documents
☐ GPO Deposit Account ☐☐☐☐☐☐-☐

☐ VISA or MasterCard
☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐

Company or personal name

Additional address/attention line

Street address

City, State, ZIP Code

(____)
Daytime phone including area code

Purchase Order No. (optional)

(Credit card expiration date)

(Authorizing Signature)

Thank you for your order!

(10/01)

Mail To: Superintendent of Documents, Government Printing Office, P.O. Box 371954 Pittsburgh, PA 15250-7954
To **FAX** your charge order, call (202) 512-2250.
To charge your subscription call (202) 512-1800.